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 ABSTRACT 
Mitochondrial Dysfunction in the Diabetic Heart: Cardioprotection from a novel 
mitochondrially-targeted therapeutic 
Erinne R. Dabkowski 
 
Cardiovascular complications leading to heart failure are the leading cause of 
death amongst both type 1 and type 2 diabetic patients.  Increased reactive oxygen 
species (ROS) generation due to hyperglycemia and an enhanced fatty acid 
environment has been suggested to lead to mitochondrial dysfunction.  Mitochondria 
are particularly susceptible to oxidative damage because the inner mitochondrial 
membrane (IMM) is the main site of ROS generation.  Mitochondrial dysfunction is 
complicated by the fact that two spatially-distinct subpopulations of mitochondria reside 
in the heart.  The subsarcolemmal mitochondria (SSM) are located at the cell periphery, 
while the interfibrillar mitochondria (IFM) situate along the myofibrils.  It has been 
suggested that these two populations of mitochondria respond differently to various 
pathologies and physiological stimuli based upon their location in the cardiomyocyte.  
The goal of the following studies was to examine whether mitochondria located in 
different areas of the cell respond differently with type 1 and type 2 diabetes mellitus 
(DM).  Type 1 DM was induced in 8 week old mice with a multiple low dose (50mg/kg) 
injection of Streptozotocin (STZ) administered for five days.  Five weeks post 
hyperglycemia onset, hearts were excised and mitochondrial subpopulations were 
isolated.  Db/db (BKS.Cg-m +/+ Leprdb/J) mice were utilized as a model of type 2 DM 
and aged 18 weeks before hearts were extracted and mitochondrial subpopulations 
isolated.  In the type 1 diabetic hearts, flow cytometry analysis of mitochondrial 
morphology indicated a decrease in size and internal complexity in the IFM with no 
changes in the SSM.  On the other hand, in the type 2 diabetic hearts, the SSM size 
and complexity were decreased.  Further, mitochondrial electron transport chain (ETC) 
activities and respiration were significantly decreased in the type 1 diabetic IFM while 
significantly decreased in SSM from type 2 diabetic hearts.  Enhanced oxidative 
damage, assessed through lipid peroxidation by-products and nitrotyrosine formation, 
was specific to the IFM in the type 1 diabetic heart but enhanced in the SSM of the type 
2 diabetic heart.  Proteomic assessment revealed altered proteomic profiles in the type 
1 diabetic IFM; however, changes were greater in the SSM of the type 2 diabetic heart.  
These data suggest for the first time, that depending on their location within the cell, 
mitochondria respond differently with type 1 and type 2 diabetic insults.  The 
mitochondria located between the myofibrils are more dysfunctional in the type 1 
diabetic heart; however, the mitochondria located beneath the sarcolemma are more 
dysfunctional in the type 2 diabetic heart.  This emphasizes the importance of 
incorporating spatial location when examining mitochondrial dysfunction in the diabetic 
heart.  Further, because the IMM is particularly susceptible to oxidative damage, we 
examined whether overexpression of a mitochondrially-targeted antioxidant enzyme, 
mitochondrial phospholipid hydroperoxide glutathione peroxidase (mPHGPx), provides 
 
 
protection in the diabetic heart. MPHGPx transgenic mice and controls were made 
diabetic through multiple low dose injections of STZ.  Five weeks following 
hyperglycemia onset, in vivo analysis of cardiac contractile function revealed 
significantly decreased ejection fraction and fractional shortening in the diabetic heart, 
which was reversed with mPHGPx overexpression.  MPHGPx overexpression in the 
diabetic heart increased mitochondrial ETC complex I, III, and IV activities in the 
diabetic IFM, with no differences on the SSM.  Enhanced hydrogen peroxide production 
and lipid peroxidation were significantly attenuated in the diabetic IFM with 
overexpression of mPHGPx, with no changes in the SSM.  MPHGPx is a unique 
antioxidant in that it has the ability to insert into the IMM and directly scavenge lipid 
hydroperoxides.  Therefore, we assessed a phospholipid within the IMM essential for 
proper mitochondrial function, cardiolipin, and found preservation of cardiolipin in the 
diabetic IFM with overexpression of mPHGPx.  These results indicate that mPHGPx 
overexpression provides cardioprotective benefits to the diabetic heart.  Further, 
cardioprotection is associated with enhanced IMM function and preservation of a key 
IMM constituent, cardiolipin.  These findings provide further rationale for the use of 
mPHGPx as a potential mitochondrially-targeted therapeutic that is capable of providing 
protection in the diabetic heart 
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SPECIFIC AIMS 
 
Heart failure is the leading cause of death among diabetic patients.  
Cardiovascular abnormalities, such as diabetic cardiomyopathy, contribute to the onset 
of heart failure with diabetes mellitus (DM) (1).  Increased reactive oxygen species 
(ROS) and mitochondrial dysfunction have been suggested to contribute to the 
pathogenesis of DM (1, 12, 14).  Mitochondria are particularly susceptible to oxidative 
damage because the inner mitochondrial membrane (IMM) is the main site of ROS 
generation and is enriched with protein and lipid constituents that are easily oxidized 
(12). Mitochondrial dysfunction in the diabetic heart is complicated by the fact that there 
are two spatially distinct mitochondrial subpopulations interfibrillar (IFM) and 
subsarcolemmal (SSM).  These two subpopulations are not only spatially distinct within 
the cell but have been suggested to respond differentially with various pathologies (3, 4, 
6-10, 13). We hypothesize that one population may be more susceptible to 
diabetes-associated oxidative stress and ultimately contribute to overall 
mitochondrial and contractile dysfunction present with both type 1 and type 2 
diabetes mellitus. 
Overexpression of an antioxidant enzyme specific to the mitochondria may 
provide protection against increased ROS generation and subsequent disruption of the 
mitochondrial membrane.  Mitochondrial phospholipid hydroperoxide glutathione 
peroxidase (mPHGPx) is an antioxidant enzyme specific to the IMM that is capable of 
scavenging peroxidized phospholipids such as cardiolipin hydroperoxide.  MPHGPx 
reduces hydroperoxide groups on phospholipids, lipoproteins and cholesterol esters and 
may be beneficial in preserving mitochondrial membrane integrity and subsequent 
electron transport chain function (ETC)(2, 5, 11).   
Our long term goal is to mechanistically determine how mitochondrial dysfunction 
is associated with the pathogenesis of diabetes mellitus and to examine whether 
specifically targeted therapeutics are protective.  The Objectives of this proposal are: (1) 
determine the effect of a type 1 diabetic insult on two distinct mitochondrial 
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subpopulations; (2) examine whether mitochondrial subpopulations are differentially 
afflicted with type 2 diabetes mellitus; (3) to determine whether overexpression of a 
mitochondrial specific therapeutic is protective in mitochondrial subpopulations with type 
1 DM.  The Central Hypothesis of this proposal is that the IFM are more dysfunctional 
with type 1 and type 2 DM resulting from an enhanced oxidative environment and 
diminished membrane integrity.  Further, we believe that overexpression of a 
mitochondrial specific antioxidant capable of preserving the IMM may serve as a 
potential therapeutic.  Our central hypothesis is based on preliminary data in our 
laboratory suggesting that the IFM have diminished electron transport chain activities, 
enhanced ROS production, and increased oxidative damage resulting in disruption of 
the mitochondrial membrane with type 1 DM. Our preliminary data indicate that 
transgenic overexpression of mPHGPx will provide relief to the mitochondrial membrane 
by preserving constituents situated in the membrane such as the ETC and this will 
contribute to enhancing overall function with type 1 DM.  Our rationale for the proposed 
research is to elucidate differential mechanisms and key components of mitochondrial 
dysfunction with DM that ultimately will aid in developing more spatially targeted 
therapeutics.  
 
Specific Aims: 
 
Aim 1: Determine the influence of a type 1 diabetic phenotype on specific 
mitochondrial subpopulations in the heart.  To address Aim I, we will first isolate the 
subsarcolemmal (SSM) and interfibrillar (IFM) subpopulations in the diabetic heart to 
examine the effects of streptozotocin (STZ)-induced type 1 DM.   
1.1 Overall subpopulation morphological and functional changes will be observed 
including size, complexity, lipid profile (cardiolipin) and total electron transport chain 
activities including ATP production.  
 
 xix 
 
1.2 Oxidant production and subsequent oxidative damage will be assessed in the 
mitochondria by measuring ROS generation, lipid and protein oxidation. 
 
 
1.3 Distinct proteomic profiles including specific proteomic modifications will be 
examined within the mitochondrial subpopulations with type 1 DM.  
 
These findings will provide insight into the mechanism of mitochondrial dysfunction 
associated with diabetic cardiomyopathy and offer a spatially-specific therapeutic target 
within the mitochondrial subpopulations. 
 Working Hypothesis 1:  We hypothesize that there will be an increase in oxidative 
stress and damage resulting in diminished mitochondrial membrane integrity 
accompanied by overall mitochondrial dysfunction in both diabetic mitochondrial 
subpopulations.  More specifically, we believe that IFM will be more susceptible to 
damage with STZ-induced type 1 DM primarily due to their higher respiratory rates and 
subsequent oxidative environment. Due to the IFMs primary role in ATP production for 
contractile function, we believe the IFM will contribute to diabetic cardiomyopathy-
associated dysfunction to a greater extent than the SSM. 
 
Aim 2: To determine the influence of  a type 2 diabetic phenotype in two distinct  
mitochondrial subpopulations.  To address Aim 2, mitochondrial subpopulations, 
SSM and IFM, will be isolated from a db/db mouse hearts to examine whether they are 
differentially affected with a type 2 diabetic phenotype. 
2.1 Overall subpopulation morphological and functional changes will be observed        
including size,   complexity, lipid profile (cardiolipin) and total electron transport chain 
activities including ATP production.   
 
2.2 Oxidant production and subsequent oxidative damage will be assessed in the 
mitochondria by measuring ROS generation, lipid and protein oxidation. 
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2.3 Distinct proteomic profiles including specific proteomic modifications will be 
examined within the mitochondrial subpopulations with a type 2 diabetic phenotype.  
 
Working Hypothesis 2: We hypothesize that there will be an increase in oxidative 
stress and damage resulting in diminished mitochondrial membrane integrity 
accompanied by overall mitochondrial dysfunction in both type 2 diabetic mitochondrial 
subpopulations.  More specifically, we believe that IFM population will be more 
susceptible with a db/db type 2 diabetic phenotype primarily due to their higher 
respiratory rates and subsequent oxidative environment. Due to the IFMs primary role in 
ATP production for contractile function, we believe IFM will contribute to diabetic 
cardiomyopathy-associated dysfunction to a greater extent than the SSM. 
 
Aim3: To determine whether overexpression of a mitochondrial specific 
therapeutic is protective in mitochondrial subpopulations with a type 1 diabetic 
phenotype. To address Aim 3, a transgenic mouse line overexpressing mPHGPx will 
be employed in an effort to determine whether its presence can be protective with type 
1 diabetes-induced mitochondrial and cardiac contractile dysfunction.  
3.1 Cardiac contractile function will be assessed in type 1 diabetic mPHGPx 
overexpressing mice. 
 
3.2 Overall subpopulation morphological and functional changes will be observed 
including size, complexity, phospholipid content (cardiolipin) and total electron 
transport chain activities including ATP production in type 1 diabetic mPHGPx 
overexpressing animals. 
 
3.3 Oxidant production and subsequent oxidative damage will be assessed through 
measuring ROS generation, and lipid and protein oxidation in mitochondrial 
subpopulations from type 1 diabetic mice with mPHGPx overexpression.  
 
 xxi 
 
3.4 Distinct proteomic profiles including specific proteomic modifications will be 
examined within the mitochondrial subpopulations of type 1 diabetic mice with 
mPHGPx overexpression. 
 
Working Hypothesis 3: We hypothesize that overexpression of mPHGPx will decrease 
oxidative stress and damage with type 1 DM.  More specifically, overall mitochondrial 
structure and function will be protected through preservation of the IMM including 
cardiolipin, a phospholipid critical to membrane integrity and the stabilization of the 
ETC.  Because our preliminary data has suggested that the IFM are at greatest risk for 
oxidative damage associated with DM, protection will be greatest in the IFM and will 
lead to a reduction of diabetic cardiomyopathy-associated contractile dysfunction.   
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1.1 Diabetes Mellitus 
Diabetes Mellitus (DM) is characterized by elevated levels of blood glucose 
resulting from defective insulin production, insulin action or a combination of both.  DM 
can lead to a variety of complications and ultimately death if left untreated.  There are 
several types of DM including type 1, type 2, gestational and DM resulting from genetic 
defects.  Because DM is characterized by persistent hyperglycemia, the following 
criteria are used to diagnose DM (138). 
 
 
The two most common types of DM are type 1 (5-10%) and type 2 (90-95%) DM. 
1.1a Type 1 DM 
 
Type 1 DM, also referred to as insulin-dependent DM (IDDM) or juvenile-onset 
DM, is characterized by loss of insulin-producing beta cells in the pancreas leading to 
diminished insulin production.  Type 1 DM is primarily considered to be immune-
mediated where beta cell loss is due to autoimmune attack (63).  Type 1 DM is usually 
prevalent in children and young adults, although disease onset can occur at any age. In 
Condition 2 hour glucose (mg/dl) Fasting glucose (mg/dl) 
Normal <140 <110 
Impaired fasting glucose <140 ≥110 and <126 
Impaired glucose 
tolerance 
≥140 <126 
Table 1.1 DM characterization (138) 
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adults, type 1 DM accounts for 5 to 10 percent of all diagnosed cases of DM.  The main 
treatment for type 1 DM is monitoring glucose levels and taking artificial insulin 
injections. Diabetic ketoacidosis is a complication that may occur predominantly with 
type 1 DM due to the lack of insulin production and is characterized by high blood 
sugar, acidosis and high ketone body levels causing a low blood pH.  Without treatment, 
diabetic ketoacidosis may be fatal (113).  Risk factors for type 1 DM may be 
autoimmune, genetic, or environmental. No known way to prevent type 1 DM exists. 
Several clinical trials for the prevention of type 1 DM are currently in progress or are 
being planned. 
1.1b Type 2 DM 
Type 2 DM, also referred to as insulin-independent DM (NIDDM), is by far 
majority of all diabetic cases (90-95%).  It is characterized by insulin resistance or 
reduced insulin sensitivity and sometimes diminished insulin secretion.  The insulin 
resistance is believed to be due to a defect or lack of insulin receptors in cell 
membranes.  In the early stages of type 2 DM, reduced insulin sensitivity causes an 
increase in insulin and glucose in the blood and this can be avoided through 
medications that increase insulin sensitivity or decrease glucose production (107).  
However, type 2 DM progresses, often insulin replacement is necessary due to lack of 
insulin production (26). Dyslipidemia is also characteristic with type 2 DM, though may 
be present with the type 1 population, and consists of elevation in triglyceride levels, low 
HDL cholesterol values, and small dense LDL particles. This lipoprotein pattern is 
associated with insulin resistance and is present even before the onset of DM. Small 
dense LDL particles are highly atherogenic because of their enhanced susceptibility to 
oxidative modification and increased uptake by the arterial wall.  Type 2 DM is 
associated with older age, obesity, family history of DM, history of gestational DM, 
impaired glucose metabolism, inactivity and race/ethnicity (CDC, 2007). Type 2 DM can 
often be treatable with diet and exercise as there is a link between obesity, insulin 
resistance and developing type 2 DM (148).  Severe long-term complications can result 
from untreated type 2 DM and uncontrolled type 1 DM including renal failure due to 
diabetic nephropathy, vascular disease (including coronary artery disease), vision 
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damage due to diabetic retinopathy, loss of sensation or pain due to diabetic 
neuropathy, liver damage and heart failure from diabetic cardiomyopathy.  These effects 
are ultimately linked to uncontrolled glucose levels, hyperglycemia, and altered 
substrate metabolism with both type 1 and 2 DM (13). Ultimately, heart failure and 
cardiovascular complications are the leading cause of death amongst diabetic patients 
(6). 
1.1c Significance.   
The increasing prevalence of DM is staggering.  In 2007, it was stated that 23.6 
million of the US population 20 years and older, approximately 7.8 percent of the 
population, have DM.  Approximately 12 million of 11.2% of all men 20 and older have 
DM while 11.5 million of women have it.  It is has been suggested that by the year 2030, 
incidence of DM is suspected to reach over 366 million (141).  It is believed that these 
shocking statistics are mainly due to sedentary lifestyles and poor diets.   
1.1d Race/Ethnicity 
It is important to note that African Americans, Hispanic/Latino Americans, 
American Indians, and some Asian Americans and Native Pacific Islanders are at 
particularly high risk for type 2 DM and its complications.  Further, type 2 DM amongst 
the listed Race/Ethnicities in children and adolescents is also being diagnosed more 
often (141). 
1.1e Cost 
In 2007, it was estimated that total costs (direct and indirect) from DM were 174 
billion dollars.  Direct medical costs were approximately 116 billion dollars, while indirect 
(disability, work loss and premature mortality) were 59 billion dollars.  This emphasizes 
the impact DM has beyond physical well-being (141). 
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1.2 Diabetic Cardiomyopathy 
Coronary Artery disease (CAD) and hypertension play a major role in contributing 
to heart failure in type 2 diabetic patients.  However, with both type 1 and type 2 diabetic 
patients there is a deterioration of heart function termed as diabetic cardiomyopathy 
which is independent of atherosclerosis.   In a clinical setting, Rubler et al. (38) was first 
to acknowledge the existence of a diabetic cardiomyopathy in patients with congestive 
heart failure who had no evidence of coronary atherosclerosis, hypertension, valvular or 
congenital heart diseases.  Regan et al (111) further provided evidence for diabetic 
cardiomyopathy in four adult diabetic patients without coronary artery disease.  These 
patients were found to have increased left ventricle (LV) end diastolic pressure (EDP), 
normal LV end diastolic volume (EDV), decreased LV compliance, and decreased 
ejection fraction. Further epidemiologic studies, the Framingham study (111), also 
revealed an association of a specific cardiomyopathy with DM.  They found that a 2.4-
fold greater incidence of heart failure in diabetic men and a 5.1-fold increase in women.  
These epidemiological studies indicated that diabetic patients can have a greater risk of 
developing heart failure independent of coronary artery disease, hypertension, serum 
cholesterol, and age suggesting that DM might be a cause of dilated cardiomypathy or 
heart failure. 
1.2a Myocardial Lipotoxicity 
It is well-established that type 2 DM is associated with obesity which leads to 
myocardial liptoxicity.  Lipotoxicity can further contribute to cell death and subsequent 
cardiac dysfunction.  Enhanced myocardial tryglcyeride (TG) and cholesterol content 
have been shown in LV biopsies from human type 2 diabetic hearts.  Further, Oil Red O 
staining of heart sections also revealed enhanced lipid deposition in type 2 diabetic 
hearts (10).  An initial increase in myocardial fatty acid (FA) uptake and oxidation has 
been well documented in humans with  both type 1 and type 2 DM, as well as in many 
different animal models (14). Enhanced FA can disrupt the integrity of the plasma and 
mitochondrial membranes by altering phospholipid content.  This in turn can alter key 
signaling cascades as well as proper energy production from the mitochondria (10). 
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1.2b Cell death 
Myocardial biopsies of both type 1 and type 2 diabetic patients with heart failure 
independent of ischemia revealed enhanced apoptosis and necrosis within the heart 
(43).  Increased cardiomyocyte apoptosis has also been described in STZ-induced rats 
(model of type 1 DM) (17) ob/ob and db/db mice (model of type 2 DM) (5).  The 
mechanism of enhanced cell death is not well understood, though it is has been 
suggested ROS-induced damage of mitochondria will induce cytochrome c release 
which inturn, activates the caspase 3 and the mitochondrial driven apoptotic pathway 
(17).  Further, it has been suggested that hyperglycemia induces cell death through a 
Rac 1 mediated increase in NADPH and mitochondrial ROS in both the db/db and STZ 
diabetic mouse hearts (129). 
1.2c Interstital Fibrosis 
Diabetic cardiomyopathy is also characterized by interstitial and perivascular 
fibrosis.  Regan et al. (112) found enhanced collagen deposition around vessels and 
between myofibrils of diabetic patients.  There was an increased accumulation of 
collagen type I and III fibers predominantly in the epicardial and perivascular regions, 
whereas type IV was found in the endocardial layer in human diabetic patients (3).  
Mechanisms of enhanced cardiac fibrosis in the diabetic heart are not entirely 
understood.  One study suggested that TGFB1 receptor II, receptor for TGFB cytokine, 
was enhanced in the diabetic myocardium (4).  Further, fibrosis has also been observed 
in STZ diabetic mice and was associated with enhanced PKCB1 (147).  Interestingly, 
myocardial fibrosis was not found in db/db mice (144).  Ultimately, fibrosis in the heart 
can contributes to cardiac dysfunction the diabetic heart(10). 
1.2d Contractile Dysfunction 
Diastolic dysfunction (DD) is the most prominent defect with diabetic 
cardiomyopathy and it is characterized by a decrease in compliance and slower rates of 
relaxation (128, 156).   Flow and tissue doppler analysis in type 1 and type 2 diabetic 
patients revealed diastolic dysfunction without coronary artery disease (12).  Further DD 
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was also found in animal models of type 2 and type 1 DM including ob/ob, db/db mice, 
ZDF rats and STZ mice (12, 100).  Potential mechanisms contributing to DD include but 
are not limited to, lipid accumulation in the heart and altered calcium handling.  Impaired 
calcium reuptake in ob/ob mice was associated with contractile dysfunction (62).  
Further, reduced contractility in isolated cardiomyocytes from db/db mice were 
associated with enhanced diastolic sarcoplasmic reticulum SR-Ca2+ leak, reduced 
Ca2+ release, and lower peak systolic and diastolic calcium (31, 144).  It has been 
suggested that DD precedes systolic dysfunction (SD). One study using PV loops to 
asses contractile function in STZ mice and Zucker diabetic fatty rats revealed systolic 
dysfunction in both models.  STZ mice showed delayed LV relaxation, while the ZDF 
exhibited enhanced LV stiffness.  Previously, we and others have published showing 
decreased systolic and diastolic function in STZ-induced type 1 diabetic mice through 
reduced rate of contraction and relaxation, and diminished contractility in the heart and 
in isolated cardiomyocytes (28, 128, 131).  Mechanisms of hyperglycemia induced 
cardiac dysfunction include but are not limited to: increased polyol pathway, increased 
advanced glycation end product (AGE) formation, increased protein kinase c isoform 
expression, increased hexosamine pathway flux, altered cardiac metabolism, and 
lipotoxicity which leads to increases in oxidative stress (40, 69, 107, 117).  Below is a 
suggested mechanisms of cardiac dysfunction in the diabetic heart (10). 
 
 
 
 
 
 
 Figure 1.1 Mechanisms that contribute to cardiac dysfunction in the diabetic 
heart(10). 
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1.2e Metabolic Disturbances 
In both the type 1 and type 2 diabetic hearts there is altered substrate utilization 
(2).  A decrease of glucose utilization in the heart leads to an initial enhanced FA 
utilization (149).  Because FA are considered inefficient as substrates, increased FA 
oxidation in diabetic hearts is in combination with an increase in myocardial oxygen 
consumption which leads to reduced cardiac efficiency in rodent models (61) and in 
type 1 and type 2 diabetic patients.  The enhanced FA utilization leads to a decrease in 
ATP which may play a larger role with type 2 DM due to higher overall free fatty acid 
(FFA) levels than in type 1 DM (36).   It has been shown that inhibition of 
hypertriglyceridema in diabetic animals inhibited the development of diabetic 
cardiomyopathy (36).   Elevated FA levels are believed to be one of the major 
contributing factors to the pathogenesis of DM.  Enhanced FFA trigger cell death, 
diminish glucose oxidation, and lead to high oxygen requirements for FFA metabolism. 
This inturn leads to accumulation of toxic FFA intermediates.  These toxic intermediates 
can pool within the mitochondria causing mitochondrial dysfunction and damage (149).  
Oxidative stress caused by these toxic intermediates has been suggested to disrupt 
calcium homeostasis.  Diminished calcium sensitivity and decreased contractile proteins 
may further contribute to LV dysfunction (36). 
1.2f Oxidative Stress 
Oxidative stress, the imbalance between ROS formation and antioxidant 
defense, has been suggested to lead to altered myocyte morphology, function and 
protein content contributing to diabetic cardiomyopathy. Both human and animal studies 
have suggested that increased oxidative stress is associated with an accumulation of 
lipids and FA in the diabetic heart.  Below is a suggested mechanism of FA-induced 
cardiac dysfunction through multiple facets including enhanced oxidative stress (Figure 
1.2) (14). 
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Boudina et al. found that hydrogen peroxide production and subsequent oxidative 
damage to lipids was increased in the db/db model of type 2 DM (11).   Similarly, our lab 
has suggested enhanced superoxide production in STZ-induced type 1 DM (28).  These 
data suggest that in both the type 1 and type 2 diabetic hearts, there is evidence for an 
enhanced oxidative environment within the mitochondria which can disrupt proper 
oxidative phosphorlyation and adequate energy production.  Further, though majority of 
ROS are generated from the mitochondria, other mechanism of ROS generation with 
DM exist such as NADPH oxidase (81).  ROS can interact with nitric oxide (NO) and 
lipids to form nitrotyrosine and lipid hydroperoxides which are detrimental for cells and 
mitochondria (43).  Further, it has also been suggested that hyperglycemia can impair 
and decrease the amount of antioxidants within the diabetic heart making it vulnerable 
to ROS-induced damage.  Epstein et al. has shown that overexpression of antioxidants 
such as metallothionein, MnSOD and catalase in the heart offered protection against 
the development of type 1 diabetic cardiomyopathy (83, 154).   
 
 
Figure 1.2 Mechanisms of Diabetic Cardiomyopathy (14). 
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1.3 Mouse Models of Diabetic Cardiomyopathy 
 Research on rodent models of type 1 and type 2 DM and the use of genetic 
engineering techniques in mice have advanced our understanding of the development 
and progression of human diabetic cardiomyopathy (14).  Rodents model are beneficial 
in studying underlying mechanisms of diabetic cardiomyopathy because they are 
resistant to atherosclerosis (without genetic alterations) which allows examination of 
diabetic cardiomyopathy dysfunction in diabetic models without confounding effects of 
atherosclerosis.  There are many different rodent models of type 1 DM and type 2 DM in 
both rats and mice.  Below is a table (Table 1.2) of multiple rodent models of type 1 and 
type 2 DM and their phenotypes (14). 
 STZ OVE26 Akita ob/ob db/db ZDF 
Cardiac size =  ↓/= ↑ ↑ ↑ 
Cardiac function ↓ ↓ ↓ ↑/↓ ↓ ↓ 
Cardiac efficiency ↓  = ↓ ↓ = 
Mitochondrial energetics ↓ ↓ ↓ ↓ ↓  
Lipid storage ↑   ↑ ↑ ↑ 
Fatty acid oxidation ↑  ↑ ↑ ↑ ↑ 
Glucose oxidation ↓  ↓ ↓ ↓ ↓ 
Ca2+ handling  ↓ ↓ ↓ ↓ ↓ = 
Oxidative stress ↑ ↑  ↑ ↑  
 STZ OVE26 Akita ob/ob db/db ZDF 
 
 
We utilize the STZ model (Type 1 DM) and db/db model (Type 2 DM) for 
experimentation.  STZ is a glucosamine-nitrosourea antibiotic that is similar to the 
structure of glucose and is taken up through GLUT2 glucose transporter in the beta 
cells (high GLUT2 receptors) and causes the akylation of DNA (122). DNA damage 
induces activation of poly ADP-ribosylation which leads to depletion of cellular NAD+ 
and ATP. Enhanced ATP dephosphorylation after STZ administration offers a substrate  
Table 1.2 Cardiac Phenotypes of Rodent Models of Diabetic 
Cardiomyopathy(14). 
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for xanthine oxidase resulting superoxide radical formation.  STZ releases toxic 
amounts of NO that inhibits aconitase activity and contributes to DNA damage.  
Ultimately, beta cells undergo necrosis and insulin production is disrupted.  We utilize 
the STZ protocol established by the Animal Models of Diabetic Complications 
Consortium (AMDCC) which recommends mulitiple low-dose (50mg/kg) injection of STZ 
spread out over 5 consecutive days (www.amdcc.org).  Rodents typically develop 
hyperglycemia 7-14 days post first injection of STZ and show increased serum FAs, 
triglycerides, cholesterol and glucose levels with very low levels of insulin (14). Many 
studies have reported diminished systolic and diastolic function which progresses with 
duration of STZ induced DM.  Nielsen et al. reported decreased rates of circumferential 
shortening and fractional shortening with echocardiographic analyses (95).  Further, 
reduced LV systolic pressure and decreased rates of contraction were also observed 
(68).  DD has been further shown through enhanced LV diastolic pressure and 
abnormal mitral inflow and pulmonary venous flow (139).  We have shown decreases in 
rate of contraction, relaxation and enhanced developed pressure at five weeks post 
hyperglycemia onset (28).   Further, studies have also revealed enhanced oxidative 
stress through both the mitochondria and through NADPH oxidase, in the STZ mouse 
heart.  STZ hearts have also shown changes to calcium handling including disruption of 
mitochondrial calcium energetics (14).  Importantly, STZ-induced diabetic 
cardiomyopathy can be reversed with regular insulin injections emphasizing the lack of 
insulin and glucose utilization being the cause of cardiac abnormalities in these mice not 
the STZ drug itself (145).  The most important advantages of the STZ model are that 
DM can be easily induced in mice and rats at multiple time points (different ages) and 
genetically altered mice can be easily examined with a diabetic phenotype, allowing 
researchers to study specific mechanisms of dysfunction underlying diabetic 
cardiomyopathy in hopes of identifying key targets.  Other models of type 1 DM that are 
commonly used are the Akita mouse and the OVE26 mouse.  They differ from the STZ 
model in that they are genetically engineered mice that are diabetic from birth (TABLE 
2).  Ove26 mouse model was generated in 1989 by Epstein et al (35).  Overexpression 
of the Ca+2 binding protein calmodulin in beta cells led to insulin-deficient DM within the 
first week of life due to beta cell damage.  Ove26 have increased serum TG levels, 
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reduced insulin levels, and are able to live approximately 1 to 2 years.  In the OVE26 
mouse, contractility analysis of isolated cardiomyocytes revealed altered peak 
shortening, prolonged time to peak shortening, prolonged time re-lengthening, and 
reduced maximal velocities of shortening and re-lengthening (33).  However, unlike the 
STZ model, no significant differences in contractile function were found in Langendorff 
perfusions of OVE26 diabetic hearts (83).  Although the OVE26 mouse allows for 
examination of type 1 DM independent of utilizing a potentially toxic drug (STZ), DM 
exists initially at a very early state in postnatal development which  may alter cardiac 
development in a way that does not truly mimic type 1 DM.  The Akita mouse model of 
type 1 DM was more recently discovered by Yoshiolka et al (155).  This mouse 
develops DM due to a single base pair substitution in the INS2 gene resulting in 
improper folding of proinsulin which leads to protein aggregate-induced ER stress in the 
pancreas leading to B-cell destruction (155).  Akita mice develop hyperglycemia at 5 to 
6 weeks of age and have elevated serum fatty acids and triglycerides (15).  In vivo 
analysis of contractile function through echocardiography did not reveal cardiac 
contractile abnormalities (85) in the Akita mouse, suggesting cardiac contractile 
dysfunction is not apparent in this model.  However, FAO rates are enhanced while 
glucose oxidation rates are decreased (15).  Further, mitochondrial dysfunction is 
present including alterations to FAO and OHPHOS proteins (16).   
Several mouse models of type 2 DM exist including ob/ob and db/db mice.  
Ob/ob mice develop DM due to recessive mutations in the obesity gene (ob or Lep).  In 
ob/ob mice, obesity and DM result from leptin deficiency and the inability to suppress 
appetite (42).  By 4 weeks of age, ob/ob mice (C57BL/6) are moderately obese, 
hyperinsulinemic and altered glucose tolerance (13).  By 15 weeks of age, ob/ob mice 
are obese and develop type 2 DM.  Ob/ob mice further develop cardiac hypertrophy but 
have little impairment in systolic function.  Further, in isolated working heart perfusions, 
contractile function is not impaired in the ob/ob mice (14).  Therefore, in our lab we 
utilize db/db mice because we are interested in cardiac abnormalities associated with 
type 2 DM.  Db/db mutations are another model of obesity and type 2 DM that develops 
because of lack of leptin action (24).  Leptin action is impaired in db/db mice due to 
13 
 
dysfunctional leptin receptors.   Insertion of a premature stop codon within the db 
transcript leads to the long form of the leptin receptor being replaced with the short-form 
isoform.  The long form is responsible for leptin action in the hypothalamus to regulate 
appetite and body weight and lack of this form leads to obesity(24).  Db/db mice 
develop severe type 2 DM by 8 weeks of age and have early hyperinsulinemia, 
enhanced fatty acids and triglycerides (13).  Further, contractile abnormalities have 
been observed in db/db (C57BL/Ks) mice.  Db/db mice assessed with echocardiography 
develop cardiac hypertrophy, reduced fractional shortening and velocity of 
circumferential shortening (126).  Further, cardiac output, LV-developed pressure and 
cardiac power are all reduced in isolated, working db/db hearts (14).  Isolated 
langendorff perfused db/db hearts have similar contractile dysfunction as seen through 
decreased rates of contraction, peak systolic pressure, rate pressure product and 
developed pressure (8). Diastolic function is also impaired in db/db mice as assessed 
through echocardiography or MRI analysis (136). Mitochondrial dysfunction has also 
been observed in db/db mice along with enhanced mitochondrial superoxide formation 
and a subsequent increase in oxidative damage by-products (11).  
1.4 Mitochondrial Dysfunction and DM  
There is evidence that mitochondrial dysfunction is associated with type 1 and 
type 2 DM.  Altered substrate utilization, oxidative stress, mitochondrial morphology, 
mitochondrial number and calcium energetics are all altered in the type 1 and 2 diabetic 
setting. Mitochondrial dysfunction encompasses a wealth of mitochondrial defects 
including but not limited to, alterations to mitochondrial bioenergetics, altered 
mitochondrial number and morphology, calcium dysregulation and enhanced oxidative 
stress.  
1.4a Mitochondrial number and morphology  
Utilizing Electron Microscopy (EM), biopsies of skeletal muscle from subjects with 
type 2 DM and obesity revealed mitochondria of smaller size and a decrease in density 
of the mitochondria located beneath the sarcolemma (71, 114).  Type 1 DM is also 
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associated with alterations in mitochondrial morphology. Skeletal muscle mitochondria 
of STZ rats showed a loss of cristae and an increase in lipid droplets surrounding the 
mitochondria (19). Alloxan induced diabetic rats revealed a decrease in mitochondrial 
number in liver and heart, with mitochondrial swelling and disrupted mitochondrial 
membranes and cristae (87).  Further, Epstein et al found swollen mitochondria in the 
hearts from OVE26 mice (131).  A recent study using EM to examine heart mitochondria 
of Akita mice, revealed reduced cristae density and larger mitochondria than the wild-
type (WT) mice (16). On the other hand, the same group (34) revealed that 
mitochondrial number was increased and that mitochondria were smaller in cardiac 
muscle of db/db mice compared with WT.  Interestingly, we have shown decreases in 
size and internal complexity of those mitochondria located along the myofibrils in the 
STZ-induced type 1 diabetic heart.  Taken together, morphologic alterations of the 
mitochondria seem to differ depending on duration and model of DM being examined.  
Variations between the studies are mostly due to differing methods used for 
assessment. 
1.4b Mitochondrial energetics with type 2 DM mellitus  
Studies of type 2 diabetic human subjects and rodents provide evidence for 
deficiencies in oxidative phosphorylation in mitochondria from skeletal muscle. Kelley et 
al. (71) studied mitochondria isolated from human skeletal muscle biopsy specimens 
obtained from type 2 diabetic, obese, and lean individuals. They found reduced NADH 
oxidoreductase and reduced citrate synthase activity in the mitochondria from the 
diabetic and obese patients as compared to lean subjects.  Mitochondrial respiration 
has been also been assessed in human muscle in vivo by using 13C nuclear magnetic 
resonance (NMR) to assess TCA flux rates along with 31P NMR to assess 
phosphorylation of ADP. These studies showed that skeletal muscle oxidative 
phosphorylation was impaired in individuals with type 2 DM.  The authors suggested 
that defects in oxidative phosphorylation were associated with increased 
intramyocellular lipid (110).  Further, Nielsen et al. showed enhanced lipid deposition in 
the sarcolemmal region of the skeletal muscle from type 2 diabetic patients (94).  
Several groups have suggested decreased mRNA expression of several genes 
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associated with oxidative phosphorylation such as genes regulated by PGC-1α (90).  
Examination of protein expression in skeletal muscle from type 2 diabetic patients 
revealed decreases in ATP synthase and creatine kinase B which contribute to overall 
ATP synthesis (56). Mitochondrial dysfunction has also been observed in various rodent 
models of type 2 DM. Boudina et al reported decreased respiration with 
glutamate/malate and palmitoyl-carnitine as substrates in saponin-permeabilized heart 
muscle fibers isolated from db/db mice compared with lean controls (11).  These 
authors also reported decreases in expression of F1 α-subunit of ATP synthase and an 
increase in fatty acid–induced proton leak.  Utilizing a high-fat feeding model, Koves et 
al. (74) showed that high-fat feeding was associated with decreased TCA proteins in 
skeletal muscle and an inability of mitochondria to switch from fat substrate utilization to 
glucose utilization. This suggests that high-fat fed rodents have increased rates of beta-
oxidation but are not capable of dealing with enhanced fatty-acid substrates supply. 
1.4c  Mitochondrial energetics in Type 1 DM  
Early studies with type 1 DM revealed decreased respiration with complex I and  
complex II substrates in liver and skeletal muscle mitochondria isolated from rodents 
made diabetic with STZ (48).  Several studies in rodents suggested that respiration is 
impaired in mitochondria isolated from heart and brain mitochondria (28, 39, 91).  
Recently Bugger et al. examined heart mitochondria of Akita mice and reported 
decreased ATP synthesis and decreased state 3 respiration with complex I substrates 
pyruvate and glutamate, but no differences with a fatty acid substrate, palmitoyl 
carnitine (15).  Sevitz et al reported a decrease in state 3 respiration, ADP/O ratio and 
ATP synthesis rate in mitochondria from heart and gastrocnemius muscle from STZ 
diabetic rats (54).  Interestingly, these findings were more pronounced in 8-week than in 
2-week diabetic rats suggesting the importance of examining multiple time points to truly 
understand the mechanism of pathogenesis with type 1 DM.   In a human study, 
analysis of skeletal muscle mitochondria that were subject to discontinuation of insulin 
treatment resulted in a decrease in ATP production (70).  These studies suggest that 
respiration and subsequent ATP production in skeletal muscle and heart mitochondria 
are dysfunctional in the type 1 diabetic setting.   
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1.4d Calcium Regulation 
Under conditions of high matrix calcium concentrations and enhanced ROS, the 
permeability transition pore (PTP) opens disrupting the IMM function.  This further 
triggers disruption of ionic homeostasis and uncoupling of oxidative phosphorlyation 
which results in cell death (119). Oliveira et al. observed reduced mitochondrial calcium 
uptake and enhanced mitochondrial PTP (mPTP) opening in heart mitochondria from 
STZ-treated rats (99).  PTP opening due to calcium accumulation and enhanced ROS 
has been attributed to structural changes in the IMM lipids which inturn disrupts function 
and structure of the respiratory chain.  Oliveria et al. further reported increased 
sensitivity to calcium-triggered reduction in membrane potential and prevention of this 
with cyclosporine A suggested that this was due to enhanced mPTP opening (99).    
Further, our lab has suggested that the interfibrillar mitochondria had decreased 
membrane potential, enhanced propensity for mPTP opening and enhanced 
cytochrome c release in 10 week old STZ-treated mice (150).  Taken together, these 
studies suggest that DM-induced changes in calcium regulation and ROS may result in 
damage to the IMM and trigger apoptosis. 
1.4e Oxidative Stress 
Enhanced ROS production and oxidative damage have been suggested to play a 
critical role in the pathogenesis of type 1 and type 2 DM.  Many studies have shown that 
elevated glucose and free fatty acids levels present in the diabetic state drive the 
formation of ROS (32, 96, 152).  This inturn, decreases mitochondrial function and 
contributes to many of the complications seen with DM.   It is believed that enhanced 
substrate flux through the mitochondria enhances electron leak and subsequently ROS 
formation. Oxidative stress occurs when ROS are generated in excess through the 
reduction of oxygen and inadequate antioxidant defense. ROS include superoxide 
radicals, hydroxyl radicals, hydrogen peroxide, nitric oxide (NO), and peroxynitrite (151).  
ROS production is also increased with DM due to an increase in circulating FFA causing 
a lipotoxic environment within the mitochondria (149). For example, pooled neutral fatty 
acids within the mitochondria due to the inability to utilize efficiently are more 
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susceptible to oxidative damage.  Oxidative modification to these lipids can initiate 
greater oxidative damage to proteins and lipid constituents within the IMM contributing 
to mitochondrial dysfunction (149).  Excess ROS production can lead to oxidation of 
lipids, DNA, and proteins.  Levels of markers of lipid peroxides, such as 8-iso-
prostaglandin F2α (55), conjugated dienes, and lipid hydroperoxides (88), are increased 
with  type 1 DM while  antioxidant capacity is reduced (88).  Because the IMM is the 
main site of ROS production, it is particularly susceptible to oxidative damage.   An 
increase in superoxide production in the mitochondria has been suggested to directly 
inhibit ETC complex activities causing overall diminished mitochondrial respiration 
(131).  Abel et al. suggested that mitochondrial uncoupling, due to enhanced ROS 
generation and lipid peroxidation by-products, contributed to enhanced oxygen 
consumption without an increased in ATP.  Hence, reduced cardiac efficiency was seen 
in the db/db and ob/ob hearts (11). 
1.5 Mitochondrial Subpopulations 
There are two spatially and biochemically distinct mitochondrial subpopulations 
located within the cardiomyocyte (101).  These two subpopulations are termed 
subsarcolemmal, SSM, and interfibrillar, IFM, mitochondria due to their location within 
the cell.  The SSM mitochondria are located just beneath the cell periphery and are 
more variable in shape than the IFM ranging up to 4 µm in size.  The IFM are densely 
packed between the myofibrils within the contractile apparatus and are smaller but more 
elongated ranging up to 2 µm in length (101, 132).  Below is a representative figure of 
where the mitochondria are located within the cell (Figure 1.3). 
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Through a series of centrifugations and protease digestion, Palmer et al. isolated and 
characterized these two subpopulations of mitochondria from rat cardiac muscle in 1977 
(101).  They determined that specific activities of succinate dehydrogenase and citrate 
synthase were higher in the IFM as compared to SSM and that IFM oxidized all 
substrates 1.5 times faster than the SSM.  Later studies established that the SSM 
possess mainly lamelliform cristae whereas the IFM are mainly tubular or a mixture of 
tubular (rather than flat) and lamelliform cristae (115).  This is important because it is 
suggested with the tubular cristae, there is a decrease in intracristal space which leads 
to a higher concentration of protons within these structures, thus increasing ATP 
synthase activity which enables oxidative phosphorylation (115).  This is in agreement 
with the fact that the IFM have 1.5 fold higher oxidative rates and 3 fold higher ATP 
production.  It has been suggested that the SSM produce ATP primarily for active 
transport of electrolytes and metabolites through sarcolemma, while the IFM produce 
ATP for contractile purposes primarily due to their location within the cell (101). In 
skeletal muscle, protein import rates differ between subpopulations, suggesting import 
of malate dehydrogenase was 3-4 fold higher in the IFM even though Grp75, an import 
protein, was lower in protein expression (137).  It is suggested that import rate is higher 
in the IFM due to the higher respiratory rates, higher membrane potential and elevated 
Figure 1.3 Mitochondrial subpopulations. 
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ATP synthesis.  Adhihetty et al. has also suggested that in skeletal muscle, IFM have a 
greater propensity for oxidant induced apoptosis (1).  However, in heart, Palmer et al. 
suggested the capacity for calcium uptake in SSM was less than that of IFM, leading to 
release of cytochrome C from only SSM (102).  This release is known to involve the 
PTP and occurs prior to apoptosis (75). More recently, it has been observed that the 
SSM are significantly more oxidized and have higher oxygen tension at rest due to their 
closer proximity to the capillaries in skeletal muscle (124).  
Many have observed and suggested that these two spatially-distinct 
subpopulations respond differently with various physiological and pathological stimuli 
including ageing, I/R, exercise, caloric restriction, high fat feeding and heart failure (1, 
20, 27, 28, 37, 66, 71, 73, 77, 78, 114).  With ischemia, it has been suggested that 
injury to both SSM and IFM takes place.  However, ischemia in rabbit heart resulted in 
decreased oxidative phosphorylation (through cytochrome c oxidase) affects only the 
SSM (80).  Further, the longer duration of ischemia, the greater damage to cardiolipin in 
the SSM.   These two subpopulations have also been shown to be differentially affected 
with various cardiomyopathies and heart failure (79).  Hoppel et al. observed decreased 
oxidative phosphorylation (50% reduction) specific to IFM in hearts from hamsters that 
develop cardiomyopathy at four months of age (59).  Utilizing a dog model of heart 
failure, Rosca et al. suggested that both SSM and IFM had a 50% reduction in oxidative 
phosphorylation along with decreased ETC activity (118). With a high fat diet and heart 
failure, there is an upregulation in enzymes involved with fatty acid oxidation in only 
SSM and an increase in state 3 respiration with fatty acid substrates such as palmitoyl 
carnitine (118).  King et al. (73) reported significantly diminished state 3 and state 4 
respiration in both SSM and IFM from STZ-induced rat heart which is in contrast to our 
previous study suggesting only the IFM are affected (28).  Though aging is not 
necessarily a “disease”, it does have profound effects on mitochondria.  In particular, 
mitochondrial subpopulation response with aging has been studied extensively.  With 
aging, it has been suggested that only the IFM have decreased ETC activities, 
particularly at complex III, and elevated Hydrogen peroxide formation accompanied with 
enhanced oxidative damage (58, 66, 77).  These results indicate that mitochondria 
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located in different parts of the cell respond differently with various pathological insults, 
highlighting the importance of taking into account spatial location when evaluating 
mitochondrial dysfunction in cardiac and skeletal muscle. 
1.6 Inner Mitochondrial Membrane (IMM) 
The inner mitochondrial membrane (IMM) is particularly susceptible to ROS-
induced oxidative damage because it is the major source of ROS production.  We and 
others have shown that protein constituents and lipids within the IMM seem to be at risk 
with both type 1 and type 2 diabetic-associated dysfunction. 
1.6a Mitochondrial ROS production 
The ETC is the main site of superoxide generation through electron leakage as 
substrates passing through the ETC (134).  ROS include the superoxide radical, O2·−, hydrogen 
peroxide, H2O2, and the hydroxyl radical, OH·.  At physiologic pH, superoxide dismutates or  is 
catalyzed by superoxide dismutase (SOD) to form H2O2 (41). Superoxide is able to generate the 
more reactive hydroxyl radical through a series of steps dependent on the presence of redox 
metals (ie. Iron, copper). This reaction is termed the fenton reaction.  Iron-sulfur centered 
proteins including electron transport chain proteins and aconitase all can react with hydrogen 
peroxide and increase the formation of hydroxyradicals.  Hydroxyradicals can readily react with 
lipids within the inner mitochondrial membrane and cause disruption of the IMM integrity. 
Mitochondria are the major intracellular site of superoxide production (108).  It 
has been suggested that complex I and III are the major sites of ROS production (108).  
It is important to note that mitochondrial ROS may be generated at other sites as well, 
such as α-ketoglutarate dehydrogenase, and aconitase where conversion of superoxide 
to the hydroxyl radical results in inactivation of the enzyme (45).  Other sources of ROS 
beyond mitochondria do exist and are as follows; oxygen radicals from peroxisomal β-
oxidation of fatty acids, NADPH oxidase, xanthine oxidase, arachidonic acid 
metabolism, and microsomal P-450 enzymes (7, 18). 
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1.6b Cardiolipin 
One phospholipid predominantly within the IMM that is absolutely essential for 
proper mitochondrial function is cardiolipin (CL).  In mammals, CL is localized 
predominantly in the IMM (25% heart IMM, 4-5% heart OM) where it facilitate 
mitochondrial function through a variety of mechanism (30).  CL contains three glycerol 
backbones and four acyl chains (Figure 1.4) resulting in a structure that plays a role in 
proper mitochondrial function.  CL is unique among other phospholipids because its 
diphosphatidylglycerol structure combined with four acyl chains which make it dimeric 
and results in a conical structure (60). 
 
 
 
 
 
 
In mitochondria, CL in necessary for formation of contact sites between inner and 
outer membrane, stabilization of respiratory chain complexes and in the mitochondrial 
apoptotic signaling pathway (60).  The abundance of unsaturated double bonds makes 
CL molecules more susceptible to ROS induced damage and this inturn, can precipitate 
further damage (60).  The essential role of CL in mitochondrial function and cardiac 
function has been understood through understanding genetic basis of barth syndrome.  
Barth syndrome patients have mutations in an X-linked gene, tafazzin, which induces 
alterations in CL metabolism.  This inturn causes mitochondrial dysfunction and 
ultimately result in a dilated-cardiomyopathy.  Tafazzin is the only enzyme that has been 
Figure 1.5 Cardiolipin Structure. 
lipidlibrary.aocs.org/Lipids/dpg/index.htm 
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proven to be involved in CL acyl chain remodeling in vivo (53, 121, 146).  CL has been 
shown to interact with multiple IMM proteins including the ETC complexes that are 
involved in OXPHOS (120).  CL is required for optimal activity of complex I (NADH 
ubiquinone oxidoreductase) (44), complex III (ubiquinone cytochrome c oxidoreductase) 
(44, 76), complex IV (cytochrome c oxidase) (125) and complex V (ATP synthase) (44).  
CL also allows the association and stabilization of “supercomplexes” (157).  
Supercomplex formation is thought to improve stabilization of respiratory chain 
complexes by abolishing the need for movement of substrates and products between 
complexes.  CL is also required for proper activity and function of IMM carriers such as 
adenine nucleotide translocator, and carnitine-acylcarnitine, citrate, phosphate and 
pyruvate carriers (97).  CL has also been suggested to play a role protein import into the 
mitochondria (60). However, it is not clearly understood how CL contributes to proper 
function of these carriers.  It is thought that CL stabilizes the protein domain through a 
clamp-like manner with its two negatively charged head groups.  Further, CL is 
suggested to function as a proton trap, restricting pumped protons within its polar head 
and subsequently providing structural basis for IMM potential and contributing protons 
for the ATP synthase (50). 
Cardiolipin modulation has been observed in a number of pathologies including 
ischemia/reperfusion, aging and DM (22, 52, 103-106).  These changes to CL include: 
loss of CL content, changes in CL synthase activity, changes in acyl chain composition, 
and CL peroxidation.  Han et al. (52) found depletion of the most predominant species 
of CL as well as remodeling of the remaining cardiolipin species in diabetic myocardium.  
Further, CL alterations occur as early as 5 days post STZ injection suggesting a 
potential contributor to the dysfunction observed in the type 1 diabetic heart including 
mitochondrial dysfunction (52). 
1.6c Mitochondrial Proteome 
Several studies have shown that mitochondrial proteomes seen to be 
preferentially altered in the diabetic heart (16, 51, 67, 131, 140).  Utilizing isotope 
labeling and two-dimensional gel electrophoresis, Turko et al. revealed up-regulation of 
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fatty acid beta-oxidation proteins and down-regulation of several key ETC proteins.  
Further, they also examined decreases in VDAC-1, HSP60 and GRP75 in the STZ-
induced type 1 diabetic rat hearts (140).  Utilizing the same model of type 1 DM (STZ), 
Hamblin et al. found that 12/24 proteins in the LV identified as changing were 
mitochondrial proteins.  Similar to Turko et al., FAO proteins were upregulated in the 
diabetic heart while TCA cycle and glycolytic proteins were down-regulated in the 
diabetic heart (51).  In another model of type 1 DM (OVE26), Shen et al. revealed 12 
out 20 proteins changing to be mitochondrial proteins.  In contrast to the previous 
studies, majority of mitochondrial proteins, including ATP synthase subunits, were up 
regulated in the OVE26 heart (131).  Using a label-free approach, Bugger et al. utilized 
the Akita mouse model of type 1 DM and assessed proteomic alterations in 
mitochondria from kidney, heart, liver and brain (16).  This study revealed that majority 
of proteins changing were in the liver, with little significant changes in the heart.  These 
differences may be due to differences in the animal models that were used, differing 
proteomic approaches and shen et al. and Hamblin et al. used heart tissue while Turko 
et al. and Bugger et al. examined isolated mitochondria.  Nevertheless, all of these 
studies examined modulation of the mitochondrial proteome with DM.  Interestingly, no 
proteomic study has revealed changes in mitochondrial-encoded proteins, only nuclear 
encoded proteins.  Downregulation of nuclear encoded mitochondrial proteins can be 
through several different mechanisms including: alterations in mitochondrial protein 
import, miRNA upregulation, transcriptional dysregulation or post-translational 
modifications that target nuclear-encoded proteins for degradation.  Mitochondrial 
protein dysregulation can ultimately contribute to overall mitochondrial dysfunction, 
disruption of oxidative phosphorylation and other key mitochondrial processes. An 
oxidative environment can often lead to enhanced post-translational modification (PTM) 
to proteins including oxidations and deamidations (23).  Though the contribution of 
deamidation and oxidation to protein dysfunction is somewhat unclear, these PTMs may 
alter protein structure/function making the protein more susceptible for degradation by 
the proteasome system (65, 116).   Oxidative conditions have also been considered as 
a way through which proteins become more susceptible to deamidation.  Though the 
underlying mechanism is not for certain, the evidence suggests that oxidative conditions 
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may induce an increased flexibility of the polypeptide backbone or unfolding of the 
proteins, allowing for deamidation (23).  Moreover, UV irradiation which causes 
increased ROS formation, lead to an increased protein deamidation in cultured cells 
(23) 
1.7 Antioxidant Defense 
Mitochondria have several mechanisms of defense against enhanced oxidative 
stress (47). One mechanism is uncoupling of the mitochondria which would reduce 
superoxide generation by decreasing mitochondrial membrane potential (135).  
However, this is achieved by decreasing oxidative phosphorylation and subsequent 
ATP production. In addition to this, there are multiple enzymatic reactions that decrease 
enhanced ROS generation.   These enzymatic reactions include: dismutation of 
superoxide to H2O2 by manganese superoxide dismutase (MnSOD) and scavenging of 
H2O2 by catalase, glutathione peroxidases (GPX), or peroxiredoxins (47).  
Peroxiredoxins are a group of antioxidant enzymes that reduce hydrogen peroxide and 
alkyl hydroperoxides with reducing equivalents provided through the thioredoxin system.  
Peroxiredoxins can exist in the mitochondria, cytoplasm and peroxisome.  Prdx3 and 
prdx5 are both found in the mitochondria (133).  
 
1.6a MnSOD 
MnSOD (SOD2) is also a mitochondrial targeted antioxidant that catalyzes the 
dismutation of superoxide into oxygen and hydrogen peroxide.  The SOD-catalysed 
dismutation of superoxide may be written with the following half-reactions: 
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M(n+1)+ − SOD + O2− → Mn+ − SOD + O2 
Mn+ − SOD + O2− + 2H+ → M(n+1)+ − SOD + H2O2 
 
 
Mice lacking SOD2 die several days after birth most likely due to enhanced oxidative 
stress (82).   Mice lacking SOD1 develop a hepatocellular carcinoma, enhanced age-
related muscle mass loss, increased cataract formation and a decreased lifespan (34, 
93).  Knockout mice of any of the SOD enzyme are more susceptible to ROS-induced 
damage by oxidant supplementation (127).  Shen et al. found that overexpression of 
MnSOD in the OVE26 model of type 1 DM provided protection in the heart through 
improving mitochondrial respiration, mitochondrial mass and preserving cardiomyocyte 
contractility (130).  However, overexpression of MnSOD did not completely restore 
respiratory capacity in mitochondria from the OVE26 hearts and overexpression altered 
expression of other antioxidant enzymes (130). 
1.6b Glutathione Peroxidases 
Glutathione peroxidases are enzymes that posses peroxidase activity whose 
main biological role is to protect the cell from oxidative stress and oxidative damage. 
There are several isozymes encoded by different genes, which vary in different cellular 
locations and have different substrates.  Mammalian GPx1-4 are all selenoproteins, 
whereas GPx6 is a selenoprotein in humans with cysteine-containing homologues in 
rodents.  GPx1-3 are homotetrameric proteins, and catalyze the reduction of hydrogen 
peroxide and organic hydroperoxides, whereas GPx4 has a monomeric structure and 
directly reduces phospholipid and cholesterol hydroperoxides.  GPx4 is also involved in 
sperm maturation and male fertility due to its role in the sperm motility (84, 142) .  The 
presence of selenium is necessary for the antioxidant properties of glutathione 
Figure 1.6 SOD-catalyzed dismutation of superoxide 
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peroxidase.  The mechanism of action of these selenoproteins is at the selenocysteine 
site, which is in a Se (-) form as resting state. This is oxidized by the peroxide to SeOH 
which is then trapped by a GSH molecule to Se-SG and by another GSH molecule to 
Se (-) again, releasing a GS-SG by-product.  Glutathione peroxidase 1 (GPx1) is the 
most abundant GPx and it is found in the cytoplasm and mitochondria of mammalian 
tissues, and the substrate is hydrogen peroxide (84). 
An example reaction that glutathione peroxidase catalyzes is: 
2GSH + H2O2 → GS–SG + 2H2O 
*GSH represents reduced monomeric glutathione 
*GS–SG represents glutathione disulfide. 
Glutathione reductase then reduces the oxidized glutathione to 
complete the cycle: 
GS–SG + NADPH + H+ → 2 GSH + NADP+ 
 
 
Transgenic mice overexpressing Gpx1  were more resistant to paraquat and other 
oxidant induced stressors (21).  Though many studies suggest protection with increased 
levels of GPx1, one study suggested that transgenic overexpression of GPx1 lead to 
insulin resistance and obesity (89).  These authors found that GPx1 tg mice developed 
hyperglycemia, hyperinsulinemia, and elevated plasma leptin levels.  They also 
exhibited reduced phosphorylation of Akt after insulin stimulation.  It was suggested that 
GPX1 activity may interrupt with insulin function and signaling by depleting ROS in the 
cytosol which is necessary for insulin signaling (89).  
1.6c Glutathione Peroxidase 4 
Glutathione peroxidase 4 (GPx4), also referred to as phgpx, has a high 
preference for lipid hydroperoxides and is expressed in all cell types.  It has several 
forms including mitochondrial, cytoplasmic and nuclear.  However, GPx4 is found in 
Figure 1.7 Glutathione peroxidase mechanism of action. 
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much lower levels than other GPxs with the exception of being highly expressed in the 
testes.  Glutathione peroxidase 4 is the only antioxidant that is capable of reducing lipid 
hydroperoxides to alcohols and to reduce free hydrogen peroxide to water (84, 143).  
Similar to other GPxs, the selenoalate anion is most likely oxidized by a hydroperoxide 
to selenenic acid and then reduced in its active state with two molecules of GSH, 
involving a selenadisulfide step.  Normally, GSSG (oxidized GSH) is recycled by 
glutathione reductase (GR) at the expense of NADPH/H+ (Fig. 7A) (143).  However, at 
low GSH levels (Fig. 7B), Gpx4 is the only Gpx that can convert into a protein thiol 
peroxidase and introduces disulfide bridges into proteins.  If free thiols are no longer 
available, GPX4 may also become cross-linked through selenenylsulfide bridges (*) or 
disulfide bridges to other proteins. 
 
  
 
 
As stated earlier, Gpx4 has three forms; mitochondrial, cytoplasmic and nuclear.  
Studies found that the nuclear form was expressed from its own promoter located 
upstream from the alternative exon (86, 92), where alternative transcription initiation at 
exon 1 determines if the longer (mitochondrial) form or the shorter (cytosolic) form is 
expressed.  Many studies have shown that cytosolic  Gpx4 is expressed in most tissues 
Figure 1.8 Glutathione peroxidase 4 catalysis. 
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whereas the nuclear form is mostly in the testis (123).  Further, the mitochondrial Gpx4 
is mostly found in the testes as well (87).  In converse to Gpx1, Gpx4-knockout mice die 
at embryonic stage (E7.5) indicating that Gpx4 is a very important and an essential 
selenoprotein (64, 153).   A constitutive knockout of Gpx4, Gpx4+/-, suggested that lung 
fibroblasts with one Gpx4 allele were more susceptible to hydrogen peroxide, cadmium 
and cumene hydroperoxide (46).  On the other hand, several transgenic models have 
been generated which overexpress Gpx4 including one model from our lab.  Mice 
overexpressing human Gpx4 are more resistant to diquat-induced liver damage through 
preservation of ATP and diminished oxidative damage (109).  Utilizing the same tg 
animal, Ran et al. also suggested that overexpression of Gpx4 provided protection 
against oxidative stress-induced apoptosis as well as attenuated plaque formation in 
ApoE deficient mice (49).  Transgene expression was approximately 3 fold higher than 
the endogenous Gpx4 level, and it was expressed in multiple compartments including 
mitochondria, cytosol, nuclei and microsome.  All of these reports in mice are in 
agreement with numerous cell culture studies showing Gpx4 protects cells against 
apoptosis, oxidants, DNA-damaging agents, and glucose depletion (25).   In contrast, 
we have generated a transgenic mouse line in which Gpx4 is targeted specifically to the 
mitochondria and at a much higher expression relative to previous Gpx4 constructs 
(109), enabling us to determine the influence of mitochondrial-specific overexpression of 
this enzyme (29).  Our lab has suggested that overexpression of mitochondrial Gpx4 
(mPHGPx) preserves cardiac contractile and mitochondrial function following I/R (29).  
Transgenic overexpression of mPHPGx also attenuated accumulation of lipid 
peroxidation by-products and preserves mitochondrial function in both subpopulations of 
mitochondria following I/R (29).  MPHGPx is an enzyme specific to the IMM, and it 
scavenges phospholipid hydroperoxides including cardiolipin hydroperoxide in an 
attempt to preserve mitochondrial inner membrane integrity (9, 57, 98). Removal of 
cardiolipin from the mitochondria disrupts mitochondrial function emphasizing that it is 
absolutely essential for proper mitochondrial function. As stated earlier, cardiolipin is 
located predominantly within the IMM where it interacts with a large number of 
mitochondrial proteins.  Interaction effects functional activation of enzymes, especially 
those within the ETC (72).   Cardiolipin has been identified as an integral component of 
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mitochondrial complex III, complex IV and the ADP-ATP-carrier (ANT), and it is known 
to be essential for the stability of the structure of ANT. Removal of cardiolipin breaks up 
the ETC complexes and decreases functionality of the IMM (72).  Thus, the ability to 
preserve such a phospholipid within the IMM with overexpression of mPHGPx may be a 
critical component in providing mitochondrial protection.  Hence, our goal is to elucidate 
a possible mechanism of protection with DM utilizing our mitochondrial specific PHGPx 
overexpressing mouse.   
1.8 Summary 
One in three Americans born after 2000 will develop DM in their lifetime. These 
statistics are shocking and implicate the necessity for possible diabetic therapeutic 
strategies.  Mitochondrial dysfunction and an enhanced oxidative milieu seem to be 
underlying contributors to the pathogenesis of diabetic cardiomyopathy. Our ultimate 
goal is to determine whether mitochondria located in different parts of the cell are 
impacted differentially with DM in hopes of elucidating potential mechanisms involved in 
mitochondrial dysfunction.  Further, mPHGPx transgenic overexpression should 
contribute to our understanding of the role played by this enzyme during type 1 DM, 
opening its door as a potential mitochondrially-driven therapeutic.   
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ABSTRACT 
 
Cardiomyopathy is the leading cause of heart failure among diabetic patients, 
and mitochondrial dysfunction has been implicated as an underlying cause in the 
pathogenesis. Cardiac mitochondria consist of two spatially, functionally, and 
morphologically distinct subpopulations, termed subsarcolemmal mitochondria (SSM) 
and interfibrillar mitochondria (IFM). SSM are situated beneath the plasma membrane, 
whereas IFM are embedded between myofibrils. The goal of this study was to 
determine whether spatially distinct cardiac mitochondrial subpopulations respond 
differently to a diabetic phenotype. Swiss-Webster mice were subjected to 
intraperitoneal injections of streptozotocin or citrate saline vehicle. Five weeks after 
injections, diabetic hearts displayed decreased rates of contraction, relaxation, and left 
ventricular developed pressures (P<0.05 for all three). Both mitochondrial size (forward 
scatter, P<0.01) and complexity (side scatter<0.01) were decreased in diabetic IFM but 
not diabetic SSM. Electron transport chain complex II respiration was decreased in 
diabetic SSM (P<0.05) and diabetic IFM (P < 0.01), with the decrease being greater in 
IFM. Furthermore, IFM complex I respiration and complex III activity were decreased 
with diabetes (P<0.01) but were unchanged in SSM. Superoxide production was 
increased only in diabetic IFM (P<0.01). Oxidative damage to proteins and lipids, 
indexed through nitrotyrosine residues and lipid peroxidation, were higher in diabetic 
IFM (P<0.05 and P<0.01, respectively). The mitochondria-specific phospholipid 
cardiolipin was decreased in diabetic IFM (P<0.01) but not SSM. These results indicate 
that diabetes mellitus imposes a greater stress on the IFM subpopulation, which is 
associated, in part, with increased superoxide generation and oxidative damage, 
resulting in morphological and functional abnormalities that may contribute to the 
pathogenesis of diabetic cardiomyopathy 
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INTRODUCTION 
 
Diabetic cardiomyopathy has been implicated as a primary cause of heart failure 
among diabetic patients and it is thought to occur independent of vascular pathogenesis 
(22, 27, 39, 52, 63).  The hyperglycemic environment presented by diabetes mellitus 
leads to enhanced reactive oxygen species (ROS) generation and though many 
potential sources of ROS exist, the mitochondrion is considered to be the primary site 
(6, 8, 15, 28, 50).  Several sites in the electron transport chain (ETC) are particularly 
prone to the formation of ROS and include oxidizable electron carriers in the inner 
mitochondrial membrane (12, 32).  This has implications for ETC proteins because a 
major constituent of these structures is their iron-sulphur centers (39), which can react 
with ROS such as superoxide (O2•-) or hydrogen peroxide (H2O2) and produce the 
highly reactive hydroxyl radical (•OH) (14).  Increased mitochondrial ROS production 
has been linked to mitochondrial dysfunction (13, 50, 51, 53, 54) which can in turn alter 
the integrity of the inner mitochondrial membrane, facilitating further dysfunction in the 
mitochondria.   In particular, proteins and lipids within the mitochondria are critical 
targets of elevated ROS production, and their oxidative modification potentiates 
mitochondrial dysfunction, by limiting adequate production of ATP.  One potential target 
of mitochondrial dysfunction is the mitochondrial-specific phospholipid, cardiolipin.  
Cardiolipin is a diphosphatidylglycerol enriched in the inner membrane, containing 
oxidatively-sensitive acyl groups that may act as selective targets for ROS (33, 34, 46).  
Cardiolipin interacts with a number of mitochondrial proteins including F0F1-ATPase, 
ANT, cytochrome C, and ETC complexes I, III, and IV, and its oxidative modification 
may be a critical event for apoptosis initiation (23).   
The cardiac myocyte contains two distinct mitochondrial subpopulations that are 
characterized by their spatial arrangement within the cell.  These two disparate 
populations have been termed subsarcolemmal mitochondria (SSM) and interfibrillar 
mitochondria (IFM) due to their subcellular locations which either abut the sarcolemma 
or situate between the contractile apparatus (44, 49).  In addition to spatial differences, 
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mitochondrial subpopulations differ in structure, size, ATP levels, protein import rates, 
substrate utilization, and other biochemical properties (1, 21, 26, 28, 31, 34, 38, 44).  
Morphologically, IFM are smaller, more compact and possess functionally greater 
respiratory rates, supplying ATP mainly for contractile function.  SSM are larger, more 
variable in shape, producing ATP primarily for electrolyte and protein transport across 
the plasma membrane (44).  The two mitochondrial subpopulations respond differently 
to physiological stimuli, including exercise, aging, obesity, fasting, apoptotic initiators, 
and ischemia/reperfusion (I/R) injury (1, 31, 34, 38, 48, 57).   Decreased ETC function 
and elevated oxidative stress has been reported in SSM following myocardial I/R, with 
no difference observed in the IFM (33).  Using electron microscopy, Kelley et al. 
observed decreased IFM size in skeletal muscle of type 2 diabetic patients, which was 
not observed in SSM (28).  Others have observed decreased IFM ETC function with 
aging (21, 26).  These findings indicate that though mitochondria are similar in their 
central role in cellular function, spatially distinct populations are influenced by 
pathological states differently, requiring careful examination of individual mitochondrial 
subpopulations. 
Because much of the previous work examining the impact of diabetes mellitus on 
mitochondrial disposition has been performed on total mitochondria, it is difficult to 
assess the impact of the pathology on spatially distinct mitochondrial populations.  The 
goal of this study was to determine the differential response of individual mitochondrial 
subpopulations subjected to a diabetic phenotype, to further our understanding of their 
specific contribution to the pathogenesis of diabetic cardiomyopathy.  Our results 
indicate that the IFM subpopulation is affected by diabetes mellitus to a greater extent 
than SSM as reflected by greater morphological changes, elevated ROS, and enhanced 
oxidative damage.  This study is the first to determine the spatial influence of the 
diabetic phenotype on cardiac mitochondrial dysfunction.  
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MATERIALS AND METHODS 
Experimental Animals and Diabetes Induction 
The animal experiments in this study conformed to the National Institutes of 
Health (NIH) guidelines for the care and use of laboratory animals and were approved 
by the West Virginia University Animal Care and Use Committee (WVU-ACUC).  
Female Swiss Webster mice (Harlan, Indianapolis, IN), were housed in the West 
Virginia University Health Sciences Center animal facility.  Mice were given unlimited 
access to a rodent diet and water.  Diabetes was induced in eight week old mice 
following the protocol of the Animal Models of Diabetic Complications Consortium 
(AMDCC), using multiple low-dose streptozotocin (STZ; Sigma, St. Louis, MO) 
injections.  A multiple low-dose STZ protocol was chosen, because previous reports 
indicate that this model limits the body weight losses associated with diabetic protocols 
(24, 29).  Injections of 50 mg/kg body weight STZ dissolved in sodium citrate buffer (pH 
4.5), were performed daily for five consecutive days following six hours of fasting.  Mice 
that served as vehicle controls were given the same volume per body weight of sodium 
citrate buffer.  One week post injection, hyperglycemia was confirmed by measuring 
urinary glucose (Chemstrip 2GP Urine test strips, Roche Diagnostics, Indianapolis, IN), 
where >2000 mg/dL was considered diabetic.  To confirm the diabetic phenotype 
urinary glucose levels were monitored weekly using a DiaScreen 50 Urine Chemistry 
Analyzer (Arkray, Edina, MN), and DiaScreen 10 reagent strips.  Five weeks post 
hyperglycemia onset, animals were sacrificed for further experimentation.   
 
Cardiac Contractile Function 
Hearts from diabetic and control animals were isolated and transferred to a 
Langendorff set-up for contractile studies as previously described (19, 20, 59).  In brief, 
hearts were removed from anesthetized mice, and immersed in cold cardioplegic 
solution.  After cannulation of the aorta on a luer stub, hearts were perfused retrograde 
at 37C with a modified Krebs-Henseleit buffer (in mmol/L:  0.5 pyruvate, 0.4 caprylic 
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acid, 118 NaCl, 4.7 KCl, 2.25 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 25 NaHCO3, 0.5 
Na2EDTA, 5.5 glucose) that was subject to oxygenation.  A small fluid-filled balloon was 
inserted into the left ventricular (LV) cavity and coupled to a pressure transducer (Argon 
Medical Devices, Athens, TX).  The balloon was inflated until the end-diastolic pressure 
reached 10 mmHg.  Platinum wires were placed on the surface of the right atrium and 
used to pace the heart at 420 beats/min (7 Hz) with increasing voltage until the heart 
rate was consistent (captured).  During this time period, hearts remained submerged in 
a 37C jacketed chamber, and a heat lamp attached to a variable AC transformer was 
utilized to maintain temperature which was monitored by a needle temperature probe 
inserted just prior to the luer cannula (Physitemp, Clifton, NJ).  Hearts were perfused for 
15 minutes to achieve a stable cardiac function, and then followed for an additional 45 
minutes yielding a total protocol time of 1 hour.  During this time, digitized recordings of 
the LV pressure and its first derivative, as well as heart rate were captured on an IBM-
compatible PC using ChartPro software (AD Instruments, Colorado Springs, CO).  LV 
peak systolic pressure (PSP), developed pressure (DP), maximum speed of contraction 
(+dP/dt), and maximum speed of relaxation (-dP/dt) were analyzed from the recordings 
using ChartPro software. 
 
Preparation of Individual Mitochondrial Subpopulations 
Five weeks following hyperglycemia onset, animals were sacrificed and hearts 
removed.  Hearts were rinsed in phosphate buffered saline (PBS, pH 7.4), then blotted 
dry and weighed.  Subsarcolemmal mitochondria (SSM) and interfibrillar mitochondria 
(IFM) were isolated on ice following the methods of Palmer et al. with minor 
modifications (44).  Briefly, the ventricles were minced and homogenized 1:10 (w/v) in 
cold Chappel-Perry buffer (in mmol/L: 100 KCl, 40 Tris HCl, 10 Tris-Base, 5 MgCl2, 1 
ATP, 1 EDTA, pH 7.4).  The homogenates were than centrifuged at 800 x g for 10 
minutes. The supernatant was extracted and centrifuged again at 9,000 x g to isolate 
the SSM.  The SSM pellet was washed and centrifuged two more times at 9,000 x g and 
once more at 5,000 x g to obtain a clean SSM fraction.  The remaining pellet from the 
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800 x g spin was resuspended in Buffer 2 (in mmol/L: 100 KCl, 5 MgSO4, 5 EGTA, 50 
Tris HCl, pH 7.4) and exposed to 5 mg/kg of trypsin for 10 minutes (49).  After 10 
minutes, the IFM pellet was diluted two-fold with buffer and spun down at 5,000 x g for 5 
minutes.  The supernatant was discarded and the pellet was resuspended in buffer and 
spun down at 800 x g for 10 minutes.  The supernatant was saved and the pellet 
resuspended and spun down again at 800 x g for 10 minutes to maximize IFM yield.  
Next, supernatants were combined and spun down at 9,000 x g to yield the IFM.  IFM 
were washed several times and spun down at a final spin of 5,000 x g for 10 minutes.  
Pellets were resuspended in a sucrose buffer (in mmol/L: 220 sucrose, 70 mannitol, 10 
Tris HCl, 1 EDTA, pH 7.4) and protein concentrations were determined using the 
Bradford method and bovine serum albumin as a standard (4).  Superoxide (O2•-) 
production, oxygen consumption, nitrotyrosine protein and lipid peroxidation were 
assessed on freshly isolated subfractions. 
 
Mitochondria Size and Internal Complexity 
To index mitochondrial subpopulation size and complexity, we performed flow 
cytometry analyses using a FACS Calibur equipped with a 15 mw 488 nm argon laser 
and 633 red diode laser (Becton and Dickinson, San Jose, CA, USA) as previously 
described (8, 9).  Each individual parameter (gating, size, and complexity) was 
performed using specific light sources (laser, photomultiplier tube) and specific 
detectors.  MitoTracker Deep Red 633 (Invitrogen, Carlsbad, CA) which moves into 
intact mitochondria due to membrane potential, was used to selectively stain intact 
mitochondria (EM: 633 nm; fluorescent 633 red diode laser) and exclude debris which 
contains no membrane potential, enabling accurate gating (R1) of the mitochondria.  
Once the gating parameters were established, gated events (20,000 per sample) were 
subsequently examined using the forward scatter detector (FSC; 488 nm argon laser 
and diode detector) and side scatter detector (SSC; photomultiplier tube and 90° 
collection lens) and represented in FSC vs. SSC density plots.  Geometric mean 
(arbitrary units, AU) representing FSC (logarithmic scale) was used as an indicator of 
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size while values from SSC (logarithmic scale) were used to indicate complexity in the 
subpopulations.  Though the FSC arbitrary unit is proportional to the individual 
mitochondria particle size, the absolute value still remains an arbitrary unit.  Thus, to 
confirm the absolute mitochondria size, we utilized a flow cytometry size calibration kit 
(Invitrogen, Carlsbad, CA) which utilizes a set of microsphere suspensions (0.5 µm – 6 
µm) to serve as reliable size references for flow cytometric analyses.   All flow 
cytometric measurements were performed under the supervision of the West Virginia 
University Flow Cytometry Core Facility. 
 
Mitochondrial Cardiolipin Content  
Cardiolipin was determined as previously described (16).  Briefly, isolated 
mitochondrial subpopulations (200 µg) were incubated with a synthetic phospholipid 
1,1’,2,2’- tetramyristoylcardiolipin (T14:0 CL; Avanti Polar Lipids, Alabaster, AL) that 
served as an internal standard.  Total lipids, including the internal standard, were 
extracted using the method of Bligh and Dyer (3).  Briefly, MeOH/H2O and chloroform 
were added to the sample, mixed, and then centrifuged at approximately 200 x g for 10 
minutes.  The chloroform layer was extracted from each sample then dried under a 
nitrogen stream.  Each sample was resuspended in 4 mL of chloroform:MeOH (1:1) and 
washed with 1.8 mL of 20 mM LiCl aqueous solution.  The organic layer was dried 
under a nitrogen stream and the residue resuspended in 1 mL of chloroform and then 
filtered through a 0.2 µm PTFE syringe filter into a 5 mL glass centrifuge tube.  The 
filtrate was filtered a second time with a 0.2 µm PTFE syringe filter and then dried under 
a nitrogen stream.  Samples were resuspended in 500 µL/mg protein in 
chloroform/MeOH (1:1) and diluted further before injection into the mass spectrometer.  
LiOH (50 nmol/mg of protein) was added to each sample just prior to analysis.   
Cardiolipin detection was performed by electrospray ionization mass 
spectrometry (ESI-MS) using a quadrupole ion trap Finnigan LCQ DECA 
(ThermoFisher, Waltham, MA) operated in the negative-ion mode.  Mass spectrometer 
instrument conditions included a spray voltage of 5.2 kV, capillary voltage of -4V, 
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heated capillary temperature of 300 °C, and a sheath gas (N2) flow rate of 40 arbitrary 
units.  The cardiolipin solution was infused using a 100 µL syringe at a flow rate of 5 µL 
per minute.  Mitochondrial cardiolipin and internal standard spectra were identified in the 
full scan mode.  The peak intensities of cardiolipin:internal standard were estimated 
using single ion monitoring on doubly charged m/z 723 and m/z 619 in both diabetic and 
control mitochondria.  
 
Electron Transport Chain Respiration 
State 4 respiratory capacity was assessed in isolated mitochondrial 
subpopulations following the method of Hofhaus et al. (18), with slight modifications 
(19).  Following mitochondrial subpopulation isolation, samples were resuspended in 
respiration buffer (in mmol/L: 20 Hepes, 10 MgCl2, 250 sucrose) and equal volumes 
were loaded into a Gilson chamber (Gilson, Middleton, WI) attached to a YSI 5300 
biological oxygen monitor (YSI Inc. Yellow Springs, OH).  Respiration through complex 
I, complex III, and complex IV were determined by measuring the rate of oxygen 
consumed in the presence of specific substrates.  These substrates included glutamate/ 
malate for complex I, succinate for complex II and, ascorbate/N, N, N’, N’-tetramethyl-p-
phenylenediamine (TMPD) for complex IV and was calculated as the fraction that was 
sensitive to the specific inhibitors rotenone (complex I), antimycin (complex III), and 
sodium cyanide (complex IV).  Assessment of complex III respiration was performed 
spectrophotometrically as previously described by following the reduction of cytochrome 
c in the presence of reduced decylubiquinone (60).  Protein content was determined 
following the Bradford method as above, and values expressed as nanomoles of O2 
consumed per minute, per mg protein (complex 1, II, IV), or nanomoles substrate per 
minute per mg protein (complex III).   
 
 
 
55 
 
Electron Paramagnetic Resonance (EPR) Spectroscopy 
An EPR spin trapping technique was used to detect short-lived free radicals such 
as hydroxyl (•OH) and superoxide (O2•-) (62). This method is based on the reaction of a 
short-lived radical binding with a paramagnetic compound to form a relatively long-lived 
free radical product (spin adduct).  This adduct can then be observed using conventional 
EPR whereby the intensity of the signal is used to measure the amount of short-lived 
radicals trapped.  The hyperfine couplings of the spin adduct are generally 
characteristics of the original trapped radicals.  This method is ideal for detection and 
identification of free radicals because of its specificity and sensitivity.   All EPR 
measurements were conducted using a Bruker EMX spectrometer (Bruker Instruments 
Inc., Billerica, MA) and a flat cell assembly.  Hyperfine couplings were measured (to 0.1 
G) directly from magnetic field separation using potassium tetraperoxochromate 
(K3CrO8) and 1,1-diphenyl-2-picrylhydrazyl (DPPH) as reference standards (5, 25).  The 
Acquisit program was used for data acquisitions and analyses (Bruker Instruments Inc., 
Billerica, MA 01821).  Isolated heart mitochondria subpopulations were resuspended in 
500 µl of 1 x PBS (pH 7.4).  One hundred µg of each sample was brought up to 200 µL 
with PBS and incubated with the spin trap 5,5-dimethyl-1-pyrroline-N-oxide (DMPO, 200 
mM) in the presence or absence of excess complex I respiratory substrates glutamate 
and malate reaching an end volume of 500 µL.  Samples were incubated for three 
minutes at 37°C and then transferred to an EPR flat cell for measurement at room 
temperature with instrument settings of 63.6 milliwatt, modulation amplitude 1G, 
receiver gain 1.00 X 105, conversion time 40.960 ms, and time constant 40.960 ms.  All 
spectra shown are in accumulation of three scans. The reaction of xanthine and 
xanthine oxidase was used as a reference.  The relative radical concentration was 
estimated by measuring the peak-to-peak height (mm) of the observed spectra. 
 
Protein Nitrotyrosine Content 
Oxidatively- modified proteins were examined by measuring nitrosylated groups 
introduced into protein side chains using a commercially available kit (Cell Sciences, 
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Canton, MA).  Nitrotyrosine-containing proteins were measured using a solid-phase 
enzyme-linked immunosorbent assay based on the sandwich principle.  Samples were 
incubated in microtiter wells coated with antibodies recognizing nitrotyrosine residues.  
Following incubation and washing, a biotinylated secondary antibody (tracer) was 
added, followed by washing and addition of a streptavidin-peroxidase conjugate.  Color 
development was measured spectrophotometrically at 450 nm, following addition of 
tetramethylbenzidine (TMB) using a Biotek Synergy HT plate reader (Biotek, Winooski, 
VT), and values were compared against known nitrotyrosine standards.  
 
Lipid Peroxidation Products 
Peroxidation of lipids was assessed by measurement of malondialdehyde (MDA) 
and 4-hydroxyalkenals (4-HAE), stable end products formed from the oxidation of 
polyunsaturated fatty acids and esters.   Equal volumes of freshly isolated mitochondrial 
subpopulations were analyzed for MDA and 4-HAE by using a colorimetric assay kit 
(Oxford Biomedical Research Company, Oxford, MI).  This assay is based on the 
reaction of a chromogenic reagent, N-methyl-2-phenylindole with MDA and 4-HAE at 
45°C.  One molecule of either MDA or 4-HAE reacts with two molecules of the reagent 
to yield a stable chromophore with maximal absorbance at 586 nm.  Absorbance was 
measured on a Biotek Synergy HT plate reader (Biotek, Winooski, VT), and protein 
content was assessed as above with final values expressed per mg of protein. 
 
Statistics 
Means and standard errors were calculated for all data sets.  Data were analyzed 
with a one-way analysis of variance (ANOVA) method to evaluate the main treatment 
effect, diabetes induction (Systat; version 5.03, Evanston, IL).  Fisher’s Least Significant 
Difference (LSD) post hoc tests were performed to determine the significant differences 
among means.  When appropriate a Student’s T-test was employed.  P<0.05 was 
considered significant. 
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RESULTS 
Cardiac Contractile Function in the Diabetic Heart 
Heart weight, body weight, and heart weight/body weight ratios were not 
significantly altered following STZ treatment (Table 2.1) which is in agreement with 
other studies utilizing multiple low-dose STZ protocols (24, 29).  Analyses of non-fasting 
urinary ketone levels five weeks after the onset of diabetes were negative for diabetic 
animals (data not shown).  Five weeks after the onset of diabetes and hyperglycemia, 
animals were sacrificed and the heart removed for measurement of contractile function 
using a Langendorff perfusion apparatus.  Rates of contraction (+dP/dt) and relaxation 
(-dP/dt), as well as developed pressures (DP) were significantly decreased in diabetic 
vs. control hearts (Table 2.1; P<0.05, for all three), demonstrating decreased contractile 
function.  These data are in agreement with others examining the influence of the 
diabetic phenotype using STZ injection as a model (15, 52, 56, 58). 
 
Mitochondrial Subpopulation Morphology 
 Mitochondrial subpopulations were isolated, and yields were similar between 
control and diabetic hearts (Table 2.1).  To determine morphological differences 
between control and diabetic mitochondrial subpopulations, we used a novel flow 
cytometry approach in which gating was performed to make an accurate estimation of 
mitochondrial size and complexity.  Assessment of forward-scattered light (FSC) was 
used to estimate size, while assessment of side-scattered light (SSC), was used to 
estimate mitochondrial complexity, both of which were based on a logarithmic scale.  
Individual mitochondria subpopulations were stained with MitoTracker Deep Red 633, 
which incorporates into intact mitochondria.  In Figure 2.1A, a typical dot plot, showing 
MitoTracker Deep Red 633 stained mitochondria is shown, with intact mitochondria 
indicated in red and unstained debris indicated in black.  Using this information, we 
gated the mitochondria (R1) to exclude unstained debris, and applied the R1 gate to 
analyses on the individual subpopulations.  These analyses lend insight into relative 
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morphological differences between the two subpopulations, and help to confirm success 
of the isolation procedure.  To confirm differences in absolute mitochondria size, we 
included size calibration beads composed of microsphere suspensions ranging in size 
from 0.5 µm to 6 µm to serve as reliable size references.  Using this approach, SSM 
were larger in size (FSC) and possessed greater internal complexity (SSC) as 
compared to IFM, which were smaller and more compact (Figures 2.1B and 2.1C).  
These results are consistent with previously published reports (28, 48, 49, 55).  
Mitochondrial size was significantly decreased by 35 % (P<0.01) in the diabetic IFM as 
compared to control IFM, while SSM showed no significant changes (Figure 2.1D).  
Mitochondrial complexity in the diabetic IFM was also significantly decreased, by 40 % 
(P<0.01), as compared to control IFM (Figure 2.1E).  No significant differences in SSC 
were observed in the SSM population (Figure 2.1E).  These results indicate that only 
IFM morphology is impacted as a result of STZ-induced diabetic insult. 
 
Electron Transport Chain (ETC) Respiration 
Mitochondrial ETC respiration is altered with hyperglycemia but it is unclear 
whether these alterations are uniform between mitochondrial subpopulations.  We used 
polarography to assess changes in ETC respiration within individual mitochondrial 
subpopulations from diabetic and control hearts.  Complex I, II, and III were significantly 
decreased in diabetic IFM, relative to control (Figure 2.2A and 2.2B, P<0.01, for both; 
Figure 2.2C; P<0.05), while only complex II was significantly decreased in the SSM 
(Figure 2.2B; P<0.05).  No significant changes were observed with complex IV in either 
subpopulation (Figure 2.2D). These data indicate that STZ-induced diabetic insult 
impacts both SSM and IFM, but these effects are greater in IFM. 
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Reactive Oxygen Species (ROS) Production  
 Because the mitochondrion is centrally involved in the formation of ROS, we 
determined whether the diabetic phenotype enhanced ROS formation in a 
subpopulation specific manner.  Mitochondrial subpopulations were incubated with 
complex I substrates glutamate/malate to fuel the ETC, and ROS generation analyzed 
using EPR spectroscopy.  We observed increases in diabetic IFM spin-trapping peaks, 
relative to control IFM (Figure 2.3C, 2.3D, and 2.3H; P<0.01), and these differences 
were not observed in SSM (Figures 2.3A, 2.3B, and 2.3H).  The spin-trapping pattern 
observed was indicative of O2•-, and addition of superoxide dismutase (SOD) confirmed 
the observed spectra as O2•- (Figures 2.3E and 2.3F).  A spectrum for xanthine oxidase, 
a known O2•- generator, is included for spin-trapping pattern comparison (Figure 2.3G).  
These data suggest that ROS generation is significantly increased in the IFM, which 
may be the result of enhanced O2•- production.   
 
Oxidative Damage to Proteins and Lipids 
To determine whether oxidative stress levels are greater in a specific 
mitochondrial subpopulation, we examined protein nitrotyrosine contents, as well as 
levels of lipid peroxidation breakdown products malondialdehyde (MDA) and 4-
hydroxyalkenal (4-HAE), in both mitochondrial subpopulations following diabetic insult.  
Nitrotyrosine content was significantly greater in the diabetic IFM relative to control, and 
no significant difference was observed with the SSM (Figure 2.4, P<0.05).  MDA and 4-
HAE were significantly higher in both diabetic subpopulations as compared to control 
(Figure 2.5, P<0.01 for SSM; P<0.005 for IFM).  These data indicate that STZ-induced 
diabetic insult enhances protein modification, as a result of nitrosylation in diabetic IFM, 
with no significant impact on SSM.   Further, lipid peroxidation is enhanced in both 
mitochondrial subpopulations, but this increase may be greater in diabetic IFM. 
 
 
60 
 
Mitochondrial Cardiolipin Content 
Cardiolipin is a phospholipid unique to the mitochondrial inner membrane that is 
a diphosphatidylglycerol, containing oxidatively-sensitive acyl groups that may act as 
selective targets for ROS.  Depending on pathological state, cardiolipin content within 
mitochondrial subpopulations has been shown to be affected differently (34).  Because 
cardiolipin oxidation is susceptible to ROS (46), we examined whether diabetic 
cardiomyopathy is associated with mitochondrial subpopulation-specific alteration, and 
thus subcellular spatial influence.  Mass spectrometric analyses were performed to 
detect alterations in concentrations of the most abundant cardiolipin molecular species, 
(T18:2 cardiolipin; m/z 723) (15).  Cardiolipin and its internal standard gave both singly- 
and doubly-charged molecules (Figures 6A-D).  Cardiolipin was detected based on its 
doubly-charged signal at m/z 723 and its singly-charged ion at m/z 1447.  The internal 
standard (T14:0 CL) was detected based upon doubly- and singly-charged signals at 
m/z 619 and m/z 1238, respectively.  A ratio of cardiolipin:internal standard was 
calculated by single ion monitoring of both m/z 723 and m/z 619 to determine the 
change in cardiolipin levels between control and diabetic samples.  Using this approach, 
we observed a significant decrease of approximately 60% in diabetic IFM as compared 
to controls (Figures 6C, 6D, and 6E; P<0.01).  In contrast, no significant differences 
were observed in diabetic SSM, as compared to controls (Figure 6A, 6B, and 6E).  
These data indicate that in response to the diabetic phenotype, cardiolipin content is 
significantly decreased in the IFM subpopulation, with no significant change in the SSM. 
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DISCUSSION 
 Diabetes mellitus is associated with a cardiomyopathy that is independent of 
atherosclerosis and characterized by abnormal ventricular contractile function (2, 15, 
22, 27, 52, 63).  Diabetic cardiomyopathy has been shown to progress to heart failure in 
both type 1 and type 2 diabetic models, though at a much higher rate in the type 1 
setting (15, 52).  Using a well described and utilized model of diabetes induction, STZ 
injection, we sought to determine the effect of diabetic insult on cardiac contractile 
function.  STZ treatment had no significant impact on heart weight, body weight, or 
heart weight:body weight ratios (Table 2.1).  In contrast, STZ treatment significantly 
decreased rates of contraction (+dP/dt), rates of relaxation (-dP/dt), and developed 
pressure (DP), as compared to citrate saline-injected controls (Table 2.1).  Our 
observations are in agreement with others who have observed similar cardiac 
contractile deficits  in the diabetic context, characteristic of diabetic cardiomyopathy (2, 
15, 22, 52, 63). 
As the primary source of energy for the cardiac myocyte, mitochondria play a 
central role in cellular homeostasis.  Not surprisingly, disruption of this critical organelle 
is regarded as a key contributor to the development of pathological states, including 
diabetic cardiomyopathy (50, 53, 54).   Nevertheless, examination of mitochondria is 
complicated by the fact that two mitochondrial subpopulations are present in the cardiac 
myocyte, interfibrillar mitochondria (IFM), which situate between the contractile 
apparatus and subsarcolemmal mitochondria (SSM), which exist beneath the plasma 
membrane.  These two disparate mitochondrial subpopulations are distinguished by 
specific spatial arrangements, distinct functional properties, and differential responses 
to pathological conditions.  In general, SSM have been reported to be larger and more 
complex internally, while the IFM tend to be smaller, elongated and densely packed 
between the myofibrils (21, 31, 38, 44).  Using flow cytometric analyses, we observed 
morphological differences between SSM and IFM that were similar to other reports 
utilizing electron microscopy in cells and in isolated mitochondria (Figure 2.1) (44, 49).  
Examination of mitochondrial subpopulations from hearts subjected to STZ-treatment 
revealed decreases in both size and complexity of the IFM population, with no 
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significant effect on the SSM population (Figure 2.1).  Our findings are in agreement 
with those of Ritov et al. who observed decreases in the size of mitochondria located 
along the Z line (presumably reflective of IFM) in the vastus lateralis of type 2 diabetic 
patients (28).  In contrast, Shen et al. observed mitochondrial swelling in a novel model 
of type 1 diabetes (the OVE26 mouse), suggestive of an enhanced apoptotic program 
(54).  These conflicting results may be due to a number of differences between the 
studies.  The OVE26 mouse model utilizes transgenic modification to alter calmodulin 
levels in the pancreatic β cell, precipitating a profound early-onset diabetic phenotype 
(10).  Further, OVE26 transgenic mice are examined at approximately 4 months of age, 
a substantially longer time period of diabetes exposure than our current study of 5 
weeks.  It is possible that mitochondria display a biphasic morphological response 
during diabetic insult, characterized by an initial decrease in size, followed by an 
increase in size.  In addition, examination of the total mitochondria fraction may be 
incapable of resolving the differences between individual mitochondrial subpopulations.  
In either case, these data indicate that mitochondria display changes in overall 
morphology as a result of diabetic insult, and that these changes may be specific for a 
distinct subpopulation. 
 Because of its enhanced propensity for ROS-mediated damage, mitochondrial 
ETC function can be profoundly affected by oxidative stress-associated pathologies, 
including diabetes mellitus.  We have previously observed changes in ETC respiration 
during diabetic insult (8), which is in agreement with other reports (28, 30). Specifically, 
we observed significant decreases in oxygen consumption at both complex I and 
complex III, but not at complex IV (8).  However, examination of the effect of diabetes 
on individual mitochondrial subpopulations revealed a differential response with 
decreased respiratory activity in complex I, II, and III in IFM, while only complex II 
respiration was decreased in SSM (Figure 2.2).  Though not significant, we observed a 
decrease in complex IV respiratory activity of diabetic IFM (Figure 2.2 C).  These results 
are similar to others that have found decreased complex III and complex IV respiration 
in the IFM population with no effect in the SSM population, in response to aging (11, 
22).  Taken together, our findings indicate that ETC complex II may be a specific locus 
for the deleterious effects associated with STZ insult, imparting damage to both IFM and 
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SSM subpopulations, while effects on complex I and III may be specific to the IFM.  Our 
results suggest that with type 1 diabetes mellitus, ETC respiratory activities are 
compromised impacting both subpopulations with the effects being greatest in the IFM.  
Because the IFM population provides ATP for the contractile process, the compromise 
in ETC function of this mitochondrial population may be particularly detrimental to 
cardiac contractile function, contributing to the contractile deficits associated with 
diabetic cardiomyopathy. 
It has been suggested that an increase in ROS in response to hyperglycemia is 
the proximal defect that leads to many of the subsequent pathological consequences 
resulting from diabetes mellitus (6, 13, 28, 50).  Studies indicate that various ROS are 
increased during diabetes mellitus in the heart, including O2•- (7, 35), peroxynitrite 
(OONO•-) (43), •OH (41, 45), and hydrogen peroxide (H2O2) (36).  Using the non-
specific fluorometric probe, dichlorofluorescein (DCF), we previously observed an 
increase in ROS production in total diabetic mitochondria (8).  Our results are in 
agreement with others observing similar increases in ROS presence resulting from 
diabetic insult, using DCF as a probe (50).  However, because the DCF probe detects 
ROS in a non-specific manner, we extended our findings by determining the specific 
reactants that are increased in cardiac diabetic mitochondria, using EPR/spin trapping 
methodology.  Our results indicate that diabetic insult significantly increases O2•- only in 
the IFM, suggesting that increased ROS occurs in a subpopulation specific manner 
(Figure 2.3).  Verification of O2•- presence was accomplished by addition of exogenous 
superoxide dismutase (SOD) which essentially abolished the signal (Figure 3E and 3F).  
Comparison of the observed spectra to the spectra of a known O2•- generator, xanthine 
oxidase (Figure 2.3G), provided further confirmation to the nature of the reactant.  
These results are interesting indicating that enhanced ROS presence as a result of 
diabetes mellitus, is particularly relevant in the IFM subpopulation and that O2•- appears 
to be a primary ROS generated in diabetic mitochondria.  Our findings are similar to 
others examining different cardiac pathologies using DCF detection or amplex red 
assay (26, 57).  Moghaddas et al. found an increase in H2O2 from complex III in the IFM 
with aging, and no differences in the SSM (37).  Indirectly, our results indicating 
enhanced O2•- presence are also in agreement with Shen et al. who observed 
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restoration of mitochondrial function in MnSOD transgenic mice crossed with OVE26 
mice (53).  It should be pointed out that the primary sites for ROS generation in the 
mitochondrion are at complex I and III, thus decreases in respiration of these 
complexes, as observed in the IFM, should limit electron flux into complex III attenuating 
ROS generation.  Our results do not support this scenario, but rather may be the 
function of enhanced oxidative damage to proteins in these complexes such that, 
though electron flux through these complexes is decreased, electron leakage is greater 
resulting in amplification of ROS generation.  The results warrant further investigation. 
Overproduction of ROS represents an initial event in the pathogenesis of diabetic 
cardiomyopathy creating an oxidative imbalance in the cell.  The resulting oxidative 
milieu promotes damage to subcellular components such as membranes and proteins.  
Submitochondrial targets are particularly prone to damage from enhanced ROS due to 
their close proximity to the source of generation.  Because we observed increases in 
mitochondrial ROS generation as a result of STZ exposure, we examined oxidative 
modification to both protein and lipid components in individual mitochondrial 
subpopulations to determine whether oxidative damage occurs in subpopulation specific 
manner.  Assessment of protein modification was performed by analysis of nitrotyrosine 
adducts.  Our results indicate that only proteins from the IFM population display 
enhanced nitrosylated proteins in response to STZ exposure (Figure 2.4).  These 
findings are similar with others who have demonstrated enhanced protein carbonyl 
groups in cardiac IFM, as a result of aging (26).  Interestingly, these authors also 
observed an increase in protein carbonyls in the SSM population as a result of aging, 
though this increase was not as great as that observed in the IFM (26).  The reason for 
these differences may be related to the pathologies studied (aging vs. diabetes 
mellitus), and/or the specific protein modification examined (nitrotyrosine vs. carbonyl).   
Lipid peroxidation was determined by the combined assessment of both MDA and 4-
HAE (Figure 2.5).  Our results indicate that STZ exposure increases lipid peroxidation in 
both the SSM and IFM subpopulations, though the increase may be greater in the IFM 
(Figure 2.5).  Our findings are somewhat in agreement with others who have observed 
increases in lipid peroxidation primarily in cardiac IFM as a result of aging (26, 57).  Of 
particular interest in the current study was our observation that STZ exposure enhanced 
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lipid peroxidation in both subpopulations, though the increase appeared to be larger in 
the IFM.  Our findings are in contrast to previous reports and may be a function of the 
different pathologies examined and/or assay methodology (26, 57).  These studies 
examined lipid peroxidation in aging cardiac mitochondrial subpopulations by assessing 
4-HAE via Western blot analyses and/or MDA via spectrophotometric measurement of 
thiobarbituric acid reactive substances (TBARS).   In our current study, we assessed 
lipid peroxidation by assessing a combination of MDA and 4-HAE 
spectrophotometrically, using the chromogenic reagent, N-methyl-2-phenylindole.  
Additionally, oxidative stress to mitochondrial lipid components may be different in the 
aging context as compared to diabetic insult.  It is important to point out that while STZ 
effects are believed to be primarily associated with the pancreas its short-term 
administration has been associated with ROS generation and oxidative damage to other 
tissues such as kidney and liver (47).  Thus, one must consider the potential for a direct 
effect of STZ on the heart, independent of enhanced glucose content resulting from 
pancreatic β-cell loss. 
Diabetic mitochondria display increases in mitochondrial permeability transition 
pore (mPTP) opening (42), as well as changes in mitochondrial membrane fluidity, 
which may contribute to changes in mitochondrial membrane potential (∆Ψm) (61).  
These effects may be influenced by phospholipid content and in particular, cardiolipin, 
which would have a profound impact on mitochondrial function (16).  Cardiolipin is a 
diphosphatidylglycerol enriched in the inner membrane, containing oxidatively-sensitive 
acyl groups that may act as selective targets for ROS (17, 40).  Cardiolipin interacts with 
a number of mitochondrial proteins including components of the mPTP, cytochrome C, 
and ETC complexes, thus, its oxidative modification may be a critical event for the 
initiation of pathological states (23).  We determined whether cardiolipin was a specific 
lipid target of STZ-induced diabetic insult.  Our findings indicate that cardiolipin loss 
occurs as a result of STZ exposure only in the IFM subpopulation (Figure 6E).  Our 
results are in contrast to those of Lesnefsky et al. who observed a selective decrease in 
cardiolipin content in SSM following I/R insult (34).  These authors suggest that SSM 
possess a decreased capacity, relative to IFM, for calcium (Ca2+) accumulation which is 
a hallmark of I/R insult.  As a result, SSM sustain a faster onset for ischemic damage as 
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compared to IFM (34).  Though increased Ca2+ content may be involved in the 
pathogenesis of diabetes mellitus, its involvement has much greater effects during 
myocardial I/R, which may account for the difference in the results observed in the 
studies. 
In conclusion, we report for the first time, that STZ-induced diabetic insult 
differentially affects morphological, functional, and oxidative properties of spatially 
distinct mitochondrial subpopulations.  Type 1 diabetic insult is associated with a greater 
stress on the IFM subpopulation as indicated by increased ROS and oxidative damage, 
impacting ETC function and cardiolipin content, all of which may contribute to cardiac 
contractile dysfunction.  The heterogeneous response displayed by individual 
mitochondrial subpopulations during diabetic insult emphasizes the importance of 
incorporating spatial influence into the study of mitochondria in disease states.  
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Figure 2.1. Mitochondria subpopulation morphological assessment.  
Determination of relative size and internal complexity of distinct 
mitochondrial subpopulations using flow cytometric analyses.  (A)  
Representative density plot of isolated mitochondria stained with 
MitoTracker Deep Red 633, which incorporates into intact mitochondria.  
Intact mitochondria that take up the MitoTracker Deep Red 633 dye are 
gated (R1) and represented in red.  Noise and debris, which does not take 
up the MitoTracker Deep Red 633 is excluded from measurements (outside 
the R1 gate) and indicated in black.  (B)  Representative gated density plot 
indicating size (FSC; forward scatter) vs. internal complexity (SSC; side 
scatter) of isolated SSM.  (C) Representative gated density plot indicating 
size (FSC; forward scatter) vs. internal complexity (SSC; side scatter) of 
isolated IFM.  Analysis of forward scatter and side scatter were calculated 
per 20,000 gated events for all mitochondrial subpopulations.  Red hash 
lines indicate microsphere size references from left to right; 0.5, 1, 2, 4, and 
6 µM, respectively.  (D)  Analysis of cardiac SSM and IFM size (FSC) in 
control and diabetic.  (E) Analysis of cardiac SSM and IFM complexity 
(SSM) in control and diabetic.  Values for size and complexity are 
expressed as arbitrary units (AU) ± SEM; n=3 for each group. †P<0.01 for 
diabetic vs. control.   
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Figure 2.2 
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Figure 2.2.  Mitochondria subpopulation respiration.  Individual 
mitochondrial subpopulations were isolated from diabetic and control hearts 
and polarographic measurements performed to index oxygen consumption 
under state 4 respiration conditions.  Respiration of individual ETC 
complexes was defined as the rate of oxygen consumed in the presence of 
specific substrates, glutamate/malate (complex I), succinate (complex II), 
and ascorbate/N,N,N’,N’-tetramethyl-p-phenylenediamine (complex IV), 
and were calculated as the fraction that was sensitive to the specific 
inhibitors rotenone (complex I), antimycin (complex II), and sodium cyanide 
(complex IV).  Measurement of complex III was performed 
spectrophotometrically by assessment of the reduction of cytochrome c in 
the presence of reduced decylubiquinone.  (A) Complex I.  (B) Complex II.  
(C) Complex III.  (D) Complex IV. Values are expressed as mean ± SEM; 
n=7 for each group.  *P<0.05 for diabetic vs. control; †P<0.01 for diabetic 
vs. control. 
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Figure 2.3 
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Figure 2.3 
 
 
 
 
 
  
83 
 
 
Figure 2.3.  Mitochondria subpopulation reactive oxygen species 
(ROS) generation. Individual mitochondrial subpopulations were isolated 
from diabetic and control hearts and electron paramagnetic resonance 
(EPR) spectroscopy performed to index ROS generation.  Isolated 
mitochondrial subpopulations were incubated with DMPO in the presence 
or absence of excess complex I respiratory substrates glutamate and 
malate, incubated for three minutes at 37°C and then transferred to an EPR 
flat cell for measurement at room temperature with instrument settings of 
63.6 milliwatt, modulation amplitude 1G, receiver gain 1.00 x 105, 
conversion time 40.960 ms, and time constant 40.960 ms.  All spectra 
shown are in accumulation of three scans.  (A) Representative spectra for 
control SSM; (B) representative spectra for diabetic SSM; (C) 
representative spectra for control IFM; (D) representative spectra for 
diabetic IFM; (E) Representative spectra for SSM with the inclusion of 
superoxide dismutase (SOD) into the assay medium to confirm the 
superoxide (O2•-) signal; (F) representative spectra for IFM with the 
inclusion of superoxide dismutase (SOD) into the assay medium to confirm 
the superoxide (O2•-) signal; (G) xanthine oxidase spectra was included as 
a representative of the O2•- spectra pattern.   (H) ROS formation was 
significantly increased in diabetic IFM compared to control IFM. Values are 
expressed as mean ± SEM; n=4 for each group.  †P<0.01 for diabetic vs. 
control.  
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Figure 2.4 
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Figure 2.4.  Mitochondrial subpopulation protein nitrotyrosine 
content.  Individual mitochondrial subpopulations were isolated from 
diabetic and control hearts.  Assessment of protein nitrotyrosine residues 
was performed using a sandwich ELISA and results compared against a 
known protein nitrotyrosine standard curve.  Results are expressed as nmol 
of nitrotyrosine protein per mg of protein.  Values are expressed as mean ± 
SEM; n=5 for each group. *P<0.05 for diabetic vs. control. 
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Figure 2.5 
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Figure 2.5.  Mitochondrial subpopulation lipid peroxidation content. 
Individual mitochondrial subpopulations were isolated from diabetic and 
control hearts.  Assessment of the lipid peroxidation by-products 
malondialdehyde (MDA) and 4-hydroxyalkenals (4-HAE) was performed 
using a colorimetric assay and spectrophotometric measurement at 586 
nm.  Sample values were compared against a standard curve of known 4-
HAE and MDA, and data are expressed as µmole of MDA+4-HAE per mg 
of protein.  Values are expressed as mean ± SEM; n=5 for each group.  
†P<0.01 for diabetic vs. control.  ††P<0.005 for diabetic vs. control.  
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Figure 2.6 
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Figure 2.6.  Mitochondrial subpopulation cardiolipin content.  
Individual mitochondrial subpopulations were isolated from diabetic and 
control hearts, and lipids extracted.  Assessment of cardiolipin content was 
performed by electrospray ionization mass spectrometry (ESI-MS) on 
diluted samples from control and diabetic mitochondrial subpopulations.  
The ions of the predominant molecular species of cardiolipin (T18:2 CL, 
m/z 723) and the internal standard (T14:0 CL, m/z 619) are indicated by 
arrows.  (A) Representative negative-ion ESI-MS spectra from control 
SSM.  (B)  Representative negative-ion ESI-MS spectra from diabetic SSM.  
(C)  Representative negative-ion ESI-MS spectra from control IFM.  (D) 
Representative negative-ion ESI-MS spectra from diabetic IFM.  (E) 
Summary data of cardiolipin expressed as the ratio of m/z 723: m/z 619.  
Values are expressed as mean ± SEM; n=3 for each group.  †P<0.01 for 
diabetic vs. control. 
 
  
Table 2.1
B d H t HW/BW +dP/dt dP/dt Developed SSM IFM Group o y Weight, g
ear  
Weight, mg Ratio, mg/g
, 
mmHg/s
– , 
mmHg/s Pressure, mmHg
Protein, 
mg/g tissue
Protein, 
mg/g tissue
Control 27.4±1.3 102±4 3.7±0.1 3,398±128 2,310±114 96±2 18.9±2.1 10.3±0.8
Diabetic 28 4±0 8 108±6 3 8±0 2 1,934±116* 1,680±144* 57±3* 19 5±2 2 9 5±1 5. . . . . . . .
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Table 2.1.  Heart weight, body weight, contractile function, and 
mitochondrial yields.  Heart weight (HW), body weight (BW), and heart 
weight/body weight ratios (HW/BW) five weeks following STZ-treatment 
(Diabetic) or citrate saline injection (Control).  HW is expressed in 
milligrams (mg), BW is expressed in grams (g), and HW/BW is expressed 
as mg/g.  Functional measurements were performed in Langendorff-
perfused hearts, and are expressed as rate of contraction (+dP/dt), rate of 
relaxation (-dP/dt), and developed pressure (DP).  +dP/dt and –dP/dt are 
expressed in mm Hg/sec, and DP is expressed in mm Hg.  Individual 
mitochondrial subpopulation protein yields expressed in mg/g wet tissue.  
Values are expressed as mean ± SEM; n=8 for each group.  *P<0.05 for 
diabetic vs. control. 
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ABSTRACT 
Diabetic cardiomyopathy is associated with increased risk of heart failure in type 
1 diabetic patients.  Mitochondrial dysfunction is suggested as an underlying contributor 
to diabetic cardiomyopathy. Cardiac mitochondria are characterized by subcellular 
spatial locale including mitochondria located beneath the sarcolemma, subsarcolemmal 
mitochondria (SSM), and mitochondria situated between the myofibrils, interfibrillar 
mitochondria (IFM).   The goal of this study was to determine whether type 1 diabetic 
insult in the heart influences proteomic make-up of spatially-distinct mitochondrial 
subpopulations and to evaluate the role of nuclear-encoded mitochondrial protein 
import.  Utilizing multiple proteomic approaches (iTRAQ,  and 2D-DIGE), IFM proteomic 
make-up was impacted by type 1 diabetes mellitus to a greater extent than SSM as 
evidenced by decreased abundance of fatty acid oxidation and electron transport chain 
proteins.  Mitochondrial phosphate carrier and adenine nucleotide translocator, inner 
membrane translocases, were decreased in the diabetic IFM (p<0.05 for both).  Mitofilin, 
a protein involved in mitochondrial morphology, was diminished in the diabetic IFM 
(p<0.05). Post-translational modifications, included oxidations and deamidations, were 
most prevalent in the diabetic IFM.  Glucose-regulated protein 75 (Grp75), a 
mitochondrial protein import constituent, was decreased in diabetic IFM (p<0.05).  
Mitochondrial protein import was decreased in the diabetic IFM with no change in the 
diabetic SSM (p<0.05).  Taken together, these results indicate that mitochondrial 
proteomic alterations in the type 1 diabetic heart are more pronounced in the IFM.  
Further, proteomic alterations are associated with nuclear-encoded mitochondrial 
protein import dysfunction and loss of an essential mitochondrial import constituent, 
Grp75, implicating this process in the pathogenesis of diabetic cardiomyopathy. 
Diabetes, Mitochondria, Proteomics 
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INTRODUCTION 
Cardiovascular complications, including diabetic cardiomyopathy, are the leading 
cause of mortality among type 1 diabetic patients.  A number of studies have indicated 
that mitochondrial dysfunction underlies and is a central contributor to the dysfunction 
seen in the type 1 diabetic heart (10, 12, 33, 36).   An increasing amount of evidence 
suggests that mitochondrial subcellular location influences the pathogenesis of 
dysfunctional mitochondria in the type 1 diabetic heart (10, 23).  Cardiac mitochondria 
are characterized by different spatial location within the cell including mitochondria 
located at the sarcolemma, subsarcolemmal mitochondria (SSM), and mitochondria 
situated between the myofibrils, interfibrillar mitochondria (IFM).  We and others have 
shown that these two spatially distinct subpopulations of mitochondria are differentially 
affected with various pathological insults (10, 23, 25, 26, 30, 34, 40).  Specifically, we 
have demonstrated that the IFM display greater dysfunctional profiles with type 1 
diabetic insult, as evidenced by enhanced oxidative stress, diminished ETC function 
and decreased cardiolipin content.   
Proteomic evaluations have played an important role in furthering our 
understanding of mitochondrial dysfunction in the diabetic heart.  Several proteomic 
studies have been undertaken in various diabetic models in an effort to clarify the nature 
of the proteomic changes associated with the diabetic heart (5, 14, 20, 36, 38).  Turko et 
al. identified 30 altered mitochondrial proteins in isolated mitochondria from STZ-
induced type 1 diabetic rat hearts (38).  In particular, they observed enhanced fatty acid 
oxidation (FAO) proteins and reduction of several oxidative phosphorylation (OXPHOS) 
protein subunits.  Utilizing the iTRAQ™ labeling method, Jullig et al. identified 65 
proteins significantly changing in the STZ-induced type 1 diabetic rat heart as compared 
to control (20).  The most significant changes were increased levels of FAO enzymes 
and decreased proteins involved in OXPHOS.  In a recent study using label free 
proteome expression analyses, Bugger et al. examined mitochondrial proteomes of 
several tissues from the Akita mouse (kidney, liver, brain and heart) (5).  Their results 
indicate that FAO proteins were less abundant in liver mitochondria, whereas FAO 
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protein content was induced in mitochondria from all other tissues. In addition, levels of 
OXPHOS subunits were coordinately increased in liver mitochondria, whereas 
mitochondria from other tissues were unaffected (5).  Taken together, these data 
suggest that the cardiac mitochondrial proteome is impacted during type 1 diabetes 
mellitus, though a number of variables may contribute to conflicting results.  To date no 
one has examined proteomic differences in spatially distinct subpopulations of 
mitochondria in the type 1 diabetic heart which may offer further insight into the nature 
of this dynamic process in the type 1 diabetic heart.    
Studies examining mechanisms underlying or contributing to the proteomic 
alterations in the diabetic heart are limited (15).  Potential mechanisms of proteomic 
dysregulation may include pathological alterations in gene expression, increases in 
post-translational modifications (PTMs) of proteins, or upregulation of post-translational 
regulators such as microRNAs (miRNAs).  Alternatively, dysfunctional nuclear-encoded 
mitochondrial protein import could also disturb the proteomic composition of the 
mitochondrion.  Currently, there are approximately 1200 known proteins in the human 
mitochondrion (35), with only 13 transcribed and translated inside the organelle itself.  
As a result, the vast majority of proteins (~99%) must be imported into mitochondrion 
through a complex mechanism of translocation involving interaction between protein 
targeting signals and mitochondrial translocases (6).  To date, no study has examined 
the impact of type 1 diabetes mellitus on spatially distinct mitochondrial proteomes in 
the diabetic heart or offered insight into the mechanisms influencing specific proteomic 
profiles.  The goal of this study was to determine whether proteomic differences exist in 
subpopulations of mitochondria as well as to evaluate the role of nuclear-encoded 
mitochondrial protein import in the type 1 diabetic heart. 
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MATERIALS AND METHODS 
Experimental Animals and Diabetes Induction  
The animal experiments in this study conformed to National Institutes of Health 
(NIH) Guidelines for the Care and Use of Laboratory Animals and were approved by the 
West Virginia University Animal Care and Use Committee. Male FVB mice (Charles 
River Laboratories, Wilmington, MA) were housed in the West Virginia University Health 
Sciences Center animal facility. Mice were given unlimited access to a rodent diet and 
water. Type 1 diabetes mellitus was induced in 8-wk-old mice following the protocol of 
the Animal Models of Diabetic Complications Consortium using multiple low-dose 
streptozotocin (STZ; Sigma, St. Louis, MO) injections.   Injections of 50 mg/kg body 
weight STZ dissolved in sodium citrate buffer (pH 4.5) were performed daily for 5 
consecutive days after 6 hours of fasting.  Mice that served as vehicle controls were 
given the same volume per body weight of sodium citrate buffer. One week post-
injection, hyperglycemia was confirmed by measuring urinary glucose (Chemstrip 2GP 
Urine test strips, Roche Diagnostics, Indianapolis, IN), where >2,000 mg/dl was 
considered diabetic.  Five weeks post hyperglycemia onset, animals were sacrificed for 
further experimentation. 
 
Preparation of Individual Mitochondrial Subpopulations  
At 5 weeks post hyperglycemia onset, FVB mice and their littermate controls 
were sacrificed, and the hearts were excised.  Hearts were rinsed in phosphate buffered 
saline (PBS, pH 7.4), then blotted dry and weighed.  SSM and IFM were isolated as 
previously described following the methods of Palmer et al. (29) with minor 
modifications (10, 11, 40).  Protein concentrations were determined using the Bradford 
method with bovine serum albumin (BSA) as a standard (3). 
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iTRAQ Labeling 
Pooled SSM and IFM subpopulations (n=4) from diabetic and control hearts were 
lysed and precipitated overnight in acetone at -20°C and pellets were resuspended in 
20 μL of 0.5 M triethylammonium bicarbonate (TEAB; pH 8.5) as previously described 
(9).  Protein contents were determined using a 2-D Quant Kit (Amersham, Piscataway, 
NJ) and 100 μg of each pooled sample was than denatured with 0.1% SDS and 
reduced with 5mM tris-(2-carboxyethyl) phosphine (TCEP).  After incubation for 1 hour 
at 60°C, cysteines were blocked with 10 mM methyl methane thiosulfonate (MMTS) in 
isopropanol, and the samples were incubated at room temperature for 10 minutes.  
Addition of 10 μL of sequencing grade trypsin (Applied Biosystems, Foster City, CA) 
was added in a trypsin/protein ratio of 1:20, and the samples incubated at 37°C 
overnight.  Digested samples were labeled with the iTRAQ™ reagents following the 
protocol provided by the vendor (Applied Biosystems, Foster City, CA).  
After digestion and iTRAQ labeling, the ultra-complex protein digests were 
combined to create a 400 µg pooled protein digest sample that contained equal 
fractions of each of the four labeled samples for subsequent Multi Dimensional Protein 
Identification Technology (MudPIT) analysis (27).   After lyophilization, the digest 
mixture was reconstituted in strong cation exchange (SCX) loading buffer (5mM 
ammonium formate in 20% acetonitrile; pH 3.0) to be fractionated with SCX SpinTips 
(Protea Biosciences, Morgantown, WV) per the manufacturer’s protocol.  Briefly, the 
sample solution was loaded centrifugally onto the SCX SpinTip.  The non-adsorbing 
solution that passed through the SCX SpinTip was collected. Eight different elution 
solutions were used to fractionate the peptides (20, 60, 100, 150, 200, 250, 400, and 
500 mM ammonium formate in 10% acetonitrile) in a step-wise manner, for a total of 
nine sample fractions.  The collected fractions were cleaned by repeated lyophilization 
and reconstituted in a 0.1 M acetic acid solution, and then lyophilized to dryness.  The 
fractions were then submitted for LC-MALDI TOF/TOF mass spectral analysis for 
protein identification, characterization, and differential expression analysis.  
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Mass Spectrometry (MS) Analyses with iTRAQ™ Labeling 
The LC-MALDI mass spectrometry system utilized was an ABI Tempo LC MALDI 
spotter with Tempo LC MALDI v.2.00.09 data acquisition and processing software.  
Lyophilized SCX sample fractions were reconstituted in LC aqueous run buffer (0.1% 
trifluoroacetic acid, 2% acetonitrile) and injected onto a Zorbax C18 chromatographic 
column, 150 x 0.3 mm (Agilent Technologies, Wilmington, DE).  The peptides were 
eluted from the column using an acetonitrile/trifluoroacetic acid gradient (2-72% 
acetonitrile in 35 minutes) and spotted directly onto a MALDI plate in 6 second spot 
fractions.  The MALDI spots were analyzed using an ABI 4800 MALDI TOF/TOF 
analyzer operated with 4000 Series Explorer software.  The MS acquisition was in 
positive ion reflector mode with 400 laser shots per spectrum performed.  The 15 
strongest precursors per spot were chosen for MS/MS and the MALDI spot was 
interrogated until at least 4 peaks in the MS/MS, spectra achieved a S/N ≥ 70.   
The resulting MS/MS spectra were analyzed using ABI Protein ProteinPilot 
software 2.0 (Applied Biosystems, Foster City, CA).  The spectral data was searched 
against the mouse protein database (NCBI nr.fasta database customized to select for all 
mouse proteins) for identification of the peptides and corresponding proteins.  In 
ProteinPilot, the sample type was selected as iTRAQ 4Plex for retrieval of the isotopic 
tag information from the mass spectra.  After database correlation analysis, the proteins 
were grouped, scored, and normalized against one of four isotope correction factors.  
The Pro Group algorithm of ProteinPilot generated a ProtScore that is a cumulative 
score from each of the peptides used by the algorithm in the protein identification.  
Protein scores (ProtScore) above 2.0, 1.0, and 0.47 expressed the percent confidence 
levels of >99, >90, and >66%, respectively.  Each peptide match showed the iTRAQ 
isotopic labels, MMTS labeled cysteines, and other post-translational modifications 
present as mass spectral shifts identified during the database correlation analysis.  
Each protein identified also showed the differential protein expression compared against 
the other iTRAQ™ labeled samples for relative quantitation. 
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2D-Differential In-Gel Electrophoresis 
Sample Preparation 
 Isolated mitochondrial subpopulations were placed in lysis buffer (7 M urea, 2 M 
thiourea, 30 mM Tris, 5 mM magnesium acetate, 4% CHAPS, and 58 mM DTT) in a 
1:10 ratio.  Protein concentration of the samples was determined using a 2-D Quant Kit 
(Amersham Biosciences, Piscataway, NJ).  
  
2D-Difference In-gel Electrophoresis (2D-DIGE) and Differential-display Proteome 
Analyses 
100 µg of each mitochondria subpopulation from both diabetic and control was 
lysed with labeling buffer (7 M urea, 2 M thiourea, 4% CHAPS, 30 mM Tris, 5 mM 
magnesium acetate).  One third of each sample was removed and combined into a 
separate tube to serve as an internal standard.  50 μg of the remaining samples were 
labeled separately with 400 pmol of Cy3 or Cy5 NHS-ester minimal labeling reagents for 
30 minutes on ice in the dark. The samples were then quenched with 2 μl of 10 mM 
lysine for 10 minutes on ice in the dark.   50 μg of the combined sample was also 
labeled with 400 pmol of Cy2 and than quenched with 10 μl of 10 mM lysine.  Individual 
Cy3- and Cy5-labeled samples were combined with the same amount of the Cy2-
labeled internal standard.  Each gel contained one control and one diabetic sample from 
individual subpopulations, and the Cy3 and Cy5 dyes were alternated to account for dye 
labeling variability.  The samples were separated by standard 2D gel electrophoresis 
utilizing a manifold-equipped IPGphor first dimension isoelectric focusing unit and 24 cm 
3-10 immobilized pH gradient (IPG) strips.  The initial separation was followed by a 
second-dimension 12% SDS-PAGE homogenous on hand-cast gels.  The Cy2 (mixed 
standard), Cy3 (sample A) and Cy5 (sample B) components of each gel were visualized 
separately at 100 μm resolution with mutually-exclusive excitation/emission 
wavelengths using a Typhoon 9400 Variable Mode Fluorescence Imager (Applied 
Biosystems, Foster City, CA). A Sypro Ruby protein post-stain (Invitrogen, Carlsbad, 
CA) was used to extract protein from the gels.  Gel images were submitted to Ludesi 2D 
Analysis (Ludesi, Malmo, Sweden, http://www.ludesi.com) for spot detection, matching, 
and analysis. Control:standard and diabetic:standard normalized volume ratios were 
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calculated for each protein on every gel, and the internal standards were used to 
normalize and compare these ratios across the 10 DIGE gels.  This method allowed for 
the calculation of average abundance changes and Student’s T-test p-values for the 
variance of these ratios for each protein-pair across all 10 individual gels.   
 
Mass Spectrometry and Database Analysis 
 Proteins that were changing were excised and digested in gel with trypsin 
protease and the resulting peptides analyzed using a Micromass MALDI micro MX TOF 
Spectrometer (Waters, Milford, MA).  The resulting peptide mass maps were compared 
to sequences present in the SWISS-PROT and NCBInr databases to generate 
statistically significant identifications of proteins using GPS Explorer software (Applied 
Biosystems, Foster City, CA) running the MASCOT search algorithm.   Searches were 
performed without constraining protein molecular weight or isoelectric point, with 
complete carbamidomethylation of cysteine, partial oxidation of methionine residues, 
and one missed cleavage also allowed in the search parameters.  Molecular Weight 
Search  (MOWSE) scores from database interrogation above 58 (p<0.05), number of 
matched ions, number of matching sequence coverage, and correlation of gel region 
with predicted MW and pI were considered for each protein identification.   
 
Protein Import 
Plasmid Construction  
The fusion protein pAcGFP1-Mito (Clontech Laboratories, Mountain View, CA) 
containing the precursor subunit VIII of human cytochrome C oxidase and the green 
fluorescent protein from Aequorea coerulescens (AcGFP1) was cloned into pIVEX2.3d 
(Roche Applied Science, Indianapolis, IN) at restriction sites Not I and blunted Nco 
I/Nhe I creating pMITOGFP1.  The correct sequence was confirmed by 
dideoxynucleotide sequencing.  pMITOGFP1 was grown to a concentration of 500 ng/µl 
and isolated using mini prep plasmid DNA isolation (Qiagen, Valencia, CA).   
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In Vitro Synthesis of Mitochondrial Protein 
In vitro transcription and translation of MitoGFP1 was performed using the S30 
T7 protein expression system (Promega, Madison, WI) as per the manufacturer’s 
protocol.  Additionally, fluorescent labeling of MitoGFP1 was performed using the 
FluoroTect GreenLys tRNA in vitro labeling system (Promega, Madison, WI) as per the 
manufacturer’s protocol. MitoGFP1 and fluorescent MitoGFP1 lysates were 
subsequently used as substrates for the in vitro protein import process. 
 
Mitochondrial Protein Import 
The mitochondrial protein import procedure was performed following the protocol 
from Stojanovski et al. (37) with modifications.  Briefly, 40 µg of mitochondria was 
resuspended in 100 µl of import buffer (250 mM Sucrose, 80 mM KCl, 5 mM MgCl2, 2 
mM KH2PO4, 10 mM MOP-KOH, pH 7.2) with addition of 2 mM ATP and 2mM NADH.  
1-5 µl of bacterial lysate containing MitoGFP1 protein was added and protein import 
performed at increasing time intervals of 2, 5, and 10 minutes at 25°C.  2 µM 
valinomycin was added to stop the import reaction, and samples were centrifuged at 
12,000 x g for 5 minutes at 4°C.  The supernatant was discarded and the pellet 
resuspended in SEM buffer (250 mM Sucrose, 1 mM EDTA, 10 mM MOP-KOH, pH 7.2) 
containing 25 µg/ml trypsin, on ice.  Trypsin was subsequently inhibited by protease 
inhibitor cocktail (BioVision, Mountain View, CA). Samples were centrifuged again at 
12,000 x g for 5 min at 4°C.  Pellets were then resuspended in lysis buffer (BioVision, 
Mountain View, California), subjected to SDS-PAGE, and subsequent Western blot 
analyses performed. Quantification of blots was performed using Pierce ECL Western 
Blotting Substrate (Pierce Biotech, Rockford, IL).  The primary antibody was an anti-
GFP monoclonal antibody raised in a mouse host (Clontech Laboratories, Mountain 
View, CA).   The secondary antibody was an anti-mouse IgG horseradish peroxidase 
conjugate (Sigma, St. Louis, MO).  Quantification of chemiluminescent signals were 
detected using a G:BOX (Syngene, Frederick, MD), and data expressed as arbitrary 
optical density units.  Additionally, visualization of imported fluorescent MitoGFP1 was 
performed using a Typhoon 8600 (GE Healthcare, Piscataway, NJ) with a 532nm 
excitation.  Control for protein loading was confirmed using Ponceau staining. 
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Western Blot Analyses 
 SDS polyacrylamide gel electrophoresis (SDS-PAGE) was run on 4-12% 
gradient gels as previously described (24, 40) with equal amounts of protein loaded for 
each study treatment. Relative amounts of subpopulation-specific mitochondrial glucose 
regulated protein 75 (Grp75), translocases of the outer membrane 40 and 20 (TOM 40 
and TOM 20), translocases of the inner membrane 23 and 44 (TIM23 and TIM44), were 
analyzed using the following primary antibodies; anti-Grp75 mouse antibody (Product# 
SPA-825; Stressgen, Ann Arbor, MI ), anti-TOM40 goat antibody (Product# sc-11025; 
Santa Cruz Biotech, Santa Cruz, CA), anti-TOM 20 mouse antibody (Product # 612278; 
BD Biosciences, San Jose, CA), anti-TIM23 mouse antibody (Product # 611222; BD 
Biosciences, San Jose, CA), and anti-TIM44 mouse antibody (Product # 612582, BD 
Biosciences, San Jose, CA).  The secondary antibodies used in the analyses were 
donkey anti-goat IgG HRP conjugate (Product #sc-2020; Santa Cruz Biotech, Santa 
Cruz, CA) for TOM40, and goat-anti mouse conjugate (Product# 31430; Pierce Biotech, 
Rockford, IL) for Grp75, TOM20, TIM23 and TIM44.  Detection of signal was performed 
according to the manufacturer’s instructions as above. Autoradiographic signals and 
data analysis were performed as above.  Control for protein loading was confirmed 
using Ponceau staining. 
 
Statistics 
Means and standard errors (SEM) were calculated for all data sets.  Data were 
analyzed with a one-way analysis of variance (ANOVA) method to evaluate the main 
treatment effect, diabetes induction (GraphPad Software Inc., La Jolla, CA).  Fisher’s 
Least Significant Difference (LSD) post hoc tests were performed to determine the 
significant differences among means.  When appropriate a Student’s T-test was 
employed.  p<0.05 was considered significant. 
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RESULTS 
Proteomic Analyses 
To determine whether type 1 diabetes mellitus differentially impacts spatially 
distinct mitochondrial subpopulation proteomes, we utilized both iTRAQ and 2D-DIGE 
comparative approaches.  iTRAQ enables simultaneous identification and relative 
quantification of mitochondrial proteins through isobaric peptide tagging, while 2D-DIGE 
analysis is a quantitative technique that enables multiple protein samples to be 
separated on the same 2-D gel, thereby greatly reducing the introduction of potential 
artifacts due to gel-to-gel variations.  Figure 3.1 is an example of an MS/MS fragment 
ion (spectra) for a peptide that was used to identify a protein, Grp75.  Located below the 
spectra is an example of an iTRAQ tag mass spectral signature (m/z 114, 115, 116, and 
117) used to make a relative quantification of Grp75 within the four labeled sample 
groups (see Figure 3.1 legend for groups).  Figures 2A-D are representative 2D gels 
from four mitochondrial samples, (A) control IFM, (B) diabetic IFM, (C) control SSM, and 
(D) diabetic SSM, labeled with different Cy dyes.  In this example, an individual spot, 
identified as Grp75, is indicated by the red arrows, and the quantitative differences 
assessed by examination of peak densities which are shown in each individual 
representative gel image (Figures 3.2A-D).  Grp75 peak density was significantly 
decreased (p<0.02) in the diabetic IFM as compared to control IFM, with no changes in 
diabetic SSM as compared to control SSM. 
Proteins of Fatty Acid Oxidation (FAO).  FAO proteins were significantly altered in both 
diabetic SSM and diabetic IFM as compared to control using both iTRAQ and 2D-DIGE 
methods.  In contrast to our previous study in a type 2 diabetes mellitus model (9), 
iTRAQ analysis revealed 8 of 10 proteins involved in FAO which were decreased in the 
diabetic IFM, while 4 of 10 were decreased in the diabetic SSM (Table 3.1).  
Interestingly, carnitine palmitoyltransferase-1 (CPT-1), an outer mitochondrial 
membrane protein that mediates transport of long-chain fatty acids across the 
membrane, was significantly increased in the diabetic SSM while diminished in the 
diabetic IFM (Table 3.1).  Further, 2D-DIGE analysis identified 6 FAO proteins that were 
also significantly decreased in the diabetic IFM, while 2 of 6 were decreased in the 
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diabetic SSM (Table 3.2).  Taken together, both proteomic analyses suggest that FAO 
proteins are impaired in both diabetic SSM and IFM, with the effect being greatest in the 
IFM.  
Proteins of the Mitochondrial Respiratory Chain. Utilizing both iTRAQ and 2D-DIGE, a 
number of proteins of the mitochondrial respiratory chain were significantly altered in 
both diabetic SSM and diabetic IFM as compared to control.  With iTRAQ, 9 of 23 
respiratory chain proteins identified were significantly decreased in the diabetic IFM as 
compared to control, while 1 of 23 respiratory chain proteins identified were decreased 
in expression in the diabetic SSM as compared to control (Table 3.1).  Interestingly, 5 of 
23 respiratory chain proteins identified were increased in the SSM as compared to 
control.  In the diabetic IFM, all 4 proteins identified from complex V (ATP synthase) 
were decreased, while 2 of 6 proteins from complex I, and 1 of 4 were from complex IV 
were decreased (Table 3.1).  In the diabetic SSM, one protein each from complexes I, 
III, IV and V, respectively, were significantly increased as compared to control SSM 
(Table 3.1).  Similar to the iTRAQ analysis, 2D-DIGE analysis revealed 16 proteins of 
the respiratory chain decreased in the diabetic IFM, with 3 proteins increased in the 
diabetic SSM (Tables 3.1 and 3.2).   Proteins that were decreased in the diabetic IFM 
were from all respiratory complexes including complexes I, II, III, IV and V with the 
greatest number of decreased proteins occurring at complex I.  Similar to the iTRAQ 
analysis, several respiratory proteins were increased in the diabetic SSM suggesting a 
possible compensatory mechanism to prevent dysfunction. 
Proteins of the Citric Acid Cycle (TCA).  iTRAQ and 2D-DIGE analyses of proteins 
involved in the TCA revealed significant changes in both the diabetic SSM and IFM as 
compared to control.  In the diabetic IFM, 2 of 5 TCA proteins were decreased, while 3 
of 5 proteins were increased in the diabetic SSM (Table 1). Of particular interest was 
the observation that isocitrate dehydrogenase 2 (NADP+) displayed increased content 
in the diabetic SSM yet decreased content in the diabetic IFM (Table 3.1).  Similar to the 
iTRAQ analysis, 2D-DIGE analysis reported 6 TCA proteins decreased in the diabetic 
IFM, and 3 proteins increased in the diabetic SSM (Table 2).  These data suggest again 
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that TCA proteins and other proteins necessary for energy production are increased in 
the diabetic SSM, yet decreased in the diabetic IFM. 
Transport Proteins.  Proteins involved in transport of proteins and or substrates across 
the IMM were preferentially decreased in the diabetic IFM as compared to control IFM 
as evidenced by a decreased content in 3 of 4 proteins, with no changes in the SSM 
(Table 3.1).  Mitochondrial phosphate carrier, a protein that is involved in transport of 
phosphate groups from the cytosol to the mitochondrial matrix, was significantly 
decreased in diabetic IFM as compared to control (Table 3.1).  Another translocase 
required for exchange of ADP and ATP across the IMM, adenine nucleotide translocator 
1 (ANT1), was also significantly decreased in the diabetic IFM as compared to control 
(Table 3.1).  Interestingly, Grp75, a heat shock protein and a constituent of the 
mitochondrial import process essential for import of proteins into mitochondrion, was 
also significantly decreased only in diabetic IFM as compared to control (Tables 3.1 and 
3.2) . Western blot analyses of Grp75 (Figure 3.5C), provided confirmation of both the 
iTRAQ and 2D-DIGE results observed.  Another heat shock protein involved in folding 
and protein import into the mitochondrion, Hsp60, was also significantly decreased in 
only the diabetic IFM as revealed by 2D-DIGE analysis (Table 3.2). 
Structural Proteins.  With both iTRAQ and 2D-DIGE analyses, alterations to proteins 
involved in mitochondrial structure were apparent in only the diabetic IFM as compared 
to control with no changes in diabetic SSM.  In particular, mitofilin, a transmembrane 
IMM protein that regulates mitochondrial morphology (cristae density) and mitochondrial 
fusion and fission (18), was significantly decreased only in diabetic IFM as indicated by 
both iTRAQ and 2D-DIGE analysis (Tables 3.1 and 3.2).  Further, prohibitin-2, a protein 
involved in mitochondrial morphology as well as maintenance of mitochondrial DNA (1), 
was significantly decreased in the diabetic IFM with 2D-DIGE analysis (Table 3.2).  
These data are consistent with our previously published data suggesting that 
mitochondrial internal complexity is decreased in the diabetic IFM (10). 
 
Post-translational Modifications (PTM) 
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Utilizing MudPIT technology to assess PTM, 42 proteins were identified as 
having a PTM in the diabetic IFM while 23 proteins were identified in the diabetic SSM 
(Table 3.3).  Interestingly, 11 of the 42 proteins in the diabetic IFM contained oxidations 
on various amino acid residues.  In particular, 3 proteins of complex III, 2 proteins of 
complex V and 1 protein of complex I were oxidized in the diabetic IFM. Further, Grp75 
and mitofilin were also only oxidized in the diabetic IFM.  Additionally, 13 proteins in the 
diabetic IFM and 8 proteins in the diabetic SSM involved in the ETC presented with 
some sort of PTM including acetylations, deamidations and methylations.  Of greatest 
interest was that the majority of the modified proteins were IMM proteins, suggesting 
that this locus may be specifically impacted and as a result, play a key role in the 
pathogenesis of cardiac dysfunction associated with type 1 diabetes mellitus. 
 
Mitochondrial Protein import Construct 
Figure 3.3A is a vector map showing the insertion of MITOGFP1 cDNA that was 
cut Not I, and blunted at Nhe I.  The cDNA was inserted as a Not I, Nhe I blunt fragment 
into the PIVEX2.3d plasmid.  PIVEX2.3d has all necessary components for efficient 
protein production in a cell free bacterial protein expression lysate system including a 
T7 promoter, ribosomal binding site, and poly A tail.  The MITOGFP1 gene consists of 
an N-terminal mitochondrial targeting sequence derived from cytochrome C oxidase 
subunit VIII (targeted to the matrix) fused with AcGFP.  Translated MitoGFP1 protein is 
incubated with isolated mitochondria to allow for proper import.  Mitochondria are 
subsequently cleaned of non-imported protein, lysed, and a Western blot analysis is 
performed probing for AcGFP.  Isolated cardiac mitochondria alone does not produce a 
signal on the blot, (Figure 3.3B, lane 1) whereas pure protein lysate from the bacterial 
expression system does produce a 31 kDa band (Figure 3.3B, lane 2).  Addition of  total 
mitochondria and lysate together produce a similar 31 kDa band, which is the full length 
precursor protein yet to be completely imported, and a 27 kDa band that represents the 
mature MitoGFP1 protein in which the precursor sequence has been cleaved and 
properly imported into the mitochondrial matrix (Figure 3.3B, lane 3).   
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Mitochondrial Protein Import 
Utilizing Western blot analysis, Figures 3.4A and C show increasing amounts of 
protein abundance at 2, 5, and 10 minutes, respectively, of the mature 27 kDa 
MitoGFP1 in the control SSM and diabetic SSM subpopulations with no statistical 
difference between the samples.  Conversely, a significant decrease (40%) in the 
amount of MitoGFP1 imported into the diabetic IFM compared to control IFM is shown 
at all three time points (Fig 3.4B and D).  Additionally, fluorescent labeling and 
subsequent import of MitoGFP1 was performed to confirm our Western blot findings 
(3.4A and B).  The 31 kDa band is also decreased in the diabetic IFM compared to 
control denoting lesser amounts of precursor proteins in transit to the matrix.   
 
Protein Import Machinery 
Outer and inner mitochondrial membrane translocases essential for proper 
mitochondrial import were also analyzed by Western blot analysis.  There were no 
significant differences observed in the protein expression of TOM20, TOM40, TIM23, or 
TIM44 in either the diabetic SSM or diabetic IFM as compared to control (Fig 3.5A).  
Contrary to these results, the essential mitochondrial protein import motor Grp75 was 
significantly decreased only in the diabetic IFM subpopulation  compared to control (Fig 
3.5C) with no change in the diabetic SSM compared to control (Fig 3.5B).  These results 
indicate that of the major mitochondrial protein import constituents examined only Grp75 
is decreased in abundance during type 1 diabetic insult, and this phenomenon is 
specific to the IFM subpopulation.    
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DISCUSSION 
A significant amount of data supports the notion that mitochondrial dysfunction 
plays a critical role in the pathogenesis of diabetic cardiomyopathy. Despite the growing 
evidence for mitochondrial abnormalities underlying diabetic cardiomyopathy, the 
mechanisms involved in this dysfunction are not entirely clear.  Evidence suggests that 
mitochondrial dysfunction varies depending on subcellular location, with those 
mitochondria located between the myofibrils being affected to a greater extent in the 
type 1 diabetic heart (10, 40).  Data also suggests that dysfunction manifests via 
disturbance to the IMM as evidenced by diminished ETC complex activities, an 
enhanced oxidative environment and depletion of cardiolipin, an essential phospholipid 
required for proper mitochondrial function (31).  The goal of this study was to build upon 
our previous findings and determine whether mitochondrial subpopulation-specific 
proteomes are altered with type 1 diabetes mellitus in the heart.  In an effort to elucidate 
mechanism, we examined whether mitochondrial import of nuclear-encoded proteins is 
decreased, resulting in mitochondrial proteome dysregulation.   
Proteomic analyses have played an integral role in furthering our understanding 
of mitochondrial dysfunction in the diabetic heart.  Several proteomic studies, in a 
variety of diabetic models, have been employed to assess proteomic changes 
associated with the diabetic heart (5, 9, 14, 20, 36, 38).  However, to date no 
examination of subpopulation-specific proteomic make-up has been performed in a type 
1 diabetic model.  Proteomic profile comparisons of mitochondrial subpopulations from 
diabetic and control mouse hearts revealed that the majority of proteins changing were 
in the IFM and that almost all of these changes were decreases in protein abundances.  
Utilizing iTRAQ and 2D-DIGE methodologies afforded a number of advantages over the 
use of a single proteomic methodology including the ability to confirm experimental 
results and accuracy by essentially comparing results from each method.  By using 
MudPIT analysis combined with iTRAQ labeling, the limitations associated with 2D-
DIGE, such as solubility and separation, were bypassed.  Further, the iTRAQ approach 
enabled comparison of total protein levels, which can be more difficult using 2D-DIGE 
separation, where PTMs such as phosphorylation can alter pIs and hence gel migration 
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(20).   Utilizing 2D-DIGE allowed us to examine proteins that may be in less abundance 
and as a result, less likely to show up with iTRAQ analyses.  Because each method has 
its own unique set of advantages, the combined use of both techniques enhanced our 
level of confidence in the reported findings.     
The majority of proteins identified as changing with both 2D-DIGE and iTRAQ 
approaches in the diabetic IFM were FAO and ETC proteins.  In contrast to previous 
studies (20, 38), proteins involved in FAO (transport and/or utilization of fatty acids) 
were decreased in abundance in the diabetic IFM to a greater extent than in diabetic 
SSM.  Though only a few fatty acid utilization enzymes were also decreased in diabetic 
SSM, CPT-1, a transporter of fatty acids into the mitochondrion, was upregulated.  One 
could hypothesize that the diminished ability to utilize fatty acids within the diabetic IFM 
may have hampered its ability to produce ATP which in turn, contributed to an overall 
decrease in cardiac contractile function as reported previously (10, 39).  Additionally, 
ETC complexes and translocases within the IMM act as key contributors to overall 
oxidative phosphorylation and energy production within the mitochondrion.  In total, we 
identified 9 ETC proteins from iTRAQ analyses and 16 ETC proteins from 2D-DIGE 
analyses as being decreased in the diabetic IFM.  Jullig et al. reported decreases in 
ETC constituents that are involved in oxidative phosphorylation in total mitochondria 
(20), which is somewhat different from our current study examining mitochondrial 
subpopulations.  Further, translocases located within the IMM that are essential for 
energy production through synthesis (mitochondrial phosphate carrier) and transport of 
ATP (ANT1) were also significantly decreased only in the diabetic IFM.  Interestingly, 
Jullig et al. did not report changes in ANT1 or the mitochondrial phosphate carrier which 
may have resulted from their analyses being performed on total mitochondria as 
opposed to our study examining subpopulations of mitochondria.  Our proteomic data 
are consistent with previous reports of decreased respiratory capacity in the diabetic 
heart as well as functional data indicating down-regulation of ETC activities, specifically 
in the IFM (10, 23, 36).  Down-regulation of multiple components of the oxidative 
phosphorylation machinery and FAO proteins suggests that mitochondria in the type 1 
diabetic heart, specifically IFM, may be less efficient in producing ATP required for 
contraction and calcium homeostasis. 
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 Mitochondrial morphological abnormalities have been reported with both type 1 
and type 2 diabetes mellitus (4, 22, 36).  Previous reports suggest that IFM morphology 
is specifically impacted by diabetes mellitus (10, 22).  We reported previously that IFM 
were smaller and less complex in the type 1 diabetic heart with no changes in the SSM 
(10).  Both 2D-DIGE and iTRAQ analyses indentified mitofilin, a protein critical for 
proper cristae morphology (18), as being decreased only in the diabetic IFM.  It is 
conceivable that diminished mitofilin, along with our previous reports of depleted 
cardiolipin may have been a contributing factor to the altered IFM morphology reported 
previously (10).  
To date, no attempts have been made to define the mechanisms accounting for 
mitochondrial proteomic dysregulation in the diabetic heart.   Potential mechanisms of 
proteomic dysregulation may include alterations in gene expression, enhanced PTMs, 
or upregulation of regulators such as miRNAs (21, 28).  In the present study, PTMs 
identified included oxidations, deamidations, deacetylations and methylations, with 
oxidations and deamidations being the most prevalent.  Interestingly, the diabetic IFM 
displayed the greatest number of oxidatively-modified proteins.  These findings 
complement previous studies suggesting that enhanced mitochondrial ROS formation 
during type 1 diabetic insult may precipitate oxidative damage to mitochondrial 
constituents (2, 10, 36).  Also in agreement are the results from our previous study 
reporting increased superoxide formation in the type 1 diabetic IFM and the associated 
enhancement of protein oxidation (nitrotyrosine) within the mitochondrion (10).  Another 
PTM that was prevalent in the diabetic IFM was deamidation.  It has been suggested 
that deamidation of asparaginyl and glutaminyl residues within proteins causes 
structural and biological alterations to peptide and protein structure (32).  Though the 
contribution of deamidation and oxidation to protein dysfunction is somewhat unclear, 
these PTMs may alter protein structure/function making the protein more susceptible for 
degradation by the proteasome system (16, 32).  In addition, several proteins that were 
decreased in the diabetic IFM also contained oxidations and deamidations within their 
structure.  Interestingly, Grp75, mitofilin and several components of complex V were 
decreased in abundance with both proteomic technologies and contained oxidations 
and deamidations within their structures.  It is plausible that these modifications may 
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have contributed to altered functionality and subsequent proteasomal degradation, all of 
which may have contributed to the morphological and oxidative phosphorylation 
deficiencies present in the type 1 diabetic heart.  
Given that the majority of mitochondrial proteins are nuclear-encoded and must 
be imported into the mitochondrion, it is possible that defects in this complicated 
process may underlie proteomic dysregulation in the diabetic heart.  Nuclear-encoded 
mitochondrial proteins constitute 99% of the organelle’s proteome (6).  These proteins 
are translated in the cytoplasm and must be imported into the mitochondrion via an 
intricate mechanism involving coordination between the outer and inner mitochondrial 
membranes (7).  The two membranes come together to form a “supercomplex”, which 
creates a singular avenue for translocation of the imported protein into the IMM and 
matrix (7).  Given the vast importance of this process, protein import decrements 
resulting from pathophysiological conditions could represent a mechanism for 
mitochondrial dysfunction in the diabetic heart.  Hence, a major goal of this study was to 
gain insight into whether diabetes mellitus causes protein import deficiencies in the 
mitochondrion and determine whether this phenomenon manifests differently in 
mitochondrial subpopulations.  Utilizing a novel mitochondrial protein import 
methodology that eliminated the use of protein radiolabeling, we observed dysfunction 
of the IFM protein import process without effect to the SSM.  Previous literature 
examining mitochondrial protein import in the skeletal muscle of aging mice revealed 
enhanced cytoplasmic protein degradation, as opposed to protein import decrements as 
the contributing source of the mitochondrial dysfunction (15).  It is unclear why the 
differences were observed but they may be due in part to the different pathologies and 
tissue types examined.   
Mitochondrial protein import dysfunction has been attributed in part to cardiolipin 
loss (19).  Cardiolipin is known to surround and stabilize protein import complexes 
including TIM23, the major pore forming unit essential for protein translocation.  Studies 
examining a mutation of cardiolipin, leading to loss of the phospholipid caused reduced 
membrane potential and decreased mitochondrial protein import (17). Another potential 
mechanism of mitochondrial import dysfunction is PTMs to proteins essential for protein 
translocation.  As indicated above, we observed multiple modifications to Grp75 in the 
113 
 
diabetic IFM subpopulation.  Grp75 is a heat shock protein and the central subunit of 
the presequence translocase-associated motor complex (PAM) that binds to a 
translocating polypeptide chain and drives its movement through the IMM into the matrix 
by a reaction cycle that requires hydrolysis of ATP (6).  Previous literature examining 
inactivation of yeast Grp75 revealed a near complete inhibition of oxidase assembly 1 
protein translocation through the IMM (13).  Additionally, cardiac mitochondria in 
senescent mice were shown to have elevated Grp75 protein content as well as 
increased protein import of a mitochondrial matrix protein, malate dehydrogenase (8).  
In our study, we show a marked decrease in Grp75 protein content coinciding with 
decreased protein import in the diabetic IFM subpopulation, suggesting that Grp75 
protein content is proportional to protein import capacity.  Our examination of several 
other key translocases that play a major role in mitochondrial protein import including 
translocase of the outer membrane 20 (TOM20), outer membrane pore TOM40, inner 
membrane pore TIM23, and Grp75 docking subunit TIM44, indicated that none of these 
mitochondrial protein import constituents were decreased in the diabetic heart.  Taken 
together, these results suggest that decreased Grp75 content may underlie IFM protein 
import deficiencies during type 1 diabetic insult in the heart. 
In conclusion, we report here that type 1 diabetic insult differentially influences 
spatially distinct cardiac mitochondrial proteomes, with the greatest impact occurring to 
those mitochondria located between the myofibrils (IFM).  Further, changes in 
mitochondrial proteomic make-up are associated with dysfunction to the nuclear-
encoded mitochondrial protein import machinery and loss of a key mitochondrial protein 
import constituent, Grp75, implicating this important process in the mechanistic 
pathogenesis of diabetic cardiomyopathy. 
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Figure 3.1  
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Figure 3.1. Representative iTRAQ spectra.  Isolated mitochondrial 
subpopulations from control and diabetic hearts were labeled with iTRAQ 
reagents 114 (diabetic SSM), 115 (diabetic IFM), 116 (control SSM), 117 
(diabetic IFM) and combined for analysis with mass spectrometry.  (A) 
Representative spectra of simultaneous quantitation of a Grp75 peptide in 
control and diabetic mitochondrial subpopulations.  (B) MS/MS spectra for 
the reporter groups of the iTRAQ reagents (114,115,116 and 117) from a 
Grp75 peptide. These spectra were used along with other peptides to 
simultaneously quantify Grp75 control and diabetic mitochondrial 
subpopulations.   
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Figure 3.2 
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Figure 3.2 
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Figure 3.2. Representative 2D-DIGE gels. Samples were labeled with 
either Cy3 or Cy5 alternating between control and diabetic SSM and IFM.  
A control and treated were run on the same gel and an internal standard 
was labeled with Cy2 and run on every gel for gel to gel comparisons. (A) A 
representative gel showing Cy3 labeled control IFM and (B) is the same gel 
showing Cy5 labeled diabetic IFM.  (C) A representative gel showing Cy3 
labeled control SSM and (D) is the same gel showing Cy5 labeled control 
SSM.  Below the gel images are individual spots that were identified as 
Grp75, (indicated by the red arrow) and quantitative differences were 
assessed by examination of peak density. 
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Figure 3.3 
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Figure 3.3. pMITOGFP1 construct.  (A) pMITOGFP1 plasmid was 
generated and inserted into a bacterial cell free protein expression system 
to produce MitoGFP1 protein.  The MITOGFP1 gene consists of an N-
terminal mitochondrial targeting sequence derived from cytochrome C 
oxidase subunit VIII (red) fused with AcGFP1 (green).  The MITOGFP1 
gene was cloned into pIVEX2.3d at restriction sites Not I and blunted Nco 
I/Nhe I sites.  (B)  Western blot analysis of MitoGFP1 protein import into 
isolated cardiac mitochondria probed for AcGFP in samples containing 
40µg of mitochondria only (lane 1), 0.05 µl of MitoGFP1 protein lysate (lane 
2), or combined mitochondria and lysate (3µl) (lane 3).   The upper 31 kDa 
band represents the full length precursor MitoGFP1 in transit and yet to be 
processed while the lower 27 kDa band represents a mature cleaved 
MitoGFP1 protein residing within the mitochondrial matrix.    
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Figure 3.4 
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Figure 3.4.  Mitochondrial protein import.   Effect of type 1 diabetes 
mellitus on MitoGFP1 import in SSM and IFM subpopulations. Cardiac 
mitochondrial subpopulations from control and diabetic mice were isolated 
and incubated with 3µl of MitoGFP1 protein lysate at 2, 5, and 10 minute 
time points.  Representative Western blots from (A) SSM and (B) IFM 
protein import assay.  Graphical representation of mitochondrial protein 
import performed in (C) SSM and (D) IFM control and diabetic 
subpopulations.   Diabetic values are based upon percent of control per 
corresponding time point.  Control for protein loading was confirmed by 
Ponceau staining. Values are represented as mean ± SEM; N=8 per group. 
*p<0.05 for control vs. diabetic for all groups.  Control for protein loading 
was confirmed with Ponceau staining. 
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Figure 3.5 
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Figure 3.5 
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Figure 3.5. Western blot analysis of protein import constituents.  Key 
proteins involved in mitochondrial protein import were assessed using 
Western Blot analyses. (A) Control SSM (lanes 1-2), Diabetic SSM (lanes 
3-4), Control IFM (lanes 5-6), Diabetic IFM (lanes 7-8); translocases of the 
outer mitochondrial membrane TOM20, TOM40 and inner mitochondrial 
membrane TIM23, TIM44 protein expression. Representative Western blots 
and densitometry analysis for Grp75 protein expression in (A) SSM, and 
(B) IFM from control and diabetic hearts. Values are represented as mean 
± SEM; N=5 for each group. *p<0.05 for control vs. diabetic for all groups. 
Control for protein loading was confirmed with Ponceau staining. 
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Protein Name SSM Contol/ SSM Diabetic 
IFM Control/ 
IFM Diabetic 
Mitochondrial Fatty Acids Beta-oxidation 
  
Hydroxyacyl-coenzyme A dehydrogenase 3 
ketoacyl coenzyme A 
1.31 1.41 
Mitochondrial trifunctional protein, beta subunit 1.39 1.37 
Acetyl-coenzyme A acyl transferase 2 NS 1.23 
Acyl coenzyme A dehydrogenase, medium 
chain 
NS 1.14 
Acyl Coenzyme A dehydrogenase, very long 
chain 1.31 1.28 
2,4-dienoyl CoA reductase 1 1.30 1.40 
Enoyl coenzyme hydratase 1 NS 1.26 
Carnitine palmitoyltransferase 1 .80 1.37  
Mitochondrial Respiratory Chain 
  
ATP synthase, H+ transporting, mitochondrial 
F1 complex, Beta subunit 1.31 1.20 
ATP synthase, H+ transporting, FO complex 
subunit F .73 1.19 
ATP synthase, H+ transporting, mitochondrial 
F1 complex, O subunit NS 1.13 
Table 3.1 
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ATP synthase, H+ transporting, mitochondrial 
FO, subunit b, isoform 1 NS 1.20 
NADH dehydrogenase ubiquinone flavoprotein 
1 NS 1.17 
NADH dehydrogenase ubiquinone 1 alpha 
subcomplex 8  .79 NS 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex 12 NS 1.40 
Ubiquinol cytochrome c reductase, Rieske iron 
sulfur unit polypeptide 1 NS .83 
Cytochrome C-1 .73 NS 
Cytochrome Coxidase subunit IV isoform 1 .85 NS 
Cytochrome C oxidase subunit VIb polypeptide 
1 NS 1.43 
Electron transfer flavoprotein-ubiquinone 
oxidoreductase NS .87 
Electron transfer flavoprotein subunit alpha NS 
1.34 
 
 
Electron transfer flavoprotein beta polypeptide .83 1.17 
TCA Cycle 
  
Aconitase 2 NS 1.10 
Malate dehydrogenase 2, NAD NS .92 
134 
 
Isocitrate dehydrogenase 2 (NADP+) .86 1.33 
Pyruvate dehydrogenase (lipoamide) beta .70 NS 
Creatine Kinase .68 NS 
Transport Proteins   
Adenine nucleotide translocator, member 4 NS 1.30 
Vdac (Vdac-1)  NS .87 
Solute carrier family 25, member 3 phosphate 
carrier NS 1.47 
Grp75 NS 1.20 
Structural 
  
Inner membrane protein immt, mitofilin NS 1.36 
Miscellaneous   
Myoglobin NS .66 
Es 1 protein NS 1.25 
Multimerin 2 NS 1.13 
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Hydroxysteroid dehydrogenase like 2, isoform 
CRA_c 1.64 1.26 
Mlrq-like protein NS 1.50 
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Table 3.1. iTRAQ Proteomic analysis of mitochondrial subpopulations 
from control and diabetic hearts.  iTRAQ analysis of proteins identified 
and significantly changing, categorized into groups consisting of fatty acid 
oxidation (FAO), mitochondrial respiratory chain, citric acid cycle (TCA), 
transport proteins, structural and miscellaneous proteins in isolated SSM 
and IFM from control and diabetic hearts.  Cells highlighted in red represent 
decreased protein expression in the diabetic mitochondria compared to 
control, while cells highlighted in green are increased in diabetic vs. control.  
All values presented indicate a significant difference of at least *p<0.05 for 
control vs. diabetic groups, while NS represents no significant differences 
between any groups. N=4 for each group. 
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Protein Name 
Difference      SSM 
Diabetic vs. SSM 
Control 
Difference    IFM 
Diabetic vs. IFM 
Control 
Mitochondrial Fatty Acids Beta-oxidation 
  
Very long-chain specific Acyl-CoA 
Dehydrogenase 
-1.14 -1.25 
Long-Chain specific Acyl-CoA Dehydrogenase 
 
NS -1.21 
Isoform 2 of 2-oxoglutarate dehydrogenase E1 
Complex 
NS -1.27 
 
Medium-chain specific acyl-coA dehydrogenase
-1.45 -1.31 
mitochondrial acyl-CoA thioesterase 1 NS -1.10 
Delta(3,5)-Delta(2,4)-Dienoyl-COA 
ISOMERASE 
 
2.02 -1.11 
Mitochondrial Respiratory Chain 
  
Isoform 1 of NADH Dehydrogenase 
(Ubiquinone) Flavoprotein2 
 
1.25 -1.18 
NADH dehydrogenase iron-sulfur protein 2 NS -1.15 
Table 3.2 
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NADH-Ubiquinone Oxidoreductase 75 kda 
subunit -1.54 -1.315 
NADH Dehydrogenase Ubiquinone 1 Alpha 
subcomplex subunit 10 
 
NS -1.23 
NADH Dehydrogenase Ubiquinone Iron-sulfur 
Protein 8 
 
NS -1.15 
NADH dehydrogenase (ubiquinone) iron-sulfur 
protein 3 
 
NS -1.15 
NADH dehydrogenase (ubiquinone) iron-sulfur 
protein 4 
 
NS -1.10 
Electron Transfer Flavoprotein-ubiquinone 
oxidoreductase 
 
2.83 -1.16 
Ubquinol cytochrome c redcutase core protein 1 
 NS -1.14 
Cytochrome b-cl complex c 
 NS -1.15 
Cytochrome b-c1 complex subunit Rieske 
 NS -1.33 
Ubiquinone biosynthesis protein COQ9 
 -1.04 -1.23 
Succinate dehydrogenase (ubiquinone) iron-
sulfur unit 
 
NS -1.70 
139 
 
Atp synthase subunit beta NS -1.25 
Atp synthase subunit O 1.13 -1.67 
ATP5a1 ATP synthase subunit alpha 
 NS -1.21 
TCA Cycle 
  
Aldehyde dehydrogenase 
 1.15 -1.14 
Pyruvate dehydrogenase E1 component subunit 
Beta 
 
NS -1.29 
Dihydrolipoyllysine-residue acetyltrasnferase 
component of pyruvate dehydrogenase complex 
 
1.50 -1.25 
Malate dehydrogenase 
 2.3 -1.34 
Isocitrate dehydrogenase NAD subunit alpha 
 NS -1.46 
Aconitase hydratase NS -1.41 
Amino Acid Metabolism 
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Aspartate aminotransferase 
 NS 1.96 
ubiquitin protein ligase E3C 
 1.34 -2.3 
Oxidative Stress Related 
  
Prdx3 
 NS -1.23 
Transport Proteins   
Heat Shock Protein 60 
 -1.40 -1.50 
Grp75 NS -1.36 
Structural 
  
IMMT Mitofilin NS -1.326 
Prohibitin-2 
 NS -1.396 
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Table 3.2. 2D-DIGE proteomic analysis of mitochondrial 
subpopulations from control and diabetic hearts. 2D-DIGE analysis of 
proteins identified and significantly changing, categorized into groups 
consisting of fatty acid oxidation (FAO), mitochondrial respiratory chain, 
citric acid cycle (TCA), amino acid metabolism, oxidative stress related, 
transport proteins, and structural proteins in isolated SSM and IFM from 
control and diabetic hearts.  Cells highlighted in red represent decreased 
protein expression in the diabetic mitochondria compared to control, while 
cells highlighted in green are increased in diabetic vs. control.  All values 
presented indicate a significant difference of at least *p<0.05 for control vs. 
diabetic groups, while NS represents no significant differences between 
any groups. N=4 for each group. 
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Protein Diabetic IFM Peptide Sequence 
Diabetic IFM 
Post Translational 
Modification 
Diabetic IFM 
ATP synthase, H+ transporting 
mitochondrial F1 complex, beta 
subunit 
ALVYGQMNEPPGAR 
 
Oxidation(M)@7; Cation:K(E)@9 
Ubiquinol cytochrome c reductase 
core protein 2 
NALANPLYCPDYR 
 
Carbamidomethyl(C)@9; 
Dioxidation(Y)@12; Arg-
>GluSA(R)@13 
solute carrier family 25 
(mitochondrial carrier, adenine 
nucleotide translocator), member 
4 [Mus musculus] 
GADIMYTGTLDCWR 
 
Carbamidomethyl(C)@12; 
Dioxidation(W)@13; Arg-
>GluSA(R)@14 
ubiquinol-cytochrome c reductase 
core protein 1 
VYEEDAVPGLTPCR 
 
Oxidation(P)@8; 
Oxidation(P)@12; 
Carbamidomethyl(C)@13; Arg-
>GluSA(R)@14 
 
ubiquinol-cytochrome c reductase 
core protein 1 
NALVSHLDGTTPVCEDIGR 
 
Dioxidation(P)@12; 
Carbamidomethyl(C)@14; Arg-
>GluSA(R)@19 
acetyl-Coenzyme A 
acetyltransferase 1 
ENGTITAANASTLNDGAAALV
LMTAEAA 
QR 
Oxidation(N)@2; 
Deamidated(N)@9 
Grp75 MKETAENYLGHTAK Oxidation(M)@1 
ATP synthase, H+ transporting, 
mitochondrial F0 complex, 
subunit b, isoform 1 
QIQDAIDMEK Oxidation(M)@8 
Titin (Connectin) KMEAPPPKAPKKR Dioxidation(P)@5 
NADH dehydrogenase 
(ubiquinone) 1 beta subcomplex 8 
VEDYEPYPDDGMGYGDYPML
PNR 
Oxidation(D)@3 
 
inner membrane protein, 
mitochondrial(Mitofilin) 
RVAQDWLKEAR Deamidated(Q)@4; 
Oxidation(W)@6 
dodecenoyl-Coenzyme A delta 
isomerase 
SLHMYLEK Oxidation(M)@4 
ATP synthase, H+ transporting 
mitochondrial F1 complex, beta 
subunit 
TREGNDLYHEMIESGVINLK Deamidated(N)@5 
ATP synthase, H+ transporting 
mitochondrial F1 complex, beta 
subunit 
GSITSVQAIYVPADDLTDPAPA
TTFAHLDATTVLSR 
Acetyl@N-term; 
Deamidated(Q)@7; 
Carbamidomethyl(D)@14 
Table 3.3 
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ATP synthase, H+ transporting, 
mitochondrial F1 complex, alpha 
subunit, isoform 1 
VVDALGNAIDGK Deamidated(N)@7 
3-ketoacyl-CoA thiolase, 
mitochondrial (Beta-ketothiolase) 
AALSAGKVPPETIDSVIVGNV
MQSSSDAAYLAR 
Deamidated(N)@20 
mitochondrial trifunctional 
protein, beta 
DNGIRPSSLEQMAK Deamidated(N)@2 
mitochondrial trifunctional 
protein, beta 
LKPAFIKPYGTVTAANSSFLTD
GASAMLIMSEDR 
Deamidated(N)@16 
glutamate oxaloacetate 
transaminase 2, mitochondrial 
[Mus musculus] 
 
DDNGKPYVLPSVR Deamidated(N)@3 
glutamate oxaloacetate 
transaminase 2, mitochondrial 
[Mus musculus] 
 
KMNLGVGAYRDDNGKPYVL
PSVR 
Deamidated(N)@13 
succinate dehydrogenase Fp 
subunit [Mus musculus] 
 
NTVIATGGYGR Deamidated(N)@1 
solute carrier family 25 
(mitochondrial carrier, adenine 
nucleotide translocator) 
GDQALSFLKDFLAGGIAAAVS
K 
Protein Terminal Acetyl@N-term 
solute carrier family 25 
(mitochondrial carrier, adenine 
nucleotide translocator) 
GDQALSFLK Protein Terminal Acetyl@N-term 
ubiquinol-cytochrome c reductase 
core protein 1 
TATFAQALQSVPETQVSILDN
GLR 
Deamidated(N)@21 
ubiquinol-cytochrome c reductase 
core protein 1 
EVESIGAHLNAYSTR Deamidated(N)@10 
cytochrome c oxidase, subunit Va LNDFASAVR Deamidated(N)@2 
cytochrome c oxidase, subunit Va RLNDFASAVR Deamidated(N)@3; 
Dehydrated(D)@4 
acyl-Coenzyme A dehydrogenase, 
long-chain [Mus musculus] 
SPAHGISLFLVENGMK Deamidated(N)@13 
Grp75 ASNGDAWVEAHGK 
 
Deamidated(N)@3 
Grp75 STNGDTFLGGEDFDQALLR 
 
Deamidated(N)@3 
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Fumarate hydratase 1 YPIEHGIITNWDDMEK Methyl(H)@5 
Fumarate hydratase 1 LNDHFPLVVWQTGSGTQTNM
NVNEVISNR 
Deamidated(Q)@17 
ATP synthase, H+ transporting, 
mitochondrial F0 complex, 
subunit F 
RQASGGPVDIGPEYQQDLDRE
LYK 
Deamidated(Q)@2; 
Dehydrated(S)@4 
pyruvate dehydrogenase E1 alpha 
1 [Mus musculus] 
 
TREEIQEVRSKSDPIMLLK Deamidated(R)@9 
superoxide dismutase 2, 
mitochondrial [Mus musculus]; 
Sod2 protein [Mus musculus] 
 
FNGGGHINHTIFWTNLSPK Deamidated(N)@2 
Carnitine O-acetyltransferase 
(Carnitine acetylase) (CAT) 
IWNSSLQSNKEPVGILTSNHR Deamidated(N)@3 
NADH dehydrogenase 
(ubiquinone) 1 beta subcomplex, 9 
[Mus musculus] 
 
EAEEEFWQNQHPQPYIFPDSP
GGTSFER 
Deamidated(N)@9 
3-hydroxyacyl CoA 
dehydrogenase 
LDKFAAEHTIFASNTSSLQITNI
ANATTR 
Deamidated(N)@14 
Aldehyde dehydrogenase family 
6, subfamily A1 
NHGVVMPDANKENTLNQLV
GAAFGAAGQR 
Deamidated(N)@10 
Aldehyde dehydrogenase family 
6, subfamily A1 
IVNDNPYGNGTAIFTTNGATA
R 
Deamidated(N)@9; 
Deamidated(N)@17 
dihydrolipoamide S-
succinyltransferase 
NDVITVQTPAFAESVTEGDVR Deamidated(N)@1 
NADH dehydrogenase 
(ubiquinone) 1, subcomplex 
unknown, 2 [Mus musculus] 
 
MMNGRPGHEPLK Protein Terminal Acetyl@N-term; 
Deamidated(N)@3 
isocitrate dehydrogenase 3 
(NAD+), gamma 
KAVLASMDNENMHTPDIGGQ
GTTSQAIQDII 
Deamidated(N)@9 
 
Protein Diabetic SSM 
Peptide Sequence 
Diabetic SSM 
Post Translational Modification 
Diabetic SSM 
ATP synthase, H+ transporting 
mitochondrial F1 complex, beta 
subunit 
IPSAVGYQPTLATDMGTMQE
R 
Oxidation(P)@2 
acetyl-Coenzyme A 
acyltransferase 2 
VPPETIDSVIVGNVMQSSSDA
AYLAR 
Oxidation(P)@2 
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ubiquinol-cytochrome c reductase 
core protein 1 
VYEEDAVPGLTPCR Dioxidation(P)@12; 
Carbamidomethyl(C)@13; Arg-
>GluSA(R)@14 
ubiquinol-cytochrome c reductase 
core protein 1 
TATFAQALQSVPETQVSILDN
GLR 
Oxidation(F)@4; 
Deamidated(Q)@6; 
Deamidated(N)@21 
NADH dehydrogenase 
(ubiquinone) 1 beta subcomplex 8 
[Mus musculus] 
 
VEDYEPYPDDGMGYGDYPML
PNR 
Oxidation(D)@3 
ATP synthase, H+ transporting, 
mitochondrial F1 complex, alpha 
subunit, isoform 1 
VVDALGNAIDGK Deamidated(N)@7 
enoyl-Coenzyme A hydratase 
(trifunctional protein), alpha 
subunit 
SLNSEMDNILANLRLPAKPEV
SSDEDVQYR 
Deamidated(N)@3 
glutamate oxaloacetate 
transaminase 2, mitochondrial 
[Mus musculus]; 
ILIRPLYSNPPLNGAR Deamidated(N)@13 
glutamate oxaloacetate 
transaminase 2, mitochondrial 
[Mus musculus]; 
MNLGVGAYRDDNGKPYVLPS
VR 
Deamidated(N)@12 
ATP synthase, H+ transporting, 
mitochondrial F0 complex, 
subunit d 
NIIPFDQMTIDDLNEIFPETKLD
KK 
Deamidated(N)@1 
Electron transfer flavoprotein-
ubiquinone oxidoreductase 
IPVPILPGLPMNNHGNYIVR Deamidated(N)@12 
oxoglutarate dehydrogenase 
(lipoamide) 
SSLATMAHAQSLVEAQPNVD
KLVEDHLAVQSLIR 
Deamidated(Q)@10 
ubiquinol cytochrome c reductase 
core protein 2 [Mus musculus] 
LPNGLVIASLENYAPLSR Deamidated(N)@3 
ubiquinol cytochrome c reductase 
core protein 2 [Mus musculus] 
RGNNTTSLLSQSVAK Deamidated(N)@3 
ubiquinol cytochrome c reductase 
core protein 2 [Mus musculus] 
TSAAPGGVPLQPQDLEFTKLP
NGLVIASLENYAPLSR 
Deamidated(Q)@13; 
Deamidated(N)@22 
fumarate hydratase 1 LNDHFPLVVWQTGSGTQTNM
NVNEVISNR 
Deamidated(Q)@17 
Cytochrome c-1 AANNGALPPDLSYIVR Deamidated(N)@4 
carnitine palmitoyltransferase 2 LSAVSGPAEYLQHSIVPTMHY
QDSLPR 
Deamidated(Q)@12 
NADH dehydrogenase 
(ubiquinone) 1 alpha subcomplex, 
8 
TDRPLPENPYHSR Dehydrated(S)@12; 
Deamidated(R)@13 
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pyruvate dehydrogenase E1 alpha 
1 
KEIEDAAQFATADPEPPLEELG
YHIYSSDPPFEVR 
Deamidated(Q)@8 
pyruvate dehydrogenase E1 alpha 
1 
MVNSNLASVEELKEIDVEVR Deamidated(N)@3 
pyruvate dehydrogenase E1 alpha 
1 
TREEIQEVRSKSDPIMLLK Deamidated(R)@9 
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Table 3.3 Post-translational modifications (PTM) in mitochondrial 
subpopulations from control and diabetic hearts.   Multidimensional 
protein identification technology (MudPIT) was used to identify post-
translational modifications (PTM) of proteins from SSM and IFM from 
control and diabetic mitochondria.  Peptides presented represent only 
those peptides that have PTMs in the diabetic SSM (A) and IFM (B) and 
not present in the control group. 
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ABSTRACT 
Cardiac complications and heart failure are the leading cause of death in type 2 
diabetic patients. Mitochondrial dysfunction is central in the pathogenesis of the type 2 
diabetic heart.  However, it is unclear whether this dysfunction is specific for a particular 
subcellular region. The purpose of this study was to determine whether mitochondrial 
dysfunction in the type 2 diabetic heart is specific to a spatially distinct subset of 
mitochondria.  We investigated mitochondrial morphology, function, and proteomic 
composition of subsarcolemmal mitochondria (SSM) and interfibrillar mitochondria (IFM) 
in 18 week old db/db mice. Oxidative damage was assessed in subpopulations through 
measuring lipid peroxidation by-products and nitrotyrosine residues.  Proteomic profiles 
and post-translational modifications (PTM) were assessed in mitochondrial 
subpopulations utilizing iTRAQ™ and MudPIT technologies, respectively.  SSM from 
db/db hearts had altered morphology including a decrease in size and internal 
complexity, while db/db IFM were increased in internal complexity.  Db/db SSM 
displayed decreased state 3 respiration rates, electron transport chain (ETC) activities, 
ATP synthase activities, mitochondrial membrane potential (∆Ψm), and increased 
oxidative damage, with no change in IFM.  Proteomic assessment revealed a greater 
impact on db/db SSM as compared to db/db IFM. Inner mitochondrial membrane (IMM) 
proteins including ETC, ATP synthesis, and mitochondrial protein import machinery 
were predominantly decreased.  We provide evidence that mitochondrial dysfunction in 
the type 2 diabetic heart is associated with a specific subcellular locale.  Further, 
mitochondrial morphological and functional indices are impacted differently during type 
2 diabetic insult, and may result from modulation of spatially distinct mitochondrial 
proteomes. 
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INTRODUCTION 
Type 2 diabetes mellitus is linked to reduced life span in humans due in part to 
cardiovascular complications and heart failure (19).  Mitochondrial dysfunction and 
altered myocardial metabolism contribute to cardiovascular complications during type 2 
diabetes mellitus (3, 4).  Previous studies have observed a decrease in cardiac function, 
and decreased cardiac efficiency in db/db mice, a model of type 2 diabetes mellitus 
(42).  An increase in circulating free fatty acids present with type 2 diabetes mellitus 
leads to a pooling of fatty acids in the mitochondrion, facilitating an enhanced oxidative 
milieu.  Examination of total mitochondria from db/db mouse hearts revealed respiration 
and oxidative phosphorylation deficits, due in part to an increased oxidative 
environment in the mitochondrion (3).   
The cardiomyocyte consists of two biochemically and spatially distinct 
mitochondrial subpopulations, the subsarcolemmal mitochondria (SSM) located beneath 
the plasma membrane and the interfibrillar mitochondria (IFM), situated between the 
myofibrils (33).  These two mitochondrial subpopulations respond differently to 
physiological stimuli, including type 1 diabetes mellitus (25, 27, 30, 37).  Previously, we 
reported differential effects on spatially distinct mitochondrial subpopulations in terms of 
morphology, function, and oxidative parameters following STZ-induced type 1 diabetic 
insult, with the IFM subpopulation being most affected (12).  However, a previous study 
observed decreased complex II activity and mitochondrial DNA copy number in the 
SSM from the skeletal muscle of type 2 diabetic patients, with no significant effects on 
the IFM (37).  Examination of mitochondrial cardiac proteomic profiles has revealed 
changes in specific mitochondrial constituents suggesting that the alteration of key 
proteins involved in substrate utilization, electron transport chain (ETC) function, 
antioxidant status, and other important mitochondrial processes may be associated with 
the pathogenesis of diabetes mellitus (6, 20, 47).  A recent study examining the impact 
of endurance exercise revealed distinct subpopulation-specific mitochondrial proteome 
alterations (23).  Nevertheless, to date, no study has examined cardiac mitochondrial 
subpopulation response in a type 2 diabetic model. 
The goal of the present study was to determine how spatially distinct 
mitochondrial subpopulations in the heart of db/db mice are impacted, and to discern 
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the effects on subpopulation-specific mitochondrial proteomes.  Our results suggest that 
the SSM subpopulation displays greater dysfunction in the db/db heart, which may be 
due to specific alterations in the SSM proteome.  This data highlights the importance 
and relevance of taking into account subcellular location when examining mitochondria 
during diabetic insult. 
152 
 
MATERIALS AND METHODS 
Experimental Animals  
The animal experiments in this study conformed to National Institutes of Health 
(NIH) Guidelines for the Care and Use of Laboratory Animals, and were approved by the 
West Virginia University Animal Care and Use Committee (WVU-ACUC).  Male db/db 
mice, strain BKS.Cg-m +/+ Leprdb/J, and wild-type (WT) littermate controls (Jackson 
Laboratories, Bar Harbor, ME) were housed in the West Virginia University Health 
Sciences Center animal facility. Mice were given unlimited access to a rodent diet and 
water.  All mouse groups were aged to 18 weeks and then sacrificed for the following 
experiments. 
 
Preparation of Individual Mitochondrial Subpopulations  
At 18 weeks of age, db/db mice and their littermate controls were sacrificed, and 
the hearts were excised. Hearts were rinsed in phosphate buffered saline (PBS, pH 
7.4), then blotted dry and weighed.  SSM and IFM were isolated on ice following the 
methods of Palmer et al. (33) with minor modifications (12, 13).  Briefly, the ventricles 
were minced and homogenized 1:10 (w/v) in cold Chappel-Perry buffer (in mmol/L: 100 
KCl, 50 MOPS, 5 MgSO4·7H2O, 1 EGTA, 1 ATP; pH 7.4) at 4°C.  The homogenates 
were than centrifuged at 700 x g for 10 minutes. The supernatant containing the SSM 
was extracted and centrifuged again at 10,000 x g to isolate SSM. The SSM pellet was 
washed and centrifuged two more times at 10,000 x g and then once more at 10,000 x g 
to obtain a clean SSM fraction. The remaining pellet from the 700 x g spin was 
resuspended in KME buffer (in mmol/L: 100 KCl, 50 MOPS, and 0.5 EGTA; pH 7.4) and 
exposed to 5 mg/g of trypsin for 10 minutes.  After 10 minutes, the IFM pellet was 
diluted two-fold with buffer plus protease inhibitor cocktail (Biovision, Mountain View 
CA) to inhibit trypsin, and spun down at 700 x g for 10 minutes.  The IFM containing 
supernatant was saved and the pellet resuspended and spun down again at 700 x g for 
10 minutes to maximize IFM yield.   Next, supernatants were combined and spun down 
at 10,000 x g to yield the IFM.  The IFM were washed several times and spun down at a 
final spin of 10,000 x g for 10 minutes.  Pellets were resuspended in a sucrose buffer 
containing (in mmol/L: 220 sucrose, 70 mannitol, 10 Tris·HCl, and 1 EDTA; pH 7.4), and 
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protein concentrations were determined using the Bradford method with bovine serum 
albumin (BSA) as a standard (5). 
 
Mitochondria Size and Internal Complexity  
To index mitochondrial subpopulation size and complexity, we performed flow 
cytometry analyses using a FACS Calibur equipped with a 15 MW 488-nm argon laser 
and 633 red diode laser (Becton Dickinson, San Jose, CA) as previously described (12, 
13).  Briefly, Mitotracker deep red 633 (Invitrogen, Carlsbad, CA), which moves into 
intact mitochondria due to membrane potential, was used to selectively stain intact 
mitochondria (emission wavelength: 633 nm, fluorescent 633 red diode laser) and debris 
excluded by gating for only mitotracker deep red 633 positive events (intact 
mitochondria). Forward scatter (FSC) and side scatter (SSC) detectors were used to 
examine size (FSC) and complexity (SSC) in isolated mitochondrial subpopulations and 
represented as histograms plotted against the number of gated events as previously 
described (12, 13).  To confirm the absolute mitochondria size, we used a flow 
cytometry size calibration kit (Invitrogen), which uses a set of microsphere suspensions 
(0.5–6 µm) to serve as reliable size references for flow cytometric analyses as 
previously described (12, 13).   All flow cytometric measurements were performed under 
the supervision of the West Virginia University Flow Cytometry Core Facility. 
 
Electron Transport Chain (ETC) Respiration  
State 3 and state 4 respiration rates were assessed in isolated mitochondrial 
subpopulations as previously described (7, 8, 21) with slight modifications (13). After the 
mitochondrial subpopulation isolation, samples were resuspended in respiration buffer 
containing (in mmol/L: 80 KCl, 50 MOPS, 1 EGTA, 5 KH2PO4, and 1 mg/ml BSA) and 
equal volumes were loaded into a Gilson chamber (Gilson, Middleton, WI) attached to a 
Yellow Springs Instruments 5300 biological oxygen monitor (YSI, Yellow Springs, OH).   
The substrates glutamate (5mM) + malate (5mM), palmitoylcarnitine (40 μM) was used 
to initiate maximal respiration and measurement of state 3 (1mM ADP) and state 4 
(ADP-limited) respiration were made as previously described (7).  
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Electron Transport Chain (ETC) Complex Activities 
ETC activities of complexes I, III and IV were measured spectrophotometrically 
as previously described (12, 46).  Briefly, complex I activity was determined by 
measuring the oxidation of NADH at 340 nm as previously described (46). The assay 
mixture  for complex I contained 25 mM potassium phosphate buffer (pH 7.2), 5 mM 
MgCl2, 2 mM KCN, 2.5 mg/ml bovine serum albumin, 50 µM NADH, 10 µM 
decylubiquinone and 2 μg/ml antimycin A.  The reaction was initiated by adding purified 
mitochondria (45 µg), and the enzyme activity was measured for 3 minutes, with values 
recorded every 10 seconds after the initiation of the reaction. The complex I specific 
activity was inhibited by 2 μg/ml of rotenone.  Complex III activity was determined as 
previously described (12, 46) by following the reduction of cytochrome c at 550 nm in 
the presence of reduced decylubiquinone (50 µM).  Briefly, the assay buffer for complex 
III consisted of 500 mM sucrose, 2 mM EDTA, 100 mM Tris-HCl, (pH 7.4), 1 mM 
cytochrome c, 200 mM KCN, 1mg/ml Antimycin A and reduced decylubiquinone.   
Finally, complex IV activity was determined by measuring the oxidation of cytochrome c 
at 550 nm.  Briefly, the assay mixture for complex IV consisted of 10 mM phosphate 
buffer (pH 7.4) and 20 µM reduced cytochrome c.  Protein content was determined as 
described above (5), and values expressed as activities in nanomoles substrate 
consumed per minute per milligram of protein. 
 
ATP Synthase Activity  
ATP synthase activity was measured in frozen-thawed mitochondria as 
oligomycin-sensitive ATPase activity using an assay coupled with pyruvate kinase 
which converts the ADP to ATP and produces pyruvate from phosphoenolpyruvate. (16, 
34, 39).  Briefly, isolated mitochondria subpopulations were incubated in a buffer 
containing (in mmol/L: 20 HEPES, 5 MgCl2, 100 KCl, 5 KCN, 2.5 phosphoenolpyruvate, 
0.2 NADH, and 0.1 mg/ml pyruvate kinase, 0.1 mg/ml lactate dehydrogenase; pH 7.5-
8.0).  The reaction was initiated by addition of ATP to a desired final concentration (1 
mM) and followed by the decrease in NADH absorption at 340 nm wavelength (16).  
Absorbance was measured on a Biotek Synergy HT plate reader (Biotek, Winooski, VT), 
and protein content was assessed as above (5) with final values expressed as 
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micromoles consumed per minute per milligram of protein, which was equal to the 
micromoles of NADH oxidized per minute per milligram of protein. 
 
Mitochondrial Membrane Potential (∆Ψm) 
Mitochondrial membrane potential (∆Ψm) was measured by flow cytometry using 
the ratiometric dye 5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazol carbocyanine 
iodide (JC-1) (Molecular Probes, Carlsbad, CA), which is a lipophilic cation that enters 
selectively into mitochondria (36).  Isolated mitochondrial subpopulations were 
incubated with JC-1 for 15 minutes at 37°C, and 20,000 gated events were analyzed 
per sample.  Changes in ∆Ψm are reflected in the degree of color change from green to 
orange as membrane potential increases.  The shift to orange is due to the dye forming 
aggregates upon membrane polarization causing shifts in emitted light from 530 nm 
(green) to 590 nm (orange).  Addition of 200 μM of dinitrophenol (DNP), which collapses 
the ∆Ψm, was used as an assay control.  Measurements were performed on freshly 
isolated mitochondria subpopulations. 
 
Western Blot Analyses 
 SDS polyacrylamide gel electrophoresis (SDS-PAGE) was run on 4-12% 
gradient gels as previously described (26) with equal amounts of protein loaded for 
each study treatment. Relative amounts of subpopulation-specific mitochondrial adenine 
nucleotide translocase (ANT), cytochrome oxidase (COX IV), and ubiquinol cytochrome 
c reductase core protein 2 (UQCRC2) were assessed through the use of specific 
antibodies including: anti-ANT goat antibody (Product# sc-9300; Santa Cruz Biotech, 
Santa Cruz, CA), anti-COX IV rabbit antibody (Product# 4866; Cell Signaling, Danvers, 
MA), uncoupling protein 3 (UCP3; Product# PA1-028; Affinity Bioreagents, Golden, 
CO), and anti-Uqcrc2 mouse antibody (Product# MS304; Mitosciences, Eugene, OR).  
The secondary antibody was a goat anti-rabbit IgG HRP conjugate (Product# 
10004301; Cayman Chemical, Ann Arbor, MI) for COXIV, donkey anti-goat IgG HRP 
conjugate (Product #sc-2020; Santa Cruz Biotech, Santa Cruz, CA) for ANT and goat-
anti mouse conjugate (Product# 31430; Pierce Biotech, Rockford, IL) for Uqcrc2.  
Detection of signal was performed according to the manufacturer’s instructions, using 
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Pierce ECL Western Blotting Substrate (Pierce, Rockford, IL).  Autoradiographic signals 
were assessed using a G:Box Bioimaging System (Syngene, Frederick, MD), and the 
data captured and analyzed using GeneSnap/GeneTools software (Syngene, Frederick, 
MD). Control for protein loading was confirmed by Ponceau staining. 
 
Lipid Peroxidation Products  
Peroxidation of lipids was assessed by measurement of malondialdehyde (MDA) 
and 4-hydroxyalkenal (4-HAE), stable end products formed from the oxidation of 
polyunsaturated fatty acids and esters, as previously described (12, 13).  Equal volumes 
of freshly isolated mitochondrial subpopulations were analyzed for MDA and 4-HAE 
using a colorimetric assay kit (Oxford Biomedical Research, Oxford, MI). This assay is 
based on the reaction of a chromogenic reagent, N-methyl-2-phenylindole, with MDA 
and 4-HAE at 45°C.  One molecule of either MDA or 4-HAE reacts with two molecules of 
the reagent to yield a stable chromophore with a maximal absorbance at 586 nm. 
Absorbance was measured on a Biotek Synergy HT plate reader (Biotek, Winooski, VT), 
and protein content was assessed as described above (5) with final values expressed 
per milligram of protein.    
  
Protein Nitrotyrosine Content  
Oxidatively-modified proteins were examined by measuring nitrosylated groups 
introduced into protein side chains using a commercially available kit (Cell Sciences, 
Canton, MA) as previously described (12). Nitrotyrosine-containing proteins were 
measured using a solid-phase enzyme-linked immunosorbent assay based on the 
sandwich principle. Samples were incubated in microtiter wells coated with antibodies 
recognizing nitrotyrosine residues. After an incubation period and a wash, a biotinylated 
secondary antibody (tracer) was added, followed by a wash and the addition of a 
streptavidin-peroxidase conjugate. Color development was measured 
spectrophotometrically at 450 nm after the addition of tetramethylbenzidine using a 
Biotek Synergy HT plate reader (Biotek, Winooski, VT), and values were compared 
against known nitrotyrosine standards. 
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iTRAQ™ Labeling 
Pooled SSM and IFM subpopulations (n=4) from db/db and WT hearts were 
lysed and precipitated overnight in acetone at -20°C and pellets were resuspended in 
20 μL of 0.5 M triethylammonium bicarbonate (TEAB; pH 8.5).  Protein contents were 
determined using a 2-D Quant Kit (Amersham, Piscataway, NJ) and 100 μg of each 
pooled sample was than denatured with 0.1% SDS and reduced with 5mM tris-(2-
carboxyethyl) phosphine (TCEP).  After incubation for 1 hour at 60°C, cysteines were 
blocked with 10 mM methyl methane thiosulfonate (MMTS) in isopropanol, and the 
samples were incubated at room temperature for 10 minutes.  Addition of 10 μL of 
sequencing grade trypsin (Applied Biosystems, Foster City, CA) was added in a 
trypsin/protein ratio of 1:20, and the samples incubated at 37°C overnight.  Digested 
samples were labeled with the iTRAQ™ reagents following the protocol provided by the 
vendor (Applied Biosystems, Foster City, CA).  
After digestion and iTRAQ™ labeling, the ultra-complex protein digests were 
combined to create a 400 µg pooled protein digest sample that contained equal 
fractions of each of the four labeled samples for subsequent Multi Dimensional Protein 
Identification Technology (MudPIT) analysis (28).   After lyophilization, the digest 
mixture was reconstituted in strong cation exchange (SCX) loading buffer (5mM 
ammonium formate in 20% acetonitrile; pH 3.0) to be fractionated with SCX SpinTips 
(Protea Biosciences, Morgantown, WV) per the manufacturer’s protocol.  Briefly, the 
sample solution was loaded centrifugally onto the SCX SpinTip.  The non-adsorbing 
solution that passed through the SCX SpinTip was collected. Eight different elution 
solutions were used to fractionate the peptides (20, 60, 100, 150, 200, 250, 400, and 
500 mM ammonium formate in 10% acetonitrile) in a step-wise manner, for a total of 
nine sample fractions.  The collected fractions were cleaned by repeated lyophilization 
and reconstituted in a 0.1 M acetic acid solution, and then lyophilized to dryness.  The 
fractions were then submitted for LC-MALDI TOF/TOF mass spectral analysis for 
protein identification, characterization, and differential expression analysis.  
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Mass Spectrometry (MS) Analyses with iTRAQ™ Labeling 
The LC-MALDI mass spectrometry system utilized was an ABI Tempo LC MALDI 
spotter with Tempo LC MALDI v.2.00.09 data acquisition and processing software.  
Lyophilized SCX sample fractions were reconstituted in LC aqueous run buffer (0.1% 
trifluoroacetic acid, 2% acetonitrile) and was injected onto a Zorbax C18 
chromatographic column, 150 x 0.3 mm (Agilent Technologies, Wilmington, DE).  The 
peptides were eluted from the column using an acetonitrile/trifluoroacetic acid gradient 
(2-72% acetonitrile in 35 minutes) and spotted directly onto a MALDI plate in 6 second 
spot fractions.  The MALDI spots were analyzed using an ABI 4800 MALDI TOF/TOF 
analyzer operated with 4000 Series Explorer software.  The MS acquisition was in 
positive ion reflector mode with 400 laser shots per spectrum performed.  The 15 
strongest precursors per spot were chosen for MS/MS and the MALDI spot was 
interrogated until at least 4 peaks in the MS/MS, spectra achieved a S/N ≥ 70.   
The resulting MS/MS spectra were analyzed using ABI Protein ProteinPilot 
software 2.0 (Applied Biosystems, Foster City, CA).  The spectral data was searched 
against the mouse protein database (NCBI nr.fasta database customized to select for all 
mouse proteins) for identification of the peptides and corresponding proteins.  In 
ProteinPilot, the sample type was selected as iTRAQ 4Plex for retrieval of the isotopic 
tag information from the mass spectra.  After database correlation analysis, the proteins 
were grouped, scored, and normalized against one to four isotope correction factors.  
The Pro Group algorithm of ProteinPilot generated a ProtScore that is a cumulative 
score from each of the peptides used by the algorithm in the protein identification.  
Protein scores (ProtScore) above 2.0, 1.0, and 0.47 expressed the percent confidence 
levels of >99, >90, and >66%, respectively.  Each peptide match showed the iTRAQ™ 
isotopic labels, carbamidomethylated cysteines, and other post-translational 
modifications present as mass spectral shifts identified during the database correlation 
analysis.  Each protein identified also showed the differential protein expression 
compared against the other iTRAQ™ labeled samples for relative quantitation. 
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Statistics 
Means and standard errors (SEM) were calculated for all data sets.  Data were 
analyzed with a one-way analysis of variance (ANOVA) method to evaluate the main 
treatment effect, diabetes induction (GraphPad Software Inc., La Jolla, CA).  Fisher’s 
Least Significant Difference (LSD) post hoc tests were performed to determine the 
significant differences among means.  When appropriate a Student’s T-test was 
employed.  *P<0.05 was considered significant. 
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RESULTS 
 
Db/db Mouse Characterization  
 
 At 18 weeks, body weight was significantly increased (Supplemental data, Table 
1S; *P<0.05) in the db/db mice as compared to WT mice, which is in agreement with 
other reports (29). Analyses of fasting glucose levels, circulating free fatty acids and 
insulin levels revealed significant increases (Supplemental data, Table 4.2; *P<0.05 for 
all three) in the db/db mice as compared to WT mice, which is also in agreement with 
other reports (29).  Cardiac contractile function was assessed in isolated perfused 
hearts. Rates of contraction (+dP/dt), relaxation (-dP/dt) and developed pressures (DP) 
were all significantly decreased in db/db hearts as compared to WT hearts (Table 4.3; 
*P<0.05 for all three), demonstrating decreased contractility in the db/db heart. These 
data are in agreement with others examining the db/db model of type 2 diabetes 
mellitus (14).  
 
Mitochondrial Subpopulation Morphology 
 
Forward scatter (FSC), indicative of size, was significantly decreased in the 
db/db SSM compared to WT SSM (Figures 4.1A and 4.1E; *P<0.05), yet no significant 
change in size in the db/db IFM as compared to WT IFM was observed (Figures 4.1C 
and 4.1E).  Mitochondrial internal complexity (SSC) was significantly decreased in the 
db/db SSM as compared to WT SSM (Figures 4.1B and 4.1F; *P<0.05), while db/db IFM 
internal complexity was increased as compared to WT IFM (Figures 4.1D and 4.1F; 
*P<0.05).   
 
Mitochondrial Subpopulation Functional Assessment 
 
   Assessment of state 3 and state 4 respiration utilizing glutamate/malate 
revealed a significant decrease in state 3 respiration in db/db SSM as compared to WT 
SSM (Figure 4.2A; *P<0.05), with no significant changes between WT and db/db IFM 
161 
 
(Figure 4.2B).  Further, fatty acid stimulated state 3 and state 4 respiration with 
palmitoylcarnitine displayed significantly decreased respiration in only db/db SSM 
(Figure 4.2C; *P<0.05).  ETC complexes I, III and IV activities were significantly 
decreased in db/db SSM as compared to WT SSM (Figure 4.2E; *P<0.05 for all three), 
with no significant differences between db/db IFM and WT IFM (Figure 4.2F).  Finally, 
ATP synthase activity was significantly decreased in db/db SSM as compared to WT 
SSM (Figure 4.2G; *P<0.05), with no significant differences between db/db and WT IFM 
(Figure 4.2G).  
   
Mitochondrial Subpopulation Membrane Potential (∆Ψm) 
 
Inner mitochondrial membrane (IMM) potential, orange to green fluorescence 
ratio, was significantly decreased in the db/db SSM as compared to WT SSM (Figures 
4.3A-B and 4.3E; *P<0.05) due to a decrease in overall orange fluorescence.  No 
significant differences between db/db and WT IFM were observed (Figure 4.3C-D and 
4.3E).   
 
Mitochondrial Subpopulation Protein Expression of ANT and UCP3  
 
Western blot analysis of total ANT protein expression was significantly down in 
the db/db SSM as compared to WT (Figure 4.4A; *P<0.05), with no significant 
differences between db/db and WT IFM (Figure 4.4B).  In contrast, UCP3 expression 
was significantly increased in db/db SSM as compared to WT (Supplemental data 
Figure 4.7; *P<0.05), with no significant differences between db/db and WT IFM 
(Supplemental data Figure 4.7). 
 
Mitochondrial Subpopulation Oxidative Damage 
 
MDA and 4-HAE lipid peroxidation by-products were significantly increased in the 
db/db SSM as compared to WT SSM (Figure 4.5A; *P<0.05), with no significant 
changes with db/db IFM as compared to WT IFM (Figure 4.5A).  Similarly, there was a 
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significant increase in 3-nitrotyrosine formation in db/db SSM compared to WT (Figure 
4.5B; *P<0.05), with no changes in db/db IFM compared to WT (Figure 4.5B).   
 
Mitochondrial Subpopulation Proteome Analyses 
 
 To determine whether the db/db phenotype differentially impacts spatially distinct 
mitochondrial subpopulation proteomes, we utilized an iTRAQTM approach, which 
enabled simultaneous identification and relative quantification of mitochondrial proteins, 
through isobaric peptide tagging.  Figure 4.6A is an example of an MS/MS fragment ion 
(spectra) for a peptide that was used to identify a protein, cytochrome c oxidase subunit 
VIIa1.  Figure 4.6B is an example of an iTRAQ™ tag mass spectral signature (m/z 114, 
115, 116, and 117) used to relatively quantitate cytochrome c oxidase subunit VIIa1, 
within the four labeled sample groups (see figure legend for groups).  A second 
example of the associated iTRAQTM data is included for the protein ubiquinol 
cytochrome c reductase core protein 2 (Supplemental data; Figures 4.8A-B).   
 
Proteins of Fatty Acid Oxidation.  Fatty acid oxidation (FAO) proteins were significantly 
altered in both the db/db SSM and IFM as compared to WT (Table 4.1; *P<0.05).  
However, 5 out of 8 FAO proteins identified were significantly elevated in the db/db 
SSM as compared to WT (Table 4.1; *P<0.05).  In contrast, 3 of 8 proteins identified 
were upregulated and 3 of 8 proteins identified were down-regulated in the db/db IFM.   
 
Proteins of the Mitochondrial Respiratory Chain.  A number of proteins of the 
mitochondrial respiratory chain were significantly altered in both db/db SSM and db/db 
IFM, compared to WT controls.  Of the 18 respiratory chain proteins identified, 11 were 
significantly decreased in the db/db SSM as compared to WT, while 8 of 18 respiratory 
chain proteins identified were increased in expression in the db/db IFM compared to WT 
(Table 4.1; *P<0.05 for all).  In the db/db SSM, 3 of 12 proteins were from complex I, 2 
of 12 were from complex III, 3 of 12 from complex IV and 2 of 12 were from complex V.  
Western blot analyses of ubiquinol cytochrome c reductase core protein 2 (Figures 4.8 
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C-D), a protein of complex III, and cytochrome c oxidase subunit VIIa1 (Figures 4.6C-
D), a protein of complex IV, provided confirmation of the iTRAQTM results observed.   
 
Proteins of the Tricarboxylic Acid Cycle (TCA).  Proteins of the TCA cycle were 
significantly altered in both db/db SSM and IFM as compared to WT (Table 4.1; 
*P<0.05).  However, only 1 of 4 TCA proteins identified was increased in the db/db SSM 
while 3 of 4 proteins identified were upregulated in the db/db IFM as compared to WT. 
Antioxidant Defense Proteins.  Peroxiredoxin V (PRDX5) was the only antioxidant 
identified in our iTRAQTM analyses that was significantly decreased in the db/db SSM as 
compared to WT, while there were no significant changes observed in the IFM 
antioxidant defense components (Table 4.1; *P<0.05).   
 
Mitochondrial Transport Proteins. ANT1 was significantly decreased in the db/db SSM 
as compared to WT, yet upregulated in the db/db IFM (Table 4.1; *P<0.05).  Western 
blot analysis confirmed the overall decrease in total ANT expression in the db/db SSM, 
while total ANT was unchanged in the db/db IFM (Figures 4.4C and 4.4D).  Glucose 
regulated protein 75 (Grp75), was significantly decreased in db/db SSM as compared to 
WT (Table 4.1; *P<0.05), while there were no significant changes in db/db IFM 
compared to WT.    
 
Mitochondrial Subpopulation Post-translational Modifications 
 
Fifteen proteins presented with some type of PTM in the db/db SSM that were 
non-existent in the WT SSM, while 10 proteins were present in the db/db IFM (Table 
4.5).  Seven of 15 proteins identified were of the ETC and they included specific PTM’s, 
such as acetylations, deamidations and oxidations.  Interestingly, 3 of 10 proteins 
identified in the db/db IFM were of the ETC and they included modifications such as 
acetylations, deamidations and methylations.  Of greatest interest was that the majority 
of the modified proteins were IMM proteins, suggesting that this locus may play a key 
role in the pathogenesis of cardiac dysfunction associated with type 2 diabetes mellitus. 
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DISCUSSION 
 
Mitochondrial dysfunction is a major contributor to the development of various 
pathologies, including type 1 and type 2 diabetes mellitus (18, 24, 25, 35, 37, 38).  
Nevertheless, mitochondrial analyses are complicated by the fact that two spatially and 
functionally distinct populations of mitochondria exist in the cardiomyocyte, SSM and 
IFM.  We and others have shown that these two mitochondrial populations respond 
differently to pathological insults (12, 25, 27, 30, 37).  The goal of this study was to 
determine whether subcellular location was associated with differential impact on 
cardiac mitochondria in a type 2 diabetes mellitus model, the db/db mouse.  Our results 
indicate that SSM, located below the sarcolemma, display greater dysfunctional profiles 
as compared to IFM, which are situated between the myofibrils.  These dysfunctional 
profiles are the result of differential impact on a number of mitochondrial indices 
including structure, function, oxidative milieu, and proteome make-up. 
Morphological alterations have been associated with mitochondrial dysfunction 
(17, 24, 37, 44).  Kelley et al. reported a decrease in mitochondrial size and a decrease 
in the abundance of SSM from skeletal muscle of type 2 diabetic patients, while we 
show a decrease in size and complexity of cardiac SSM. Taken together these studies 
suggest that type 2 diabetes mellitus imparts a specific influence on SSM structure.  
Interestingly, we observed a significant increase in IFM complexity (Figure 4.1).  It is 
unclear as to why such a phenomenon occurred, and may be the result of an increased 
abundance of ETC components in db/db IFM which we observed in our proteome 
analyses (Table 4.1).  Regardless, the result is interesting and warrants further 
investigation. 
Studies suggest that mitochondrial respiration is significantly altered in the db/db 
heart. However, these analyses have focused on total mitochondria (3, 4).  In the 
current study, we observed decreases in state 3 respiration and ETC complex activities 
I, III, and IV, exclusively in db/db SSM (Figure 4.2). Our results are in agreement with 
others reporting decreases in succinate-driven respiration of SSM from vastus lateralis 
of type 2 diabetic patients (37).  Additionally, we observed a significant decrease in ATP 
synthase activity solely in the db/db SSM.  These findings indicate that the ability for 
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db/db SSM to generate ATP may be compromised, thus, those processes that have 
been suggested by others, to rely upon ATP from this source, such as signal 
transduction pathways, and substrate transport across the plasma membrane, may be 
specifically impacted (37).  Further, we observed a significant decrease in ∆Ψm in db/db 
SSM with no change in IFM (Fig. 4.3).  Alterations to ∆Ψm have been indicated to 
impact F1F0 ATP synthase function (2), and as a result, may have contributed to the 
diminished function observed in db/db SSM.  ANT, which catalyzes the exchange of 
ADP and ATP across the IMM, was significantly decreased only in db/db SSM (Fig. 
4.4A).  This observation was confirmed by the iTRAQTM analyses in which ANT1 was 
significantly decreased in db/db SSM yet increased in db/db IFM.  The increase in ANT 
in the IFM was not observed in the Western blot analyses, which may be due to the fact 
that total ANT was assessed and not ANT1.  Inhibition of mitochondrial ANT has been 
proposed to contribute to cellular dysfunction in obesity and type 2 diabetes mellitus by 
increasing reactive oxygen species and adenosine (10).  Our finding of decreased ANT 
expression is in agreement with other reports (3), and supports the hypothesis that 
decreases in ANT expression may contribute to a reduction in the ability to generate 
ATP, which was also observed (Fig. 4.3).   
Mitochondrial oxidative stress has been reported in models of both type 1 (12, 
18, 38, 44) and type 2 (3, 37) diabetes mellitus, and may play a central role in 
mitochondrial dysfunction.  In the current study lipid peroxidation and protein nitration 
products were increased only in db/db SSM (Fig. 4.5), suggesting that type 2 diabetes 
mellitus presents an enhanced oxidative environment solely to the SSM.  Increased 
reactive oxygen species production and oxidative stress by-products in a type 2 diabetic 
model has been reported previously (3), and suggested to impact submitochondrial 
components, particularly in the IMM.  Enhanced reactive oxygen species production and 
lipid peroxidation by-products can disrupt the fluidity and integrity of the IMM and further 
modify protein and lipid constituents within the membrane altering overall mitochondrial 
function (9).  Further, db/db SSM displayed decreases in PRDX5, an antioxidant that 
reduces hydrogen peroxide and alkyl hydroperoxides.  Loss of PRDX5 may have 
contributed to the enhanced oxidative environment observed in this particular population 
of mitochondria.  Interestingly, PRDX5 was the only major antioxidant significantly 
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decreased in db/db SSM.  The result suggests that loss of PRDX5 may contribute to the 
enhanced oxidative milieu observed in db/db SSM.  It is important to point out that other 
mechanisms may have also been involved in the increased oxidative stress observed in 
db/db SSM, such as accumulation of neutral fatty acids which are susceptible to 
oxidation (3, 40).  
Several groups have identified mitochondrial proteomic alterations with various 
type 1 diabetic models (6, 11, 20, 44, 47).  However, no examination of spatially distinct 
mitochondrial subpopulation profiles has been performed in any pathological model, 
including diabetes mellitus.  Kavazis et al. examined the impact of exercise training on 
cardiac SSM and IFM proteomes and observed subpopulation-specific changes (23).  
We examined the impact of type 2 diabetic insult on spatially distinct cardiac 
mitochondrial proteomes.  The use of iTRAQ™ isobaric labeling technology coupled 
with MudPIT-based mass spectral analyses of the labeled samples provides significant 
advantages over previously used methods (2-dimensional (2D) gel electrophoresis, 2D-
DIGE and label-free UPLC-MS).  These advantages include global protein identification 
and characterization of the complex samples, simple and robust isotopic labeling that 
does not bias analytical separations, and simultaneous identification and relative 
quantification of the proteomes of the four samples.  Using the iTRAQ™ approach, we 
observed an increase in FAO proteins in both SSM and IFM of db/db hearts (Table 4.1), 
which is probably due, in part, to the enhanced lipid environment present with type 2 
diabetes mellitus (1).  However, though the effect occurred in both subpopulations, the 
result was more pronounced in the SSM, which saw a greater number of FAO proteins 
increased in abundance, suggesting a more enhanced fatty acid environment presented 
to this subpopulation.  We also observed an increase in circulating free fatty acid levels 
(Supplemental data Table 4.2).  Because SSM are located at the periphery of the cell, 
they may be impacted to a greater extent by an enhanced lipid environment, as 
compared to IFM, which reside in the interior of the cell.  Nielson et al. observed lipid 
accumulation specifically surrounding the SSM in type 2 diabetic skeletal muscle 
suggesting that the SSM may be subject to a more enhanced lipid environment in the 
type 2 diabetic state based upon its proximity (31).  In addition, we observed increases 
in UCP3 protein expression in db/db SSM (Supplemental data Figure 4.7), which is in 
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agreement with other authors (41).  Because UCP3 has been suggested to be 
upregulated in the presence of enhanced free fatty acids, its expression may be 
indicative of a greater fatty acid environment in the db/db SSM.  However, though we 
observed upregulation of FAO proteins in the SSM, the ability to utilize fatty acid 
substrates (palmitoylcarnitine) was diminished in the db/db SSM (Figure 2), suggesting 
that the mitochondrial dysfunction displayed by db/db SSM at 18 weeks may be due to 
limitations to the ETC as opposed to FAO.   
In general, ETC complex proteins were primarily decreased in db/db SSM, while 
ETC and TCA cycle proteins were increased in the IFM.  The changes observed in 
db/db SSM were not specific to one ETC complex indicating that both proximal and 
distal portions of the respiratory chain were impacted.  These results indicate that 
protein loss in the SSM may be contributing to the decrease in oxidative capacity 
observed in the SSM.  Further, the majority of the proteins lost in the db/db SSM reside 
in the IMM, including ETC proteins, which may have contributed to the decrease in 
oxidative capacity observed in the SSM.  Taken together, these results suggest that the 
formation and/or organization of ETC constituents may have been impacted to a greater 
extent in db/db SSM which may have contributed to the respiratory dysfunction 
observed.  In contrast, preservation of proteins involved in mitochondrial bioenergetics 
in db/db IFM may have been sufficient to prevent loss of respiratory capacity.    
Our proteomic analyses revealed changes to a number of other key 
mitochondrial proteins (Table 4.1).  Several proteins involved in protein/substrate import 
necessary for proper mitochondrial function were significantly altered by type 2 diabetes 
mellitus.  Grp75, a mitochondrial chaperone and the active motor component of the 
mitochondrial import process, was significantly decreased only in db/db SSM which may 
have implications for the nuclear-encoded mitochondrial protein import process. Since 
the vast majority of mitochondrial proteins are encoded by nuclear sources, such a 
finding may have repercussions for a number of essential mitochondrial functions, 
including structure, function and antioxidant capacity.  
Because assessment of abundance does not entirely account for protein 
functionality, we examined PTM in the db/db heart of mitochondrial subpopulations.  
Though both mitochondrial subpopulations saw increased PTM as a result of type 2 
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diabetic insult, the result was more pronounced in the SSM, which saw a greater 
number of PTMs (Table 4.5).  Of particular interest was the observation that ETC 
proteins displayed oxidations at specific amino acid residues, and this phenomenon 
occurred only in db/db SSM.  Oxidation to these proteins found within the ETC may alter 
the structure and/or function of each protein and subsequently contribute to the 
diminished respiratory capacity reported.  As a result, this may compromise the SSM 
ability to provide adequate ATP for cellular processes (Figure 4.2).  Additionally, our 
findings suggest that IFM show less protein modifications and protein loss in 
comparison with SSM, suggesting a potential adaptive response to prevent diabetes-
induced mitochondrial dysfunction.  It should be noted that though the MudPIT-based 
mass spectral method provides a wealth of global protein identification and 
characterization information, the larger number of peptides analyzed from an 
ultracomplex sample can mask those species containing PTMs, due to the greater 
natural abundance and higher ionization efficiencies of the non-modified forms.  Other 
methods exist for assessing PTMs which may utilize selective enrichment strategies or 
enhanced sensitivity, thus additional studies may provide complementary information 
(15). 
The most interesting finding in the current study was that in a type 2 diabetic 
model, cardiac SSM are affected to a greater extent by the pathology as compared to 
cardiac IFM.  These results are in contrast with our previous findings indicating that in a 
type 1 diabetic model (streptozotocin) the IFM are most impacted by the pathology.  
These findings are probably due to differences in the phenotypes elicited by the two 
conditions, resulting from the unique pathological etiologies specific for each model.  
For example, higher free fatty acids and lipid deposition associated with the 
subsarcolemmal region during type 2 diabetes mellitus may put the SSM at greater risk 
due to their location at the cell periphery as compared to IFM (32).  It is plausible that an 
increased lipid environment in and surrounding the SSM may enhance the oxidative 
environment within the SSM contributing to their dysfunction.  Such a phenomenon 
would manifest during type 2 diabetes mellitus to a greater extent with an enhanced 
lipid environment as compared to type 1 diabetes mellitus.  Regardless, it is important to 
point out that in multiple models of both type 1 diabetes mellitus (12, 22, 43) and type 2 
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diabetes mellitus (4) oxidative stress appears to be an underlying contributor to 
mitochondrial dysfunction.  However, the mechanism in which enhanced oxidative 
stress manifests may be different between the type 1 and type 2 diabetic heart.  Further, 
it is important to point out that diminished function in either subpopulation may have 
negative implications on cardiac contraction regardless of subpopulation.  Though it has 
been speculated that each subpopulation provides ATP for specific cellular functions, 
inability to provide ATP for any of these functions may translate into contractile 
abnormalities in the heart. 
In conclusion, mitochondrial dysfunction in the type 2 diabetic heart is confined 
primarily to those mitochondria residing below the plasma membrane, SSM with 
minimal effect on those mitochondria situated between the myofibrils, IFM.  Of particular 
interest is the observation that proteins of the IMM, an important locus containing the 
ETC, ATP synthesis machinery, and protein trafficking constituents, were specifically 
impacted in the SSM as a result of type 2 diabetes mellitus.  Functional aspects of the 
IMM, such as ∆Ψm, respiration, ETC activities, and ATP synthesis were concomitantly 
diminished in the SSM.  Taken together, the combination of findings provided by our 
study offer evidence that not all cardiac mitochondria are impacted equally by type 2 
diabetic insult, but rather mitochondrial dysfunction is specific to a particular subcellular 
locale.  Our analyses of mitochondrial subpopulation proteomic compositional changes 
resulting from type 2 diabetic insult reveals submitochondrial loci at risk, and identifies 
specific proteomic targets that may be of interest for therapeutic and diagnostic 
interventions. 
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Figure 4.1. Mitochondrial subpopulation size (FSC) and internal 
complexity (SSC) in WT and db/db hearts. Determination of relative size 
and internal complexity of distinct mitochondrial subpopulations using flow 
cytometric analyses.  Mitochondrial subpopulations were stained with 
mitotracker deep Red 633, a membrane potential dependent dye, and 
gated based on incorporation of the dye.  Analysis of FSC and SSC were 
calculated per 20,000 gated events for all mitochondrial subpopulations. 
Representative histograms of FSC (A, C) and SSC (B, D) in WT SSM and 
IFM (green) vs. db/db SSM  and IFM (blue).  Values for FSC (E) and SSC 
(F) are expressed as arbitrary units (AU) ± SEM; N=4 for each group. 
*P<0.05 for WT vs. db/db. 
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Figure 4.2. Respiratory capacity of mitochondrial subpopulations in 
WT and db/db hearts.  State 3 and state 4 respiration rates with 
glutamate/malate (A, B), palmitoylcarnitine (C, D), ETC complex activities 
(E, F) and ATP synthase activity (G) were assessed in isolated 
mitochondrial subpopulations (SSM; A, C and E) and (IFM; B, D and F) 
from hearts of 18 week-old WT (black bars) and db/db mice (white bars).  
State 3 and state 4 respiration rates were determined in the presence of 
the substrates glutamate/malate, palmitoylcarnitine and state 3 respiration 
examined upon addition of ADP.  ETC complex I, III, and IV activities were 
assessed spectrophotometrically by measuring the oxidation of NADH 
(complex I), reduction of cytochrome c (complex III) and oxidation of 
cytochrome c (complex IV). Respiration rates are expressed as 
nmol/min/mg of protein while enzymatic activities are expressed as 
activity/min/mg of protein± SEM; N=6 for each group. *P<0.05 for WT vs. 
db/db. 
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Figure 4.3 
 
 
 
185 
 
 
Figure 4.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
186 
 
 
 
 
 
 
 
 
 
Figure 4.3. Flow cytometric analysis of mitochondrial subpopulation 
membrane potential (∆Ψm) in WT and db/db heart.   Membrane 
potential (∆Ψm) was assessed by staining mitochondrial subpopulations 
with JC-1 dye and assessing the shift from green to orange fluorescence 
with flow cytometry.   Representative histograms showing green and 
orange fluorescence in WT SSM (A) vs. db/db SSM (B) and WT IFM (C) vs. 
db/db IFM (D).  ∆Ψm was calculated based on orange/green fluorescence 
ratios in WT vs. db/db cardiac mitochondrial subpopulations (E). 
Orange/green fluorescence are expressed as arbitrary units (AU) ± SEM; 
N=4 for each group. *P<0.05 for WT vs. db/db. 
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Figure 4.4 
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Figure 4.4. ANT protein expression in mitochondrial subpopulations 
from WT and db/db hearts.   Representative Western blots and 
densitometry analysis for total ANT protein in (A) SSM and (B) IFM from 
WT and db/db hearts.  Values are represented as mean ± SEM; N=5 for 
each group. *P<0.05 for WT vs. db/db. 
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Figure 4.5 
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Figure 4.5. Oxidative damage in mitochondrial subpopulations from 
WT and db/db hearts.  Oxidative damage to lipids was assessed in 
mitochondrial subpopulations by measuring the lipid peroxidation by-
products malondialdehyde (MDA) and 4-hydroxyalkenals (4-HAE) using a 
colorimetric assay and compared against a standard curve of known 4-HAE 
and MDA concentrations.  Data are expressed as µmol of MDA + 4-HAE 
per mg of mitochondrial protein.  Oxidative damage to proteins was 
assessed by quantifying 3-nitrotyrosine residues through a sandwich ELISA 
and concentration determined by comparing results against a known 
protein nitrotyrosine standard curve.  Results are expressed as nmol 
nitrotyrosine/mg of protein.  Values for both lipid peroxidation and protein 
nitrosylation are expressed as mean ± SEM; N=5 for each group.   *P<0.05 
for WT vs. db/db. 
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Figure 4.6. Representative iTRAQ™ spectra and Western blot 
analysis.  Isolated mitochondrial subpopulations from WT and db/db hearts 
were labeled with iTRAQTM reagents 114 (db/db SSM), 115 (db/db IFM), 
116 (WT SSM), 117 (WT IFM) and combined for analysis with mass 
spectrometry.  (A) Representative spectra of simultaneous quantitation of 
cytochrome c oxidase subunit VIIa1 peptide in WT and db/db mitochondrial 
subpopulations.  (B) Spectra for the reporter groups of the iTRAQTM 
reagents (114,115,116 and 117) from cytochrome c oxidase subunit VIIa1 
peptide MS/MS spectra are shown. These spectra were used along with 
other peptides to simultaneously quantify cytochrome c oxidase subunit 
VIIa1 in WT and db/db mitochondrial subpopulations.  Representative 
Western blot and densitometry analysis of cytochrome c oxidase subunit 
VIIa1 in SSM (C) and IFM (D) from WT and db/db hearts.  Values are 
represented as mean ± SEM; N=5 for each group. *P<0.05 for WT vs. 
db/db. 
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Protein Name SSMD/SSMC IFMD/IFMC SSMC/IFMC 
Mitochondrial Fatty Acids Beta-oxidation 
   
Hydroxyacyl – Coenzyme A dehydrogenase 1.08  1.21  1.26 
Glutamate oxaloacetate transaminase 2 1.13  .74  .75 
Mitochondrial trifunctional protein, Beta subunit 1.20  1.19  NS 
Acyl – coenzyme A dehydrogenase, medium chain 1.16  NS .80 
3-ketoacyl-CoA thiolase, mitochondrial 1.24  NS  NS  
Acetyl-Coenzyme A acetyltransferase 1 NS .30  .54  
Dihyrolipoamide dehydrogenase  NS .75  .85 
Dodecenoyl-Coenzyme A delta isomerase  NS 1.29  NS 
Mitochondrial Respiratory Chain 
   
ATP synthase, H+ transporting mitochondrial FO complex, 
subunit d .90  NS .88 
ATP synthase H+  transporting FO subunit F isoform 2 .90  1.25  1.35 
Ubquinol cytochrome c reductase core protein 2 .76  NS NS  
Cytochrome b-c1 complex subunit 1 NS 1.44  NS 
Cytochrome c1, heme protein, mitochondrial  .85  NS 1.21 
Electron transferring flavoprotein, beta polypeptide .88  1.44  1.79 
Succinate dehydrogenase Fp subunit NS .68  .66 
NADH dehydogenase (ubiquinone) 1 alpha subcomplex 9 NS 1.16  NS 
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 10 .79  NS NS 
NADH dehydrogenase (ubiquinone) Fe-S protein 6 .70  NS  .79 
NADH dehydrogenase ubiquinone FE-S protein 7 .76  NS NS 
Cytochrome C oxidase, subunit VIc  .88  1.28  1.41 
Cytochrome C oxidase subunit Va  .75  1.20  1.75 
Cytochrome C oxidase, subunit VIIa1 .64  NS .82 
Cytochrome c oxidase subunit IV isoform 1 NS 1.16  NS 
Table  4.1 
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Cytochrome C oxidase, subunit VIb polypeptide 1 NS .81  NS 
Cytochrome C oxidase subunit II NS 1.32  NS 
TCA Cycle 
   
Isocitrate dehydrogenase 2 (NADP+) 1.12  1.23  NS 
Isocitrate dehydrogenase 3 (NAD+), alpha NS 1.28  1.35 
malate dehydrogenase 2, NAD NS .79  NS 
Succinyl-CoA ligase [ADP-forming] subunit beta, 
mitochondrial  NS 1.30   
Amino Acid Metabolism 
   
Dihydrolipamide s-succinyltransferase  NS .61  NS 
Oxidative Stress Related 
   
Peroxiredoxin V .80  NS NS 
Transport Proteins 
   
carrier family 25 (mitochondrial carrier, phosphate carrier), 
member 3 1.15  .87  1.17 
Grp75, mitochondrial hsp70  .80  NS 1.26 
Solute carrier family 25 (mitochondrial carnitine/acylcarnitine 
translocase), member 20 NS 1.28  .64 
VDAC 2 1.24  NS .67 
Carnitine O-palmitoyltransferase 1, muscle isoform  NS 1.37 .647 
Voltage-dependent anion-selective channel 1 NS .70  .77 
Voltage-dependent anion-selective channel 3 NS .50  NS 
Miscellaneous 
   
NipSnap homolog 2 NS 1.46  1.36 
Es 1 protein 1.15  .67  .85 
Elongation factor tu, mitochondrial NS .46  .73 
Aldehyde dehydrogenase  .69  NS NS 
Mirq-like protein  NS  1.21  
 
Desmin  .66  NS  NS  
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Table 4.1. Proteomic analysis of mitochondrial subpopulations from 
WT and db/db hearts.  iTRAQTM analysis of proteins identified and 
significantly changing, categorized into groups consisting of fatty acid 
oxidation (FAO), citric acid cycle (TCA), mitochondrial respiratory chain, 
amino acid related, oxidative stress, transport and miscellaneous proteins 
in isolated SSM and IFM from WT and db/db hearts.  Cells highlighted in 
red represent decreased protein expression in the db/db mitochondria 
compared to WT, while cells highlighted in green are increased in db/db 
compared to WT.  All values presented indicate a significant difference of at 
least *P<0.05 for WT vs. db/db, while NS represents no significant 
differences between any group. N=4 for each group. 
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SUPPLEMENTAL MATERIALS AND METHODS 
 
Blood Plasma Analyses 
Blood samples, taken from mice immediately after sacrifice, were centrifuged and 
the supernatant frozen at −80°C for determination of free fatty acid (FFA) 
concentrations and insulin levels.   FFAs were measured using a spectrophotometric 
based free fatty acid concentration kit (Biovision, Mountain View, CA), and insulin levels 
were determined using an enzyme-linked immunosorbent assay kit (Alpco 
Immunoassays, Salem NH). 
 
Citrate Synthase Activity 
Citrate synthase activity, a marker of mitochondrial matrix enzyme activity, was 
measured using a diode array spectrophotometer at 412 nm as previously described 
(3).  
 
Fasting Glucose Levels 
Mice were fasted 4-6 hours and blood glucose levels were determined using an 
Ascencia® Contour™ glucometer (Bayer Healthcare, Mishawaka, IN). 
 
Cardiac contractile function 
Hearts from db/db and WT animals were isolated and transferred to a 
Langendorff setup for contractile experiments as previously described (1, 2, 4). In brief, 
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hearts were removed from anesthetized mice and immersed in cold cardioplegic 
solution. After cannulation of the aorta on a luer stub, hearts were perfused retrograde at 
37°C with a modified Krebs-Henseleit buffer [containing (in mmol/l) 0.5 pyruvate, 0.4 
caprylic acid, 118 NaCl, 4.7 KCl, 2.25 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 25 NaHCO3, 0.5 
Na2EDTA, and 5.5 glucose] that was subjected to oxygenation. A small fluid-filled 
balloon was inserted into the left ventricular (LV) cavity and coupled to a pressure 
transducer (Argon Medical Devices, Athens, TX). The balloon was inflated until the end-
diastolic pressure reached 10 mmHg. Platinum wires were placed on the surface of the 
right atrium and used to pace the heart at 420 beats/min (7 Hz) with increasing voltage 
until the heart rate was consistent (captured). During this time period, hearts remained 
submerged in a 37°C jacketed chamber, and a heat lamp attached to a variable 
alternating current transformer was used to maintain temperature, which was monitored 
by a needle temperature probe inserted just before the luer cannula (Physitemp, Clifton, 
NJ). Hearts were perfused for 15 min to achieve stable cardiac function and then 
followed for an additional 45 min, yielding a total protocol time of 1 h. During this time, 
digitized recordings of the LV pressure and its first derivative as well as heart rate were 
captured on an IBM-compatible PC using ChartPro software (AD Instruments, Colorado 
Springs, CO). LV peak systolic pressure, developed pressure (DP), maximum speed of 
contraction (+dP/dt), and maximum speed of relaxation (–dP/dt) were analyzed from the 
recordings using ChartPro software. 
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Figure 4.7.  UCP3 protein expression in mitochondrial subpopulations 
from WT and db/db hearts.   Representative Western blots and 
densitometry analysis for total UCP3 protein in (A) SSM and (B) IFM from 
WT and db/db hearts.  Values are represented as mean ± SEM; N=5 for 
each group. *P<0.05 for WT vs. db/db. 
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Figure 4.8. Representative iTRAQ™ spectra and Western blot 
analysis.  Isolated mitochondrial subpopulations from WT and db/db hearts 
were labeled with iTRAQTM reagents 114 (db/db SSM), 115 (db/db IFM), 
116 (WT SSM), 117 (WT IFM) and combined for analysis with mass 
spectrometry.  (A) Representative spectra of simultaneous quantitation of a 
ubiquinol cytochrome c reductase core protein 2 peptide in WT and db/db 
mitochondrial subpopulations.  (B) Spectra for the reporter groups of the 
iTRAQTM reagents (114,115,116 and 117) from ubiquinol cytochrome c 
reductase core protein 2 peptide MS/MS spectra are shown. These spectra 
were used along with other peptides to simultaneously quantify ubiquinol 
cytochrome c reductase core protein 2 in WT and db/db mitochondrial 
subpopulations.  Representative Western blot and densitometry analysis of 
ubiquinol cytochrome c reductase core protein 2 in SSM (C) and IFM (D) 
from WT and db/db hearts.  Values are represented as mean ± SEM; N=5 
for each group. *P<0.05 for WT vs. db/db. 
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Table 4.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
Metabolic Parameters WT Db/Db 
Body Weight (g) 28.8±.77 54.4±1.0* 
Plasma Glucose (mg/dL) 127.7±6 543±27* 
Plasma Insulin (ng/mL) .82±.19 2.16±.22* 
Plasma Free Fatty Acids (uM) 230.8±36.9 668.3±97.7* 
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Table 4.2. Metabolic Parameters.  Assessment of metabolic parameters 
in WT and db/db hearts, including body weight (g), blood glucose (mg/dL), 
plasma insulin (ng/mL) and plasma free fatty acids (FFA; µmol).  Values 
are expressed as means ± SEM; N = 7 for each group. *P<0.05 for WT vs. 
db/db mice.  
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Table 4.3 
 
 
 
 
 
Contractile Parameters WT Db/Db 
DP (mm/Hg) 138±4.8 57.5±10.1* 
-DP/DT (mm/Hg/s) 5932±454.3 2072±308.9* 
+DP/DT (mm/Hg/s) 3665±144.1 1321±132.2* 
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Table 4.3. Cardiac contractile function from WT and db/db hearts.  
Functional measurements were performed in Langendorff-perfused hearts 
and are expressed as the rate of contraction (+dP/dt), rate of relaxation (-
dP/dt), and developed pressure (DP).  Values are expressed as means ± 
SEM; N = 5 for each group. *P<0.05 for WT vs. db/db mice. 
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Mitochondrial Marker Enzyme WT Db/Db 
 Citrate synthase, um/mg protein   
SSM 4367±476 4394±562 
IFM 4195±191 4870±455 
Mitochondrial yield (mg/g wt)   
SSM 9.7±.308 9.1±.219 
IFM 6.84±.15 7.7±.17 
211 
 
 
 
 
 
 
 
 
Table 4.4.  Mitochondrial marker enzyme and protein yield.  Citrate 
synthase activities from isolated SSM and IFM.  Mitochondrial protein 
yields in isolated SSM and IFM.  Values are expressed as means ± SEM; 
N=5 for WT and db/db mice.  
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Table 4.5 
Protein Diabetic SSM  Peptide Sequence  Diabetic SSM  
Post Translational Modification  
Diabetic SSM  
ATP synthase, H+ transporting, 
mitochondrial F1 complex, alpha subunit  QKTGTAEMSSILEER  Gln->pyro-Glu@N-term  
ATP synthase, H+ transporting, 
mitochondrial F1 complex, alpha subunit DSRLVLEVAQHLGESTVR  Dehydrated(D)@1; Deamidated(R)@3  
aconitase 2,  AVTQEFGPVPDTAR  Decanoyl(T)@3  
3-ketoacyl-CoA thiolase  RTPFGAYGGLLKDFSATDLTEFAAR  Deamidated(R)@1; Dehydrated(T)@2  
electron transferring flavoprotein, beta 
polypeptide [Mus musculus]; unnamed 
protein product [Mus musculus]  
YATLPNIMKAK  Trimethyl(K)@9  
cytochrome c oxidase, subunit VIc [Mus 
musculus]  SSGALLPKPQMR  Protein Terminal Acetyl@N-term  
cytochrome c oxidase, subunit VIc [Mus 
musculus]  PNCGTHYKLVPHQMAH  
Carbamyl@N-term; Deamidated(N)@2; 
Carbamidomethyl(C)@3  
malate dehydrogenase 2, NAD 
(mitochondrial) [Mus musculus]; malate 
dehydrogenase [Mus musculus]  
GYLGPEQLPDCLKGCDVVVIPAGVPR  
Oxidation(P)@5; Oxidation(P)@9; 
Carbamidomethyl(C)@11; 
Didehydroretinylidene(K)@13; 
Carbamidomethyl(C)@15  
pyruvate dehydrogenase E1 alpha 1 
[Mus musculus]  VLAGSAQKPASR  Deamidated(Q)@7  
Ndufb4 protein [Mus musculus]; NADH 
dehydrogenase 1 beta subcomplex 4 
[Mus musculus]  
SGSKYKPAPLATLPSTLDPAEYDVSPE
TR  Protein Terminal Acetyl@N-term  
cytochrome c-1 [Mus musculus]  AANNGALPPDLSYIVR  Deamidated(N)@4  
cytochrome c-1 [Mus musculus]  ANNGALPPDLSYIVR  Carbamyl@N-term; Oxidation(N)@3  
ubiquinol-cytochrome c reductase, 
complex III subunit VII, isoform CRA_b 
[Mus musculus]  
GREFGNLAR  Protein Terminal Acetyl@N-term  
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NADH dehydrogenase (ubiquinone) Fe-S 
protein 1 [Mus musculus]  EDWKIIR  Oxidation(W)@3  
isocitrate dehydrogenase 3 (NAD+) alpha  IAEFAFEYARNNHR  Deamidated(N)@11  
glutamate oxaloacetate transaminase 2  MNLGVGAYRDDNGKPYVLPSVR  Deamidated(N)@12  
glutamate oxaloacetate transaminase 2  KMNLGVGAYRDDNGKPYVLPSVR  Deamidated(N)@13  
glutamate oxaloacetate transaminase 2  ILIRPLYSNPPLNGAR  Deamidated(N)@13  
hypothetical protein LOC380773 [Mus 
musculus]; RIKEN cDNA 1810035L17, 
isoform CRA_c [Mus musculus]; SRA 
stem-loop-interacting RNA-binding 
protein,  
AASAIKGLSALR  Protein Terminal Acetyl@N-term  
low density lipoprotein receptor-related 
protein 4 [Mus musculus]  TCSPGMNSFLIFAR  
Carbamidomethyl(C)@2; 
Oxidation(M)@6  
ATP synthase, H+ transporting, 
mitochondrial F1F0 complex, subunit e 
[Mus musculus]  
VPPVQVSPLIKFGR  Oxidation(P)@8  
succinate dehydrogenase complex, 
subunit B, iron sulfur (Ip  AATVGVSLKRGFPAAVLGR  Oxidation(P)@13  
Protein IFM Diabetic  Peptide Sequence Diabetic IFM  Post Translational Modification  Diabetic IFM  
3-ketoacyl-Coenzyme A thiolase 
(trifunctional protein), alpha subunit  AGLEQGSDAGYLAESQK  
Carbamidomethyl@N-term; 
Dehydrated(E)@4; Deamidated(Q)@5  
3-ketoacyl-Coenzyme A thiolase 
(trifunctional protein), alpha subunit  SPKPVVAAISGSCLGGGLELAIACQ  
HexNAc(S)@12; 
Carbamidomethyl(C)@13; 
Carbamidomethyl(C)@24  
cytochrome c oxidase, subunit VIc [Mus 
musculus]  SSGALLPKPQMR  Protein Terminal Acetyl@N-term  
mitochondrial malate dehydrogenase 2,  AKVAVLGASGGIGQPLSLLLKNSPLVSR  Lys->Allysine(K)@21; Deamidated(N)@22  
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NADH dehydrogenase (ubiquinone) Fe-S 
protein 5  EGKYTPPPHHSGREEPRP  Methyl(E)@1; Delta:H(2)C(2)(K)@3  
coenzyme Q9 homolog [Mus musculus]  LNQVLEEEQKLVQLGQAEKR  Deamidated(Q)@3  
ubiquinol cytochrome c reductase core 
protein 2  AGSRYEDSNNLGTSHLLR  
Carbamidomethyl@N-term; 
Dehydrated(S)@3; Deamidated(R)@4  
2,4-dienoyl CoA reductase 1  SLAAEWGR  Dioxidation(W)@6  
enoyl Coenzyme A hydratase  NSSVGLIQLNRPK  Deamidated(N)@1  
dihydrolipoamide S-succinyltransferas  NDVITVQTPAFAESVTEGDVRWEK  Deamidated(N)@1  
glutamate oxaloacetate transaminase 2  KMNLGVGAYRDDNGKPYVLPSVR  Deamidated(N)@13  
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Table 4.5. Post-translational modifications in mitochondrial 
subpopulations from WT and db/db hearts.   Multidimensional protein 
identification technology (MudPIT) was used to identify post-translational 
modifications of proteins in SSM and IFM from WT and db/db mitochondria.  
Peptides presented represent only those peptides that have post-
translational modifications in the db/db SSM (A) and IFM (B) and not 
present in the WT group. 
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ABSTRACT 
 
Ischemia/reperfusion (I/R) injury elicits damage to mitochondria.  Antioxidants provide 
protection from I/R-induced mitochondrial damage.  The goal of this study was to 
determine the impact of mitochondria-specific overexpression of GPx4 (PHGPx) on 
cardiac function following I/R.  Transgenic mice were created in which PHGPx was 
overexpressed solely in the mitochondrion (mPHGPx).  MPHGPx and littermate control 
hearts were subjected to global no-flow ischemia (20 min) followed by reflow 
reperfusion (30, 60, 90 min).  Following I/R, mPHGPx hearts possessed significantly 
better rates of contraction, developed pressures, and peak-systolic pressures as 
compared to controls (P<0.05).  No differences were observed in rates of relaxation or 
end-diastolic pressures.  Lipid peroxidation was significantly lower in mitochondria from 
mPHGPx hearts as compared to controls, following I/R (P<0.05).  Electron transport 
chain (ETC) complex I, III, and IV activities were significantly higher in mPHGPx hearts 
as compared to controls, following I/R (P<0.05).  MPHGPx overexpression enhanced 
ETC complex I, III, and IV activities in subsarcolemmal mitochondria (SSM; P<0.05), 
and ETC complex I and III activities in interfibrillar mitochondria (IFM; P<0.05) following 
I/R.  These results indicate that mitochondria-specific GPx4 overexpression protects 
cardiac contractile function and preserves ETC complex activities following I/R.  These 
results provide further rationale for the use of mPHGPx as a therapeutic protectant. 
  
 
 
Ischemia, Reperfusion, Mitochondria, Free radical scavenger 
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INTRODUCTION 
 
 Oxidative processes play a major role in the pathogenesis of myocardial 
ischemia/reperfusion (I/R) injury.  Central to the pathogenesis is the role played by 
reactive oxygen species (ROS).  ROS generated during I/R initiate and potentiate 
pathological, biochemical and physiological responses that include membrane lipid 
peroxidation (LPO), disruption of cytoskeletal structure, disturbance of cellular 
oxidoreductive status, enzyme inactivation, deterioration of mitochondrial function, and 
impairment of excitation contraction coupling [1-6].  Though many potential sources of 
ROS exist in myocardium, the mitochondrion is considered to be the primary site [7-9].  
A number of studies have observed an increase in ROS production from heart 
mitochondria after I/R [10, 11].  Several sites in the electron transport chain (ETC) are 
particularly prone to ROS formation and include oxidizable electron carriers in the inner 
mitochondrial membrane [7].  This has implications for ETC proteins because a major 
constituent of many of these structures is iron-sulphur centers [12], which can react with 
ROS and produce highly reactive species such as the hydroxyl radical (OH·) [13].  
Mitochondrial ROS are generated during I/R due to electron leakage from the 
respiratory chain.  These electrons react with residual molecular oxygen leading to 
superoxide (O2·) generation [14].  A large burst of ROS occurring within the first minute 
of reperfusion contributes to the phenomenon of reperfusion injury [2, 11, 15].  
Oxidoreductive changes, decreased high energy phosphate compounds, and increased 
oxidative stress indirectly indicate that ROS are increased during I/R [2, 16]. 
 
 A primary determinant of the extent of I/R injury is antioxidant defense capacity, 
which is modest in the myocardium relative to its highly aerobic nature [17, 18].  ROS 
produced in the mitochondria are regulated by mitochondrial antioxidant enzymes which 
include manganese superoxide dismutase (MnSOD), glutathione peroxidase (GPx1), 
and mitochondrial phospholipid hydroperoxide glutathione peroxidase (mPHGPx; GPx4) 
[19, 20].  GPx4 is a monomeric enzyme with two distinct forms, a long form (L-form), 
which contains a mitochondrial targeting sequence and exists in the mitochondrion 
(mPHGPx), and a short form (S-form), void of a mitochondrial targeting sequence which 
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exists outside of the mitochondrion [21].  A third GPx4 form was identified in rat sperm 
nuclei, which contains a nuclear targeting signal, however the role of this GPx4 isoform 
is not entirely clear [21].  MPHGPx is localized predominantly at contact sites between 
the outer and inner mitochondrial membrane [22], and is of particular interest because it 
is the only antioxidant enzyme capable of reducing peroxidized acyl groups in 
phospholipids [23], fatty acid hydroperoxides [24, 25], and cholesterol peroxides [26], in 
biological membranes.  Since mPHGPx is a lipophilic enzyme associated with 
subcellular membranes, it can act directly on lipid hydroperoxides formed in the 
mitochondria [26], and as a result, is the primary antioxidant defense against oxidation 
of biomembranes within the mitochondrion. 
   
Highly reactive products derived from peroxidized lipids, such as 
malondialdehyde (MDA) and 4-hydroxy-2-nonenal (4-HNE), may contribute to the 
deleterious effects associated with I/R [27, 28].  These reactive products can disrupt 
ETC function by damaging complex constituents, which facilitates necrotic and 
apoptotic cell death [29].  Maintenance of mitochondrial phospholipid bilayer integrity is 
crucial for preservation of mitochondrial protein components, and appropriate 
membrane fluidity all of which influence mitochondrial function.  MPHGPx 
overexpression in stable cell lines inhibits the apoptotic program by preventing 
mitochondrial cytochrome C release, which may be associated with attenuation of 
oxidative stress and preservation of the phospholipid, cardiolipin [19, 30].  Our previous 
studies have indicated that adenoviral vector-mediated mPHGPx overexpression can 
preserve mitochondrial function, decrease necrosis, and inhibit apoptosis in neonatal 
cardiac myocytes subjected to simulated I/R (hypoxia/reoxygenation), all of which are 
associated with an attenuation of oxidative stress [31].  Homozygous null GPx4-
deficient mice die in utero and cell lines derived from GPx4-deficient heterozygous mice 
are more susceptible to oxidative insult [32].  Transgenic mice overexpressing GPx4 
have been shown to be protective against oxidative stress-induced apoptosis, however 
these animals express both the mitochondrial (L-form) and nonmitochondrial (S-form) 
forms of the enzyme making it difficult to determine the sole contribution of the 
mitochondrial form (L-form) during pathological insult [33].  A recent study indicates that 
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GPx4 heterozygous knockout mice possess increased life span, and decreased fatal 
lymphoma incidence, complicating our understanding of the role played by this protein 
[34].  Interestingly, Mclung et al. reported increased incidence of insulin resistance and 
obesity in GPx1 transgenic mice.  These authors speculate that persistent 
overexpression of GPx1 in the cytosol may interfere with cytosolic ROS (H2O2 tone) 
required for essential signal transduction pathways that influence insulin receptor β-
subunit and Akt phosphorylation.  As a result, maintenance of normal protein-tyrosine 
phosphatase regulation in the insulin signaling cascade is disrupted, and 
phosphorylation of insulin receptor attenuated, leading to insulin resistance and 
subsequent obesity [35].   
 
In light of these reports, we generated a novel transgenic mouse that expresses 
only the mitochondrial form (L-form; mPHGPx) of GPx4.  This model was designed to 
eliminate the influence of enhanced cytosolic peroxide scavenging, and enable 
determination of the specific role played by GPx4 in the mitochondrion.  Since the 
mitochondrion is central to the pathogenesis of myocardial I/R injury, we sought to 
determine the impact of mPHGPx overexpression on cardiac contraction and ETC 
function following global myocardial I/R insult.  Our results indicate that mitochondria-
specific overexpression of mPHGPx provides protection to both contractile and 
mitochondrial function following I/R insult. 
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MATERIALS AND METHODS 
 
MPHGPx Transgenic Mouse Development 
 The animal models used in this study conform to the NIH guidelines for the care 
and use of laboratory animals and were approved by the West Virginia University, 
School of Medicine Animal Care and Use Program.  MPHGPx transgenic mouse lines 
were generated using a chimeric transgene consisting of the rat PHGPx (GPx4) gene 
inserted into the vector pCAGGS as previously described [36-38].  The mPHGPx gene, 
a kind gift from Dr. Donna Driscoll of the Cleveland Clinic Foundation (Cleveland, OH, 
USA), consists of a 5’ mitochondria targeting sequence (MT), the GPx4 cDNA, and 3’-
UTR which includes a selenocysteine insertion sequence (SCI) (Figure 1A) [39].  Briefly, 
the pCAGGS vector places the mPHGPx gene under the control of the human 
cytomegalovirus (CMV) immediate early enhancer and chicken -actin (Ch.β-actin) 
promoter with first intron (Figure 1B) [40].  The mPHGPx cDNA was inserted into the 
Xho I cloning site of pCAGGS via blunt-end ligation, as a Bam HI/Not I fragment of 
approximately 870 bp (Figure 1B).  The chimeric transgene was cut out of the plasmid 
by Ssp I and Bam HI digestion, purified, and used to generate the transgenic mice.  The 
construct was given to the West Virginia University Transgenic Animal Core Facility 
where the pronucleus of fertilized eggs from superovulated FVB female mice crossed 
with FVB male mice were injected with 1-2 pl of the purified DNA fragment at a 
concentration of 2 µg/ml, and transferred into the oviduct of pseudopregnant CD-1 mice.  
All control and transgenic mice were generated using an FVB background, and 
experimental procedures were performed on animals of approximately 4-7 months of 
age.  Animals were maintained in individual microisolator cages within the Transgenic 
Barrier Facility and given food and water ad libitum. 
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MPHGPx Transgenic Mouse Screening 
 Mouse litters were delivered after 19-20 days of gestation.  To verify if the 
chimeric transgene was present in the genome, DNA from 4 week old mice was isolated 
from tail clips using a Qiagen DNeasy tissue kit (Qiagen, Valencia, CA).  Transgene 
screening was performed using a real-time PCR (RT-PCR) approach, in which we 
probed for the CMV immediate early enhancer (CMVIE) region using a custom 
designed fluorometric probe (Applied Biosystems, Foster City, CA).  Using this 
approach, only DNA that contains the CMVIE viral sequence is detected.  Briefly, 
sequence for the CMV region (Figure 1B) was submitted to Applied Biosystems Custom 
TaqMan® Gene Expression Assays Service and a custom FAMTM dye-labeled 
TaqMan® Minor Groove Binder (MGB) probe and two unlabeled PCR primers were 
created, by qualifying the target sequence using publicly available bioinformatics 
databases.  Isolated tail DNA, probe, primers, and universal master mix were brought 
up to 25 µl and RT-PCR performed in a 96 well plate using an Applied Biosystems 
7900HT Fast Real-Time PCR system (Applied Biosystems, Foster City, CA).  All 
samples were run in duplicate.  Mouse tail DNA from known positive transgenic mice 
generated using the same pCAGGS vector [37], as well as known littermate negative 
mice were included as internal positive and negative controls, respectively.  A reaction 
time versus cycle number amplification plot was generated and transgene positive and 
negative animals determined.  An RT-PCR approach for screening transgenic animals 
was chosen because of its enhanced sensitivity, assay speed, decreased potential for a 
false positive result, and high throughput potential. 
 
 
Cardiac Contractile Function 
Hearts from mPHGPx and littermate control animals were isolated and 
transferred to a Langendorff set-up for contractile studies as previously described [37, 
41].  In brief, hearts were removed from anesthetized mice, and immersed in cold 
cardioplegic solution.  After cannulation of the aorta on a luer stub, hearts are perfused 
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(80 mm Hg constant pressure) retrograde at 37C with a modified Krebs-Henseleit 
buffer (in mmol/L: 118 NaCl, 4.7 KCl, 2.25 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 25 NaHCO3, 
0.5 Na2EDTA, 5.5 glucose) that was subject to oxygenation.  A small fluid-filled balloon 
was inserted into the left ventricular (LV) cavity and coupled to a pressure transducer 
(Argon Medical Devices, Athens, TX).  The balloon was inflated until the end-diastolic 
pressure (EDP) reached 10 mmHg.  Platinum wires are placed on the surface of the 
right atrium and used to pace the heart at 420 beats/min (7 Hz) with increasing voltage 
until the heart rate was consistent (captured).  During this time period, hearts remain 
submerged in a 37C jacketed chamber, and a heat lamp attached to a variable AC 
transformer was utilized to maintain temperature which was monitored by a needle 
temperature probe inserted just prior to the luer cannula (Physitemp, Clifton, NJ).  
Hearts were perfused for 20 minutes to achieve a stable cardiac function, and then 
placed through an ischemic period in which pacing and perfusion were ceased for 20 
minutes.  During this time period, hearts remained submerged in a 37C jacketed 
chamber to maintain temperature.  Following the no-flow ischemic period, pacing (420 
beats/min; 7 Hz) and perfusion were reinitiated and continued for 90 minutes.  Digitized 
recordings of the ventricular pressure and its first derivative, as well as heart rate were 
captured on an IBM-compatible PC using ChartPro software (AD Instruments, Colorado 
Springs, CO).  Left ventricular developed pressure (DP), maximum speed of contraction 
(+dP/dt), and maximum speed of relaxation (-dP/dt), peak-systolic pressure (PSP), and 
EDP were analyzed from the recordings using ChartPro software. 
 
 
Creatine Kinase Release 
Creatine Kinase (CK) release was used as a determinant of cellular disruption 
and damage as previously described [37].  CK activities were measured 
spectrophotometrically at 340 nm using a kit (Teco Diagnostics, Anaheim, CA) where 
release was determined as the activity in the perfusates at various times prior to (Pre) 
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and during the reperfusion period (1, 2, 3, 4, 5, 6, 10, 30, 60, 90 min, respectively).   CK 
activities were expressed as the change in absorbance, per min, per gram of tissue. 
 
 
Isolation of Cellular Fractions 
 Isolation of cellular fractions was accomplished using a mitochondria/cytosol 
fractionation kit and nuclear/cytosol fractionation kit as previously described [31] 
(BioVision, Mountain View, CA).  Isolated mitochondria fractions were suspended in 
sucrose buffer (in mmol/L: 220 Sucrose, 70 mannitol, 10 Tris HCL, 1 EDTA; pH 7.4) and 
functional measurements were performed on fresh mitochondria.  
 
 
Isolation of Individual Mitochondrial Subpopulations 
Hearts were rinsed in phosphate buffered saline (PBS, pH 7.4), then blotted dry 
and weighed.  Subsarcolemmal mitochondria (SSM) and interfibrillar mitochondria (IFM) 
were isolated on ice following the methods of Palmer et al. [42] with minor modifications.  
Briefly, the ventricles were minced and homogenized 1:10 (w/v) in cold Chappell-Perry 
buffer (in mmol/L: 100 KCl, 40 Tris-HCl, 10 Tris-Base, 5 MgCl2, 1 EDTA; pH 7.4) [42].  
The homogenates were than centrifuged at 800 x g for 10 minutes. The supernatant 
was extracted and centrifuged again at 9,000 x g to isolate the SSM.  The SSM pellet 
was washed and centrifuged two more times at 9,000 x g.  The remaining pellet from 
the 800 x g spin was resuspended in Buffer 2 (in mmol/L: 100 KCL, 5 MgSO4, 5 EGTA, 
50 Tris-HCl; pH 7.4) and exposed to 5 mg/kg of trypsin for 10 minutes [43].  After 10 
minutes, the IFM pellet was diluted two-fold with buffer and centrifuged at 5,000 x g for 
5 minutes.  The supernatant was discarded and the pellet was resuspended in buffer 
and centrifuged at 800 x g for 10 minutes.  The supernatant was saved and the pellet 
resuspended and centrifuged again at 800 x g for 10 minutes to maximize IFM yield.  
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Next, supernatants were combined and centrifuged at 9,000 x g to yield the IFM.  IFM 
were washed several times and centrifuged at 9,000 x g for 10 minutes.  Pellets were 
resuspended in sucrose buffer as described previously and protein concentrations were 
determined using the Bradford method and bovine serum albumin as a standard [44].   
 
To verify the mitochondria subpopulation isolation procedures, we performed flow 
cytometric analyses using a FACS Calibur equipped with a 15 mw 488 nm argon laser 
and 633 red diode laser (Becton and Dickinson, San Jose, CA, USA).  MitoTracker 
Deep Red 633 (Invitrogen, Carlsbad, CA) was used to selectively stain intact 
mitochondria (EM 633nm) and exclude debris, which enabled accurate gating (R1) of 
the mitochondria.  Gated events (20,000 per sample) were examined using the forward 
scatter (FSC) and side scatter (SSC) detectors, and represented in FSC vs. SSC 
density plots.  Geometric mean (arbitrary units, AU) representing FSC (logarithmic 
scale) was used as an indicator of size while values from SSC (logarithmic scale) were 
used to indicate complexity in the subpopulations.  Though the FSC arbitrary unit is 
proportional to the individual mitochondria particle size, the absolute value still remains 
an arbitrary unit.  Thus, to confirm the absolute mitochondria size, we utilized a flow 
cytometry size calibration kit (Invitrogen, Carlsbad, CA) which contains a set of 
microsphere suspensions (0.5 µM – 6 µM) to serve as reliable size references for flow 
cytometric analyses.   All flow cytometric measurements were performed under the 
supervision of the West Virginia University Flow Cytometry Core Facility. 
 
 
MPHGPx Protein Analysis 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) was run on 4-12% 
gradient gels as described [45], with equal amounts of protein loaded.  Relative 
amounts of mPHGPx, Oct-1, cyclophilin D, Grp75, and GAPDH proteins were 
determined using specific antibodies; anti-GPx4 rabbit antibody (Product # 10005258; 
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Cayman Chemical, Ann Arbor, MI), anti-Oct-1 rabbit antibody (Product# sc-232; Santa 
Cruz Biotech, Santa Cruz, CA), anti-cyclophilin D rabbit antibody (Product# PA1-028; 
Affinity Bioreagents, Golden, CO), anti-Grp75 mouse antibody (Product# SPS825; 
Stressgen, Victoria, BC, Canada), and anti-GAPDH mouse antibody (Product# sc-
32233; Santa Cruz Biotech, Santa Cruz, CA).  The secondary antibody for all rabbit 
primary antibodies was a goat anti-rabbit IgG HRP conjugate (Product # 10004301; 
Cayman Chemical, Ann Arbor, MI).  The secondary antibody for all mouse primary 
antibodies was a goat anti-mouse IgG HRP conjugate (Product # 31430; Pierce, 
Rockford, IL).  Detection of signal was performed according to the manufacturer’s 
instructions, using Pierce ECL Western Blotting Substrate (Pierce, Rockford, IL).  
Autoradiographic signals were assessed using a G:Box Bioimaging System (Syngene, 
Frederick, MD), and the data captured and analyzed using GeneSnap/GeneTools 
software (Syngene, Frederick, MD). 
 
 
MPHGPx Enzymatic Activity Analysis 
 Phosphatidylcholine hydroperoxide (PCOOH) was used as a substrate for 
PHGPx activity measurements, and the PCOOH was synthesized using the method of 
Maiorino et al. [46], with modifications [47].  Once the reaction mixture was generated, it 
was passed through a Sep-Pak C18 cartridge (Waters, Milford MA) that had been 
washed previously and equilibrated with water.  The final substrate was eluted with 2 ml 
of methanol and utilized as a substrate for PHGPx activity assessment.  PHGPx activity 
was measured as previously described [46]. 
 
Antioxidant Enzyme Protein Analysis 
 SDS-PAGE was run on 4-12% gradient gels as above [45], with equal amounts 
of protein loaded.  Relative amounts of MnSOD, copper-zinc superoxide dismutase 
(CuZnSOD), GPx1, and catalase proteins were determined using specific antibodies; 
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anti-MnSOD goat antibody (Product # A300-448A; Bethyl Laboratories, Montgomery, 
TX), anti-CuZnSOD rabbit antibody (Product #2779; Cell Signaling, Danvers, MA), anti-
GPx1 rabbit antibody (Product # ab16798; Abcam, Cambridge, MA), and anti-catalase 
rabbit antibody (Abcam, Cambridge, MA).  The secondary antibodies were a goat anti-
rabbit IgG HRP conjugate (Product # 10004301; Cayman Chemical, Ann Arbor, MI) and 
a rabbit anti-goat IgG HRP conjugate (Product # 31402; Pierce, Rockford, IL), 
respectively.  Detection of autoradiographic signal was performed as above. 
 
 
Lipid Peroxidation Products 
Peroxidation of lipids was assessed by measurement of malondialdehyde (MDA) 
and 4-hydroxy-2(E)-nonenal (4-HNE), stable end products formed from the oxidation of 
polyunsaturated fatty acids and esters.   Equal volumes of freshly isolated mitochondria 
were analyzed for MDA and 4-HNE using a colorimetric assay kit (Oxford Biomedical 
Research Company, Oxford, MI).  This assay is based on the reaction of a chromogenic 
reagent, N-methyl-2-phenylindole with MDA and 4-HNE at 45 °C.  One molecule of 
either MDA or 4-HNE reacts with two molecules of the reagent to yield a stable 
chromophore with maximal absorbance at 586 nm.  Absorbance was measured on a 
Biotek Synergy HT plate reader (Biotek, Winooski, VT), and protein content was 
assessed by the Bradford method, as above, with final values expressed per mg of 
protein. 
 
Electron Transport Chain Complex Activities 
Respiratory capacity was assessed in total isolated mitochondria fractions and 
individual mitochondria subpopulations following the method of Hofhaus et al. [48] with 
slight modifications [31].  Following total mitochondrial or subpopulation isolation, 
samples were resuspended in respiration buffer (in mmol/L: 145 KCl, 30 HEPES, 5 
KH2PO4, 3 MgCl2, 0.1 EGTA; and 1% Fatty Acid Free BSA) and equal volumes were 
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loaded into a Gilson chamber (Gilson, Middleton, WI) attached to a YSI 5300 biological 
oxygen monitor (YSI Inc. Yellow Springs, OH).  Activities of complex I, complex III, and 
complex IV were determined by measuring the rate of oxygen consumed in the 
presence of specific substrates.  These substrates were glutamate/ malate for complex 
I, succinate for complex III, ascorbate/N, N, N’, N’-tetramethyl-p-phenylenediamine 
(TMPD) for complex IV and was calculated as the fraction that was sensitive to the 
specific inhibitors rotenone (complex I), antimycin (complex III), and sodium cyanide 
(complex IV).  Protein content was determined following the Bradford method as above, 
and values expressed as nanomoles of O2 consumed per minute, per mg protein.   
 
 
Statistics 
Means and standard errors were calculated for all data sets.  Data were analyzed 
with a two-way analysis of variance (ANOVA) method to evaluate the main treatment 
effects, mPHGPx transgene presence and I/R (Systat; version 5.03, Evanston, IL).  
Fisher’s Least Significant Difference (LSD) post hoc tests were performed to determine 
the significant differences among means.  When appropriate a Student’s T-test was 
employed.  P<0.05 was considered significant. 
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RESULTS 
 
MPHGPx Transgenic Mouse Characterization 
 MPHGPx transgenic mouse lines were created using a chimeric construct 
consisting of the mPHGPx cDNA, mitochondrial targeting sequence, and 3-UTR 
containing the SCI sequence, all of which was inserted into the multiple cloning site of 
the vector pCAGGS (Figure 5.1).  The pCAGGS vector is under the control of the CMV 
promoter, and we utilized this design to screen the transgenic mouse lines (Figure 5.1).  
Two mPHGPx transgenic mouse lines were created, mPHGPx Line 1 and mPHGPx 
Line 2 (Table 5.1).  DNA from mPHGPx Line 1 displayed CT values of approximately 
24, while mPHGPx Line 2 displayed CT value of approximately 26, indicating that Line 1 
possesses slightly greater mPHGPx cDNA content (Table 5.1).  Inclusion of DNA from a 
known positive hsp27 transgenic mouse line generated using the same pCAGGS vector 
[37] is included for comparison purpose, and displayed a CT value of approximately 25 
(Table 5.1).  In contrast, DNA from transgenic negative mice of all lines displayed CT 
values of approximately 34-35 which is similar to the CT value of water (Table 5.1).  As 
a result of our findings, we chose to perform all experimentation using mPHGPx Line 1 
transgenic and littermate control mice. 
We determined whether transgenic mice possessed increases in mPHGPx 
protein levels. Total mitochondria fractions were isolated from cardiac tissue, and 
mPHGPx protein expression determined by Western blot analysis.  MPHGPx transgenic 
positive mice possessed significantly higher levels of mPHGPx protein in the 
mitochondrial fraction of the heart (approximately 14 fold greater), as compared to 
littermate controls (Figure 5.2A; P<7.8E-08).  No significant differences were observed in 
Grp75 (mthsp70) which served as a mitochondria loading control (Figure 5.2A).  To 
confirm whether the increased protein expression observed was specific for the 
mitochondrial fraction, we probed the mitochondria, cytosol, nuclear, and total 
homogenate for mPHGPx expression.  Large increases in mPHGPx protein were 
observed in the mitochondrial fraction (Figure 5.2B).  In contrast, no mPHGPx protein 
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was observed in the nuclear fraction, and a modest amount of mPHGPx protein was 
observed in the total homogenate, which contains proteins from the mitochondria, as 
well as other compartments within the cell, thus diluting the signal (Figure 5.2B).  We 
observed a trace amount of mPHGPx protein in the cytosolic fraction (Figure 5.2B) 
which may be a function of mPHGPx preprocessing prior to mitochondrial entry.  This 
observation is similar to our previous findings using adenoviral vector-mediated 
transgene delivery of mPHGPx protein into neonatal cardiac myocytes [31].  To confirm 
the purity of the subcellular fractionation procedures, we probed cytosolic, mitochondria, 
and nuclear fractions with antibodies specific for each fraction.  Our data indicate that 
for the most part, each fraction was relatively pure, with little or no contamination 
(Figure 5.2C).  We further assessed the distribution of mPHGPx protein in individual 
mitochondrial subpopulations, and observed similar expression patterns in both SSM 
and IFM fractions (Figure 5.2D).  To confirm that transgenic positive mice expressed 
functional mPHGPx protein, we examined phosphatidylcholine hydroperoxide (PCOOH) 
scavenging.  PCOOH is a specific substrate of GPx4.  MPHGPx overexpression led to a 
significant (P<0.01) increase of approximately 14 fold in PCOOH scavenging (in µmol 
PCOOH/min/mg protein: Control, 0.29 ± 0.02; mPHGPx, 4.11 ± 0.65), indicating that the 
enhanced protein expression observed was enzymatically functional.  MPHGPx 
transgenic overexpression had no significant impact on the protein levels of four of the 
major antioxidant enzymes (MnSOD, CuZnSOD, GPx1, catalase) (Figure 5.3). 
 
 
Cardiac Contractile Function Following Global Myocardial I/R 
Heart weight (in mg: Control, 157±8; mPHGPx, 156±10), body weight (in g: 
Control, 34.5±3.2; mPHGPx, 33.4±3.2), and heart weight/body weight ratios (in mg/g: 
Control, 4.7±0.3; mPHGPx, 4.9±0.3) were not significantly altered by mPHGPx 
transgene expression.  To determine whether mPHGPx overexpression influenced 
cardiac contractile function, we examined global no-flow I/R using a Langendorff model.  
No significant differences in coronary flow were observed between mPHGPx transgenic 
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hearts and littermate control hearts at basal (in ml/min: Control, 4.97±0.22; mPHGPx, 
4.58±0.36) and 30 minutes following I/R (in ml/min: Control, 3.15±0.22; mPHGPx, 
3.84±0.50).  MPHGPx transgenic hearts tended (P<0.075) to have higher coronary flow 
rates 60 minutes following I/R (in ml/min: Control, 2.80±0.20; mPHGPx, 3.79±0.53), and 
showed significantly (P<0.05) higher flow rates 90 minutes following I/R (in ml/min: 
Control, 2.38±0.15; mPHGPx, 3.78±0.46).  Following I/R, rates of contraction (+dP/dt) 
were significantly better in mPHGPx transgenic mice as compared to control mice, at 30 
minutes into reperfusion (Figure 5.4A; P<0.01), 60 minutes into perfusion (Figure 5.4A; 
P<0.05), and 90 minutes into reperfusion (Figure 5.4A; P<0.05).  In contrast, no 
significant differences were observed in rates of relaxation (-dP/dt; Figure 5.4B).  
Developed pressures (DP) were significantly better in mPHGPx transgenic mice as 
compared to controls, 30 and 60 minutes into reperfusion (Figure 5.4C; P<0.05 for 
both), and tended to be better 90 minutes into reperfusion (Figure 5.4C; P<0.075).  
Peak-systolic pressures (PSP) were significantly greater in mPHGPx transgenic mice as 
compared to control mice at all measured time points into reperfusion (Figure 5.4D; 
P<0.05), but no significant differences were observed in end-diastolic pressure (EDP; 
data not shown), indicating that the enhanced DP observed with mPHGPx 
overexpression was due solely to an increase in PSP.  Examination of the rise in EDP 
resulting from ischemia (ischemic contracture) revealed a great deal of variance, but 
ultimately, no significant differences between control and mPHGPx transgenic (in mm 
Hg: Control, 12.04±4.17; mPHGPx, 15.99±3.36).  These data indicate that mPHGPx 
transgenic overexpression enhances cardiac contractile function relative to control 
following global no-flow I/R insult, and that this preservation of function occurs primarily 
in the reperfusion period.  
 
 
Cardiac Necrosis Following Global Myocardial I/R 
 Cellular damage was examined at various time points into the reperfusion period, 
via assessment of CK release.  Preischemic (Pre) basal CK release did not differ 
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between the two groups (Figure 5.5).  CK release was significantly great in littermate 
control hearts after ischemia at 2 minutes into the reperfusion period (Figure 5.5; 
P<0.01), with no other time point showing significant differences.  However, overall 
there was a trend for increased CK in the effluents of littermate control hearts at 1 and 3 
minutes into the reperfusion period, as compared to mPHGPx transgenic hearts (Figure 
5.5).  These results indicate that mPHGPx overexpression was capable of protecting 
against I/R-initiated cellular disruption and damage in the myocardium.  
 
 
Oxidative Damage to Mitochondrial Lipids Following Global Myocardial I/R 
Maintenance of the mitochondrial phospholipid bilayer is critical for preservation 
of mitochondrial protein components, and appropriate membrane fluidity during I/R.  
Because it is involved in lipid peroxide scavenging, we examined whether mPHGPx 
overexpression could lessen I/R-associated lipid peroxidation in the mitochondrion, thus 
preserving membrane integrity.  To index mitochondria-specific lipid peroxidation, we 
determined the content of two lipid peroxidation breakdown products, malondialdehyde 
(MDA) and 4-hydroxyalkenals (4-HNE), in total mitochondrial fractions following global 
I/R insult.  Figure 5.6 indicates that following global I/R, mPHGPx transgenic mice 
possessed approximately 40% less MDA and 4-HNE in the mitochondrial fraction as 
compared to littermate controls (P<0.05).  These data are in partial agreement with our 
previous studies examining the impact of adenoviral vector-mediated transgene delivery 
to neonatal cardiac myocytes subjected to simulated I/R (hypoxia/reoxygenation) [31] 
and indicate that mPHGPx transgenic overexpression provides protection to lipids in the 
mitochondrion. 
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Total Mitochondria ETC Complex Function Following Global Myocardial I/R 
Mitochondrial ETC complex function is altered with I/R insult, which may occur as 
a result of increased ROS generation leading to ETC complex dysfunction.  We used 
polarographic assessment to determine changes in total mitochondrial function following 
global myocardial I/R insult.  Complex I, III, and IV activities were all significantly greater 
in total mitochondria from mPHGPx transgenic hearts following global myocardial I/R 
insult (Figure 5.7; P<0.05 for all three).  These results indicate that mPHGPx 
overexpression protects mitochondrial function following global myocardial I/R insult, 
and that this protection is associated with preservation of ETC complexes I, III, and IV.  
We have previously reported that overexpression of mPHGPx via adenoviral vectors, 
preserves complex IV activity in neonatal cardiac myocytes following simulated I/R [31].  
The results from our current study are in partial agreement with our previous studies 
and collectively indicate that mPHGPx transgenic overexpression provides protection to 
mitochondria function in a number of different models of cardiac I/R insult. 
 
 
Mitochondrial Subpopulation ETC Complex Function Following Global Myocardial 
I/R 
MPHGPx transgenic overexpression provides protection to ETC complex 
function in total mitochondria fractions following global myocardial I/R, but it is unclear 
whether this protection is uniform between spatially distinct mitochondrial 
subpopulations.  Individual mitochondrial subpopulations were isolated, and flow 
cytometric analyses performed to verify the effectiveness of the isolation procedure.  
Assessment of forward-scattered light (FSC) was used to estimate size, while 
assessment of side-scattered light (SSC), was used to estimate mitochondrial 
complexity, both of which were based on a logarithmic scale.  Individual mitochondria 
subpopulations were stained with MitoTracker Deep Red 633, which incorporates into 
intact mitochondria.  In Figure A.8A, a typical dot plot, showing MitoTracker Deep Red 
633 stained mitochondria is shown, with intact mitochondria indicated in blue and 
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unstained debris indicated in green.  Using this information, we gated the mitochondria 
(R1) to exclude unstained debris, and applied the R1 gate to analyses on the individual 
subpopulations.  These analyses lend insight into relative morphological differences 
between the two subpopulations, and help to confirm success of the isolation 
procedure.  To confirm differences in absolute mitochondria size, we included size 
calibration beads composed of microsphere suspensions ranging in size from 0.5 µM to 
6 µM to serve as reliable size references.  Using this approach, SSM were larger in size 
(FSC) and possessed greater internal complexity (SSC) as compared to IFM, which 
were smaller and more compact (Figures 5.8B and 5.8C).  These results are consistent 
with previously published reports [42, 49, 50]. 
  
As above, we used polarography to assess changes in ETC complex function 
following myocardial I/R insult, within spatially distinct mitochondrial subpopulations.  
MPHGPx overexpression enhanced ETC complexes I, III, and IV activities in SSM, 
following myocardial I/R insult, as compared to controls (Figure 5.8D; P<0.05, for all 
three).  In contrast, mPHGPx overexpression enhanced only ETC complexes I and III 
activities in IFM, following myocardial I/R insult, as compared to controls (Figure 5.8E; 
P<0.05 for both).  These results indicate that the protection provided by mPHGPx 
transgenic overexpression may be subject to spatial influence within the mitochondrion.  
Further, mPHGPx overexpression may provide SSM with greater protection than IFM, 
during myocardial I/R insult. 
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DISCUSSION 
 
Myocardial I/R injury disrupts biochemical and physiological processes in the 
heart, and central to this disruption are ROS [10].  The main source of ROS during I/R is 
the ETC, which is highly susceptible to oxidative damage because many of its 
components possess iron-sulphur centers which act as targets for ROS [12].  As ETC 
components become damaged they promote injury to other mitochondrial components 
enhancing cellular dysfunction.  Studies have indicated that antioxidant defense is 
crucial in protecting mitochondrial constituents from I/R-induced damage [16-18].  
Because mitochondrial damage is a hallmark of I/R injury, an emphasis has been 
placed on generating therapeutics designed to maintain/enhance key antioxidants 
specific to the mitochondrion.  As a result, the current study was designed to test the 
hypothesis that mitochondria-specific overexpression of GPx4 could lessen oxidative 
damage resulting from myocardial I/R insult, by preserving ETC complex function 
translating into enhanced cardiac contractile function.  In an effort to understand the 
prophylactic contribution of mitochondria-specific GPx4 overexpression, we developed a 
novel transgenic mouse line that expresses GPx4 at a high level, solely in the 
mitochondrion (mPHGPx).  Analysis of GPx4 expression in the mitochondria revealed 
dramatic increases in functionally active protein expression (Figure 5.2A).  Further, 
utilization of an RT-PCR approach for transgene screening, indicated that the increase 
in GPx4 mRNA was similar in amount to other transgenic animals (hsp27) generated 
using a similar strategy [37] (Table 5.1).  To confirm whether GPx4 overexpression was 
confined to the mitochondria, we isolated extracts from various cellular compartments 
and determined GPx4 protein expression.  GPx4 protein analysis of mitochondria, 
cytosol, nuclear, and total homogenate from cardiac tissue confirmed a large increase in 
GPx4 protein specifically in the mitochondria (Figure 5.2B).  A small signal was detected 
in the cytosolic fraction of mPHGPx transgenics, which was similar to our previous 
findings using adenoviral vector-mediated gene delivery of mPHGPx to rat neonatal 
cardiac myocytes [31].  As we reported previously, this small signal may be the result of 
mPHGPx proteins destined for the mitochondria that have not been fully processed and 
as a result are awaiting entry into the mitochondria.  We verified our isolation 
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procedures by examining the expression of compartment-specific proteins.  Our results 
indicate that for the most part, the isolated fractions were pure, though slight 
contamination could be observed (Figure 5.2C).  Thus one cannot rule out the potential 
for cross contamination during isolation.   It is important to point out that mPHGPx 
expression exists primarily at contact sites between the inner and outer mitochondrial 
membranes, though it is possible in our transgenic mouse model, other 
submitochondrial locations may possess enhanced mPHGPx protein content.  The N-
terminal presequence of the mPHGPx protein contains the features of a mitochondrial 
bipartite targeting signal which directs the protein to the intermembrane space [39].  
Nevertheless, in certain cell types during development, mPHGPx expression patterns 
have been shown to be dynamic, moving from one submitochondrial site to another 
(Haraguchi).  Future studies designed to determine the specific location(s) within the 
mitochondria, would be of interest.  Because mitochondria exist as spatially distinct 
subpopulations, we examined whether mPHGPx overexpression occurred in a 
subpopulation-specific manner.  SSM and IFM, possessed similar mPHGPx protein 
levels (Figure 5.2D), indicating that expression patterns did not favor either 
subpopulation.  
  
 It is well established that myocardial I/R promotes damage to cardiac proteins 
which results in contractile dysfunction [6].  In the current study, mPHGPx 
overexpression provided protection to cardiac contractile function during I/R, and this 
protection was subject to temporal influence (Figure 5.4).  Specifically, we observed 
enhanced developed pressures (DP) in mPHGPx hearts at 30 and 60 minutes into 
reperfusion, with a trend of increase 90 minutes into reperfusion (Figure 5.4C).  Rates of 
contraction (+dP/dt) were significantly greater in mPHGPx transgenic hearts at all time 
points, but the degree of significance was greater at 30 minutes into reperfusion as 
compared to 60 and 90 minutes into reperfusion (Figure 5.4A).  Taken together, these 
results indicate that mPHGPx presence enhanced cardiac contractile function 
proximally into the reperfusion period, to a greater extent than at distal time points.  In 
contrast, no differences in rates of relaxation (-dP/dt) were observed in mPHGPx 
transgenic hearts at any time points (Figure 5.4B).  Interestingly, peak systolic 
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pressures (PSP) were greater in mPHGPx transgenic hearts at all time points into 
reperfusion as compared to controls (Figure 5.4D).  It is not entirely clear why mPHGPx 
provided these particular patterns of cardiac protection, but overall these patterns 
seemed to influence protection in the contraction phase, rather than the relaxation 
phase, with a greater impact earlier in the reperfusion period.  These results may be 
due to an overall decrease in oxidative stress during I/R, leading to preservation of 
myocyte viability and/or number.  Because our examination of cardiac contractile 
performance included analyses solely at 30, 60, and 90 minutes, it is unclear whether 
mPHGPx overexpression provided contractile protection earlier in the reperfusion 
period.  We previously observed decreased necrosis and apoptosis in neonatal cardiac 
myocytes infected with an adenoviral vector expressing mPHGPx that had been 
submitted to simulated I/R (hypoxia/reoxygenation) [31].  Examination of CK release 
following I/R indicated a cardioprotective profile in mPHGPx hearts (Figure 5.5), 
confirming our previous findings.  It is important to point out that the mechanistic 
function of mPHGPx is dependent on the use of the reducing equivalent glutathione 
(GSH).  Myocardial I/R is associated with a decrease in the ratio of reduced:oxidized 
glutathione (GSH:GSSG) [2], thus it is possible that loss of GSH reducing capacity as 
opposed to enzymatic peroxide scavenging may be the limiting factor in the 
sequestering of injurious phospholipid hydroperoxides.  Examination of combinatorial 
therapeutic approaches that couple mPHGPx overexpression with enhancement or 
preservation of GSH would be of interest for future studies. 
 
MPHGPx is associated with subcellular membranes and is the primary enzymatic 
defense against oxidation of phospholipids in biomembranes [26].  Because reactive 
products derived from the oxidation of lipids promote deleterious effects on membrane 
constituents, we examined MDA and 4-HNE content in isolated mitochondria following 
myocardial I/R.  Our results indicate that MDA and 4-HNE were collectively lower in 
mPHGPx mitochondria following myocardial I/R, as compared to controls (Figure 5.6).  
These results are in agreement with our previous findings, and confirm that, as 
expected, one locus of protection provided by mPHGPx is mitochondrial membranes 
[31].  Our results are in partial agreement with those of Ran et al. who observed 
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decreases in liver total isoprostane levels in GPx4 transgenic mice that express the 
protein in numerous cellular compartments [33].  Enhanced scavenging of lipid 
hydroperoxides by mPHGPx may allow for the preservation of phospholipids within the 
mitochondrial bilayer which ultimately protects mitochondrial function by preserving ETC 
components and influencing mitochondria permeability transition pore (mPTP) 
dynamics.  Cardiolipin, a phospholipid specific to the mitochondria, is easily oxidized 
and plays a role in maintaining cytochrome C within the mitochondria [21].  Following 
cardiolipin oxidation, cytochrome C can be released and facilitate apoptosome 
formation prior to cellular apoptosis [51].  It has been suggested that cardiolipin 
hydroperoxide is a specific target of mPHGPx action and the ability to preserve 
cardiolipin in the mitochondria may play a role in its mechanism of protection [21]. 
 
Due to the role played by mPHGPx in scavenging phospholipid hydroperoxides 
and preserving inner mitochondrial membrane integrity, we explored whether 
mitochondria specific GPx4 overexpression would be protective to ETC complexes.  
ETC complexes are surrounded by phospholipids in the inner mitochondrial membrane 
that contribute to their stability, integrity, and function.  Many of these phospholipids are 
more easily prone to oxidation which in turn can damage the ETC.  Overexpression of 
mPHGPx increased all ETC complex (complex I, III, IV) activities following myocardial 
I/R as compared to control (Figure 5.7).  These results are in partial agreement with our 
previous findings indicating that mPHGPx overexpression preserves complex IV activity 
following simulated I/R [31].  The disparity between our previous results and those from 
the current study may be due to several differences in the study designs.  First, our 
previous study utilized rat neonatal cardiac myocytes, a relatively common model used 
in simulated I/R studies.  Though the neonatal cardiac myocyte responds to the 
deleterious effects of simulated I/R, it is more resistant to hypoxic conditions, based in 
part on its greater use of glycolytic pathways for metabolism.  As a result, the oxidative 
stress imposed may have been better tolerated in the neonatal cardiac myocyte, as 
compared to the adult cardiac myocyte, which is more reliant upon oxidative processes 
for metabolism.  Further, one has to consider the difference in I/R model systems 
employed, simulated I/R vs. whole heart I/R, which may provide different stresses and 
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damage profiles.  Our studies are somewhat in disagreement with those of Liang et al., 
who observed no differences with diquat exposure in transgenic mice that overexpress 
GPx4 in multiple cellular compartments [52].  A number of differences in study design 
may have contributed to the discrepant results.  First, the GPx4 transgenic mouse 
utilized by Liang et al. displays different GPx4 expression patterns (lower) than the 
animals utilized in the current study, and they express the protein in multiple cellular 
compartments.  It is possible that the GPx4 protein levels were not large enough to elicit 
a robust protective effect to the ETC, or that the enhanced GPx4 expression in other 
cellular compartments, such as the cytosol, may have lessened the oxidative stress 
presented to the mitochondria.  It is has been previously reported that transgenic 
overexpression of GPx1 in multiple cellular compartments, such as the cytosol, may 
decrease cytosolic oxidant tone, which may impact oxidant levels within the cell [35].  
Second, these authors utilized intraperitoneal injection of diquat to elicit an oxidative 
challenge to the liver, which is somewhat different than the current study, in which a 
global I/R model was used to elicit an oxidative challenge to the heart.  Finally, these 
authors made their mitochondrial measurements following isolation of individual ETC 
complexes via blue native gel electrophoresis.  This is in contrast to the current study, in 
which classic polarography using a Clark type electrode was employed to make ETC 
complex activity measurements in intact mitochondria.  Nevertheless, the differences in 
results are interesting, and warrant further investigation.   
  
Two mitochondrial subpopulations are present in the cardiac myocyte, 
interfibrillar mitochondria (IFM), which situate between the contractile apparatus, and 
subsarcolemmal mitochondria (SSM), which exist beneath the plasma membrane [53].  
These two spatially distinct mitochondrial subpopulations are distinguished by specific 
cellular arrangements, separate functional properties, and differential responses to 
pathological conditions [42, 49, 53-57].  It has been suggested that the differential 
response observed in the two mitochondrial subpopulations during I/R may be due to 
variation in local oxygen tension within spatially distinct parts of the cell [58].  Because 
I/R impacts mitochondria subpopulations differently, we wanted to determine whether 
subpopulation-specific patterns of protection were provided by mPHGPx 
240 
 
overexpression.  Flow cytometric analyses revealed that in general, SSM appear to be 
larger and more complex than IFM, ranging in size from approximately 0.5µm to 3.0µm 
(Figure 5.8B).  Overall, the IFM were smaller, less complex and less variable in size, 
ranging from <0.5 to 2.0µm (Figure 5.8C).  These findings were comparable to what 
others have found regarding morphological differences between the two populations 
[42, 49, 50].  Examination of ETC complex activities indicated that all components of the 
ETC (complex I, III, IV) were protected with mPHGPx overexpression in the SSM 
(Figure 5.8D).  In contrast, only proximal ETC complexes (complex I, complex III) were 
protected with mPHGPx overexpression in the IFM (Figure 5.8E).  Our results suggest 
that the protective profiles provided by mPHGPx overexpression are different in spatially 
distinct mitochondria subpopulations.  This may be due in part to a difference in the 
susceptibility of spatially distinct mitochondria subpopulations to I/R, and in particular 
ETC complex IV, as reported previously [59]. 
 
In conclusion, we report for the first time, that mitochondria-specific transgenic 
overexpression of GPx4 in a mouse model provides protection to cardiac contractile 
function following myocardial I/R insult.  Further, the cardiac contractile protection 
provided by mPHGPx overexpression is associated with enhanced mitochondrial ETC 
complex activities.  These findings provide further rationale for the use of mPHGPx as a 
therapeutic protectant against I/R-induced cardiac injury. 
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Figure 5.1 
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Figure 5.1. MPHGPx transgenic mouse construction. Generation of 
mPHGPx transgenic mice was accomplished by inserting the rat mPHGPx 
cDNA (approximately 870 bp) into the plasmid pCAGGS via blunt end 
ligation. (A) Schematic of the rat mPHGPx cDNA fragment that was 
inserted into the plasmid pCAGGS. An AUG start codon at 61 bp precedes 
the mitochondria targeting sequence (MT). The AUG start codon at 141 bp 
indicates the mPHGPx translational start. The selenocysteine (SEC) codon 
is indicated as a TGA at position (277–279 bp). The selenocysteine (SCI) 
insertion sequence which is required for SEC incorporation is indicated as 
AUGA and is located in the 3′-UTR. The polyadenylation signal in the 3′-
UTR is indicated as AAA. (B) The pCAGGS vector places the mPHGPx 
gene under the control of the human cytomegalovirus (CMV) immediate 
early enhancer and chicken β-actin (Ch. β-actin) promoter with first intron. 
The approximately 870-bp rat mPHGPx cDNA was inserted into the XhoI 
cloning site of pCAGGS as a BamHI/NotI fragment. The chimeric transgene 
was cut out of the plasmid by SspI and BamHI digestion, purified, and used 
to generate transgenic mice. 
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Figure 5.2. MPHGPx protein analyses. (A) Representative Western blot 
analysis of GPx4 (PHGPx) protein expression in isolated total heart 
mitochondria from mPHGPx Line 1 transgenic positive mice and negative 
littermate controls. Lanes 1–4 are negative littermate controls, and Lanes 
5–8 are mPHGPx transgenic positives. A representative Western blot 
analysis of Grp75 (mthsp75) is included as a loading control. (B) 
Representative Western blot analysis of GPx4 (PHGPx) protein expression 
in various cellular compartments of mPHGPx transgenic mouse heart and 
littermate control mouse heart. Mi, mitochondria; Cy, cytosol; Nu, nucleus; 
Hom, total homogenate. Lanes 1–4 are from a negative littermate control, 
and Lanes 5–8 are from a mPHGPx transgenic positive. (C) Representative 
Western blot analysis of compartment-specific markers for verification of 
subcellular fractionation. Mi, mitochondria (CycD); Cy, cytosol (GAPDH); 
Nu, nucleus (Oct-1). (D) Representative Western blot analysis of GPx4 
(PHGPx) protein expression in individual mitochondrial subpopulations of 
mPHGPx transgenic mouse heart and littermate control mouse heart. SSM, 
subsarcolemmal mitochondria; IFM, interfibrillar mitochondria. Lanes 1-2 
are from a negative littermate control, and Lanes 3–4 are from a mPHGPx 
transgenic positive. 
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Figure 5.3 
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Figure 5.3. Antioxidant enzyme protein analyses. Representative 
Western blot analyses of mitochondrial superoxide dismutase (MnSOD), 
cytosolic SOD (CuZnSOD), glutathione peroxidase (GPx1), and catalase 
protein expression in total heart homogenate from mPHGPx transgenic 
positive mice and negative littermate controls. Lanes 1–3 are negative 
littermate controls, and Lanes 4–6 are mPHGPx transgenic positives. A 
representative Western blot analysis of GAPDH is included below as a 
loading control. 
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Figure 5.4 
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Figure 5.4. Cardiac contractile function following I/R. (A) Rate of 
contraction (+dP/dt) in mPHGPx transgenic and littermate negative controls 
30, 60, and 90 min following global I/R insult. (B) Rate of relaxation (-dP/dt) 
in mPHGPx transgenic and littermate negative controls 30, 60, and 90 min 
following global I/R insult. (C) Developed pressure (DP) in mPHGPx 
transgenic and littermate negative controls 30, 60, and 90 min following 
global I/R insult. (D) Peak systolic pressure (PSP) in mPHGPx transgenic 
and littermate negative controls 30, 60, and 90 min following global I/R 
insult. All functional measurements were performed in Langendorff-
perfused hearts. Rates of contraction (+dP/dt) and rates of relaxation (-
dP/dt) are expressed as mm Hg/second. DP and PSP are expressed as 
mm Hg. Values are mean ± SE; N = 8 for each group. P < 0.05 for 
mPHGPx transgenic vs littermate control. †P < 0.01 for mPHGPx 
transgenic vs littermate control. ††P < 0.075 for mPHGPx transgenic vs 
littermate control. 
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Figure 5.5 
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Figure 5.5. Creatine kinase release following I/R. Creatine kinase (CK) 
release was measured in effluents from reperfused hearts at various time 
points after ischemia. Measurements were taken prior to ischemia (Pre), 1, 
2, 3, 4, 5, 6, 10, 30, 60, and 90 min into the reperfusion period. Values are 
mean ± SE; N = 4 for each group. †P < 0.01 for mPHGPx transgenic vs 
littermate control. 
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Figure 5.6 
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Figure 5.6. Total mitochondria lipid peroxidation content following I/R. 
Total mitochondria fractions were isolated from mPHGPx transgenic and 
littermate control hearts following global I/R insult, and lipid peroxidation 
measurements performed. Assessment of the lipid peroxidation by-
products malondialdehyde (MDA) and 4-hydroxyalkenals (4-HAE) was 
performed using a colorimetric assay and spectrophotometric 
measurement at 586 nm. Sample values were compared against a 
standard curve of known 4-HAE and MDA, and data are expressed as 
µmole MDA + 4-HAE per mg of protein. Values are expressed as 
mean ± SE; N = 5 for each group. P < 0.05 for mPHGPx vs control. 
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Figure. 5.7. Mitochondria electron transport chain (ETC) function 
following I/R. Total mitochondria fractions were isolated from mPHGPx 
transgenic and littermate control hearts following global I/R insult, and 
polarographic measurements performed to index oxygen consumption. 
Activities of individual ETC complexes were defined as the rate of oxygen 
consumed in the presence of specific substrates, glutamate/malate 
(complex I), succinate (complex III), and ascorbate/N,N,N′,N′-tetramethyl-p-
phenylenediamine (complex IV), and were calculated as the fraction that 
was sensitive to the specific inhibitors rotenone (complex I), antimycin 
(complex III), and sodium cyanide (complex IV). Values are mean ± SE; 
N = 8 for each group. P < 0.05 for mPHGPx vs control. 
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Figure 5.8 
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Figure. 5.8. Mitochondria subpopulation electron transport chain 
(ETC) function following I/R. Individual mitochondrial subpopulations 
were isolated from mPHGPx transgenic and littermate control hearts and 
polarographic measurements performed to index oxygen consumption. 
Activities of individual ETC complexes were defined as the rate of oxygen 
consumed in the presence of specific substrates, glutamate/malate 
(complex I), succinate (complex III), and ascorbate/N,N,N′,N′-tetramethyl-p-
phenylenediamine (complex IV), and were calculated as the fraction that 
was sensitive to the specific inhibitors rotenone (complex I), antimycin 
(complex III), and sodium cyanide (complex IV). (A) Representative density 
plot of isolated mitochondria stained with MitoTracker Deep Red 633, which 
incorporates into intact mitochondria. Intact mitochondria that take up the 
MitoTracker Deep Red 633 dye are gated (R1) and represented in blue. 
Noise and debris, which do not take up the MitoTracker Deep Red 633, are 
excluded from measurements (outside the R1 gate) and indicated in green. 
(B) Representative gated density plot indicating size (FSC; forward scatter) 
vs internal complexity (SSC; side scatter) of isolated SSM. (C) 
Representative gated density plot indicating size (FSC; forward scatter) vs 
internal complexity (SSC; side scatter) of isolated IFM. Analyses of forward 
scatter and side scatter were calculated per 20,000 gated events for all 
mitochondrial subpopulations. Red hash lines indicate microsphere size 
references from left to right: 0.5, 1, 2, 4, and 6 μM, respectively. (D) SSM 
ETC complex function following myocardial I/R. (E) IFM ETC complex 
function following myocardial I/R. Values are expressed as mean ± SE; 
N = 6 for each group. P < 0.05 for mPHGPx vs control. SSM, 
subsarcolemmal mitochondria; IFM, interfibrillar mitochondria.
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 Cycle Number 
Transgenic Positives  
mPHGPx Line 1 24.3 
mPHGPx Line 2 26.0 
Hsp27tg 25.4 
Transgenic Negatives  
mPHGPx Line 1 34.8 
mPHGPx Line 2 34.7 
Hsp27tg 34.5 
Water 34.0 
Table 5.1 
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Table 5.1.  MPHGPx Transgenic Mouse Screening.  Verification of chimeric 
transgene presence was accomplished using a real-time PCR approach.  Isolated 
genomic tail DNA was examined by probing for the cytomegalovirus (CMV) immediate 
early enhancer region indicated in Figure 1B, using a custom designed probe.  A lower 
cycle number indicates increasing transgene presence.  Two mPHGPx transgenic 
mouse lines were generated, mPHGPx Line 1 and mPHGPx Line 2 with cycle numbers 
between 24 and 26.  Inclusion of DNA from a known transgenic line (hsp27 tg) 
developed using the same pCAGGS plasmid is included as a positive internal control, 
and has a cycle number of approximately 25.  Littermate controls for mPHGPx Line 1, 
mPHGPx Line 2, hsp27 tg, and a water control (no DNA) are included as internal 
negative controls and display cycle numbers of approximately 34-35.   
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ABSTRACT 
 
Mitochondrial dysfunction plays a critical role in the pathogenesis of type 1 
diabetes mellitus (DM).  Evidence suggests that the inner mitochondria membrane 
(IMM) and its constituents are specific targets for the deleterious effects associated with 
type 1 DM.  As a result, maintenance of IMM integrity represents a specific locus for 
testing directed prophylactic intervention.  We previously reported that type 1 DM 
imparts differential effects on spatially distinct mitochondrial subpopulations, 
subsarcolemmal (SSM) and interfibrillar (IFM).  The goal of this study was to determine 
whether overexpression of a mitochondrially-targeted antioxidant enzyme, mitochondria 
phospholipid hydroperoxide glutathione peroxidase 4 (mPHGPx), which scavenges 
phospholipids in the IMM, could elicit protection to mitochondria during type 1 diabetic 
insult, and if the protection was subpopulation-specific.  MPHGPx transgenic mice and 
littermate controls were made diabetic through multiple low dose injections of 
streptozotocin (STZ).  Five weeks following hyperglycemia onset, in vivo analysis of 
cardiac contractile function revealed significantly decreased ejection fraction and 
fractional shortening in the diabetic heart (*P<0.05), which was reversed with mPHGPx 
overexpression (*P<0.05).  MPHGPx overexpression in the diabetic heart, was 
associated with increased mitochondrial state 3 and state 4 respiration and electron 
transport chain complex I, III, and IV activities in IFM (*P<0.05), with no differences on 
SSM.  Hydrogen peroxide production and lipid peroxidation were significantly 
attenuated in the diabetic IFM with overexpression of mPHGPx (*P<0.05 for both), with 
no changes in the SSM.  An essential IMM component, cardiolipin was preserved in the 
IFM with ovexpression of mPHGPx in the diabetic heart.  Enhanced post-translational 
modifications to IMM were also attenuated in the diabetic IFM with overexpressioin of 
mPHGPx.  These results indicate that mPHGPx overexpression provides 
cardioprotection to the diabetic heart through enhanced mitochondrial function and 
specifically preservation of IMM. 
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INTRODUCTION 
 
Mitochondrial dysfunction is a major contributor to diabetic cardiomyopathy-
associated dysfunction in the type 1 diabetic heart (7, 13, 43, 46).  The resultant 
enhanced reactive oxygen species (ROS) generation and subsequent oxidative damage 
have been suggested to play a major role in the dysfunction.   Elevated glucose and 
free fatty acid levels present in the diabetic heart have been suggested to drive the 
formation of ROS (10, 30, 51).  It is believed that initially, increased flux of metabolic 
substrates generates increased electron leak which leads to enhanced ROS production.  
The mitochondrion itself is particularly susceptible to oxidative damage because the 
inner mitochondrial membrane (IMM) is a main site for ROS generation (9).  This has 
implications for IMM integrity in that the IMM is enriched with polyunsaturated fatty acids 
and oxidizable electron carriers (12, 23) that are targets of ROS.  Further, many of 
electron transport chain (ETC) proteins are prone to oxidation because they contain 
iron-sulphur centers (29), which readily react with ROS and precipitate cellular damage.  
Enhanced mitochondrial ROS generation has been suggested to directly inhibit ETC 
complex activities decreasing overall mitochondrial respiration (46). We previously 
reported that those mitochondria located between the myofibrils, interfibrillar 
mitochondria (IFM), have enhanced ROS production and subsequent oxidative damage 
which is associated with diminished overall mitochondrial function in the type 1 diabetic 
heart (7).    
Many proteins and lipids within the IMM are critical targets of elevated ROS 
production, and their oxidative modification further contributes to mitochondrial 
dysfunction by limiting sufficient production of ATP.  One potential target within the IMM 
is the mitochondrial-specific phospholipid, cardiolipin.  Cardiolipin is a 
diphosphatidylglycerol enriched in the IMM, containing oxidatively-sensitive acyl groups 
that may act as selective targets for ROS (19).  Cardiolipin plays an essential role in 
stabilizing protein complexes and translocases within the IMM, facilitating proper 
mitochondrial function.  Cardiolipin directly interacts with a number of mitochondrial 
proteins within the IMM including F0F1-ATPase, ANT, cytochrome c, protein import 
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machinery, and ETC complexes I, III, and IV (19, 45).   Cardiolipin is more susceptible 
to oxidation due to the double bonds located within its fatty acid side chains and it has 
been suggested that following cardiolipin oxidation, cytochrome c is released which 
initiates apoptosis (20).  Several authors have suggested remodeling and depleted 
content of cardiolipin in the diabetic heart (15).  Previously, we have shown that the 
most predominant species of cardiolipin is decreased in the IFM suggesting that it is a 
potential target for damage associated with type 1 diabetes mellitus (7).   
Antioxidants play a vital role in defense against enhanced oxidant production in 
the diabetic heart.  Phospholipid hydroperoxide glutathione peroxidase (PHGPx; GPx4), 
is a monomeric antioxidant enzyme with two distinct forms, a long form (L-form), which 
contains a mitochondrial targeting sequence and exists in the mitochondrion 
(mPHGPx), and a short form (S-form), without a mitochondrial targeting sequence 
which exists in the cytosol (25, 50).  MPHGPx is unique in that it is the only antioxidant 
enzyme capable of reducing peroxidized acyl groups in phospholipids, fatty acid 
hydroperoxides and cholesterol peroxides (25, 48, 50) in mitochondrial membranes.  
Since mPHGPx is a lipophilic enzyme, it can interact directly with lipid hydroperoxides 
within the IMM, and it has been suggested to be the primary antioxidant defense against 
biomembrane oxidation within the mitochondrion (20, 41). Homozygous null GPx4-
deficient mice die in utero and cell lines derived from GPx4-deficient heterozygous mice 
are more susceptible to oxidative insult (14).  Previous work from our laboratory 
indicates that transgenic overexpression of mPHGPx preserves cardiac contractile 
performance and mitochondrial function while attenuating the accumulation of lipid 
peroxidation by-products during ischemia/reperfusion insult (8).  Nevertheless, to date, 
no examination has been undertaken to determine whether overexpression of PHGPx 
provides protection to the diabetic heart.  Thus, the goals of the current study were the 
following; 1) determine whether mPHGPx overexperession preserves cardiac contractile 
function in the type 1 diabetic heart; 2) determine whether mPHGPx overexperession 
preserves mitochondrial function in the type 1 diabetic heart; and 3) determine whether 
mPHGPx overexpression impacts cardiolipin modeling in the type 1 diabetic heart.   
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MATERIALS AND METHODS 
 
Experimental Animals and Diabetes Induction  
The animal experiments in this study conformed to National Institutes of Health 
(NIH) Guidelines for the Care and Use of Laboratory Animals and were approved by the 
West Virginia University Animal Care and Use Committee. Mixed sex FVB mice 
(Charles River Laboratories, Wilmington, MA) were housed in the West Virginia 
University Health Sciences Center animal facility. Mice were given unlimited access to a 
rodent diet and water.   MPHGPx transgenic mouse lines were generated as previously 
described (16, 18, 26).  Briefly, the pCAGGS vector places the mPHGPx gene under 
the control of the human cytomegalovirus (CMV).  All littermate control and transgenic 
mice were generated using an FVB background, and experimental procedures were 
performed on animals of approximately 8 weeks of age.  Type 1 diabetes mellitus was 
induced in 8-wk-old control and transgenic (mPHGPx) mice following the protocol of the 
Animal Models of Diabetic Complications Consortium using multiple low-dose 
streptozotocin (STZ; Sigma, St. Louis, MO) injections.   Injections of 50 mg/kg body wt 
STZ dissolved in sodium citrate buffer (pH 4.5) were performed daily for 5 consecutive 
days after 6 hours of fasting. Mice that served as vehicle controls were given the same 
volume per body weight of sodium citrate buffer. One week postinjection, hyperglycemia 
was confirmed by measuring urinary glucose (Chemstrip 2GP Urine test strips, Roche 
Diagnostics, Indianapolis, IN), where >2,000 mg/dl was considered diabetic.  Five 
weeks post hyperglycemia onset, animals were killed for further experimentation.   
 
Echocardiographic Assesment  
Transthoracic echocardiography was performed in conscious mice following the 
protocols provided by the Animal Models of Diabetic Complications Consortium 
(AMDCC; www.amdcc.org). Briefly, Left ventricular (LV) fractional shortening (%FS) 
and ejection fraction (%) were assessed in all mice with echocardiography which was 
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equipped with a 13-MHz linear probe (Vivid i; GE Medical Systems, Milwaukee, 
Wisconsin, USA). With mice in the left lateral decubitus position, a parasternal short-axis 
view was obtained for LV M-mode imaging at the papillary muscle level and LV chamber 
dimensions were determined.  LV fractional shortening and LV ejection fraction are 
calculated from the M-mode measurements.  
 
Preparation of Individual Mitochondrial Subpopulations  
At 5 weeks post hyperglycemia onset, control, diabetic, mPHGPx and mPHGPx 
diabetic were sacrificed, and the hearts were excised. Hearts were rinsed in phosphate 
buffered saline (PBS, pH 7.4), then blotted dry and weighed.  SSM and IFM were 
isolated as previously described following the methods of Palmer et al. (33) with minor 
modifications (6-8, 52).  Protein concentrations were determined using the Bradford 
method with bovine serum albumin (BSA) as a standard (1).   
 
Mitochondria Size and Internal Complexity  
To asses mitochondrial subpopulation size and complexity, we performed flow 
cytometry analyses using a FACS Calibur equipped with a 15 MW 488-nm argon laser 
and 633 red diode laser (Becton Dickinson, San Jose, CA) as previously described (6-8, 
52).  All flow cytometric measurements were performed under the supervision of the 
West Virginia University Flow Cytometry Core Facility.  
 
Electron Transport Chain (ETC) Respiration  
State 3 and state 4 respiration was assessed in isolated mitochondrial 
subpopulations as previously described (2, 3, 17) with slight modifications (8). Isolated 
mitochondrial subpopulations were resuspended in respiration buffer containing (in 
mmol/L: 80 KCl, 50 MOPS, 1 EGTA, 5 KH2PO4, and 1 mg/ml BSA) and equal volumes 
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were loaded into a Gilson chamber (Gilson, Middleton, WI) attached to a Yellow Springs 
Instruments 5300 biological oxygen monitor (YSI, Yellow Springs, OH).   The substrates 
glutamate (5mM) + malate (5mM) were used to initiate respiration and measurement of 
state 3 (1mM ADP) and state 4 (ADP-limited) respiration were made as previously 
described (6-8).  
 
Electron Transport Chain (ETC) Complex Activities 
ETC activities of complexes I, III and IV were measured spectrophotometrically 
as previously described (6-8, 49).  Briefly, complex I activity was determined by 
measuring the oxidation of NADH at 340 nm, complex III activity was determined by 
following the reduction of cytochrome c at 550 nm in the presence of reduced 
decylubiquinone (50 µM), and complex IV activity was determined by measuring the 
oxidation of cytochrome c at 550 nm.  Protein content was determined as described 
above (1), and values expressed as activities in nanomoles substrate consumed per 
minute per milligram of protein. 
 
ATP Synthase Activity  
ATP synthase activity was measured in mitochondrial subpopulations as 
oligomycin-sensitive ATPase activity using an assay coupled with pyruvate kinase 
which converts the ADP to ATP and produces pyruvate from phosphoenolpyruvate as 
previously described. (6, 11, 39, 44).  Protein content was assessed as above (1) with 
final values expressed as nanomoles consumed per minute per milligram of protein, 
which was equal to the nanomoles of NADH oxidized per minute per milligram of 
protein. 
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Lipid Peroxidation Products  
Lipid peroxidation by-products malondialdehyde (MDA) and 4-hydroxyalkenal (4-
HAE), stable end products formed from the oxidation of polyunsaturated fatty acids and 
esters, were assessed as previously described (6-8).  Absorbance was measured on a 
Molecular Devices Flex Station 3 spectrophotometer (Molecular Devices, Sunnyvale, 
CA) and protein content was assessed as described above (1) with final values 
expressed per milligram of protein.    
 
Mitochondrial Membrane Potential (∆Ψm) 
Mitochondrial membrane potential (∆Ψm) was measured on freshly isolated 
mitochondria by flow cytometry using the ratiometric dye 5,5’,6,6’-tetrachloro-1,1’,3,3’-
tetraethylbenzimidazol carbocyanine iodide (JC-1) (Molecular Probes, Carlsbad, CA) as 
previously described (6, 52).  Addition of 200 μM of dinitrophenol (DNP), which 
dissipates ∆Ψm, was used as an assay control.   
 
Cardiolipin 
 Mitochondrial subpopulations were isolated from control, mPHGPx, diabetic and 
mPHGPx diabetic hearts.  An n=4 for each of the four groups was pooled and sent off to 
Avanti Polar Lipids (Alabaster, AL) for cardiolipin analysis.  Extraction and analysis of 
total cardiolipin species was based on the protocols of Sparagna et al. (47) and Minkler 
et al. (27). 
 
Hydrogen Peroxide (H2O2) Production 
H2O2 production in isolated mitochondrial subpopulations was determined using 
the oxidation of the fluorogenic indicator amplex red in the presence of horseradish 
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peroxidase (54).  The concentrations of horseradish peroxidase and amplex red in the 
incubation were 0.1 unit/ml and 50 μM and detection of fluorescence was assessed on 
a Molecular Devices Flex Station 3 fluorescence plate reader (Molecular Devices, 
Sunnyvale, CA) with 530 nm excitation and 590 nm emission wavelengths.  Standard 
curves were obtained by adding known amounts of H2O2 to the assay medium in the 
presence of the substrates amplex red and horseradish peroxidase.  Final values were 
calculated and presented as pmol/mg of protein.  H2O2 production was initiated in 
mitochondria using glutamate (5.0 mM) /malate (5.0 mM) as substrates. The addition of 
catalase diminished fluorescence confirming dissipation of H2O2 presence in the 
sample. 
 
Multi Dimensional Protein Identificiation Technology (MudPIT)  
Pooled IFM subpopulations (n=4) from control, diabetic, and mPHGPx diabetic 
hearts were analyzed for post-translational modifications as previously described (6).  
Briefly, samples were lysed and precipitated overnight in acetone at -20°C and pellets 
were resuspended in 20 μL of 0.5 M triethylammonium bicarbonate (TEAB; pH 8.5).  
Protein contents were determined using a 2-D Quant Kit (Amersham, Piscataway, NJ) 
and pooled samples were than denatured with 0.1% SDS and reduced with 5mM tris-(2-
carboxyethyl) phosphine (TCEP).  After incubation for 1 hour at 60°C, cysteines were 
blocked with 10 mM methyl methane thiosulfonate (MMTS) in isopropanol, and the 
samples were incubated at room temperature for 10 minutes.  10 μL of sequencing 
grade trypsin (Applied Biosystems, Foster City, CA) was added in a trypsin/protein ratio 
of 1:20, and the samples incubated at 37°C overnight.  After digestion, the ultra-
complex protein digests were subject to  Multi Dimensional Protein Identificiation 
Technology (MudPIT) analysis (24).   After lyophilization, the digest mixture was 
reconstituted in strong cation exchange (SCX) loading buffer (5mM ammonium formate 
in 20% acetonitrile; pH 3.0) to be fractionated with SCX SpinTips (Protea Biosciences, 
Morgantown, WV) per the manufacturer’s protocol.  Briefly, the sample solution was 
loaded centrifugally onto the SCX SpinTip.  The non-adsorbing solution that passed 
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through the SCX SpinTip was collected. Eight different elution solutions were used to 
fractionate the peptides (20, 60, 100, 150, 200, 250, 400, and 500 mM ammonium 
formate in 10% acetonitrile) in a step-wise manner, for a total of nine sample fractions.  
The collected fractions were cleaned by repeated lyophilization and reconstituted in a 
0.1 M acetic acid solution, and then lyophilized to dryness.  The fractions were then 
submitted for LC-MALDI TOF/TOF mass spectral analysis for identification of proteins 
and post-translational modifications that are present.  
 
Mass Spectrometry (MS) Analyses 
The LC-MALDI mass spectrometry system utilized was an ABI Tempo LC MALDI 
spotter with Tempo LC MALDI v.2.00.09 data acquisition and processing software.  
Lyophilized SCX sample fractions were reconstituted in LC aqueous run buffer (0.1% 
trifluoroacetic acid, 2% acetonitrile) and was injected onto a Zorbax C18 
chromatographic column, 150 x 0.3 mm (Agilent Technologies, Wilmington, DE).  The 
peptides were eluted from the column using an acetonitrile/trifluoroacetic acid gradient 
(2-72% acetonitrile in 35 minutes) and spotted directly onto a MALDI plate in 6 second 
spot fractions.  The MALDI spots were analyzed using an ABI 4800 MALDI TOF/TOF 
analyzer operated with 4000 Series Explorer software.  The MS acquisition was in 
positive ion reflector mode with 400 laser shots per spectrum performed.  The 15 
strongest precursors per spot were chosen for MS/MS and the MALDI spot was 
interrogated until at least 4 peaks in the MS/MS, spectra achieved a S/N ≥ 70.   
The resulting MS/MS spectra were analyzed using ABI Protein ProteinPilot 
software 2.0 (Applied Biosystems, Foster City, CA).  The spectral data was searched 
against the mouse protein database (NCBI nr.fasta database customized to select for all 
mouse proteins) for identification of the peptides and corresponding proteins.  After 
database correlation analysis, the proteins were grouped and scored.  The Pro Group 
algorithm of ProteinPilot generated a ProtScore that is a cumulative score from each of 
the peptides used by the algorithm in the protein identification.  Protein scores 
(ProtScore) above 2.0, 1.0, and 0.47 expressed the percent confidence levels of >99, 
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>90, and >66%, respectively.  Each peptide match showed post-translational 
modifications present as mass spectral shifts identified during the database correlation 
analysis.   
 
Statistics 
Means and standard errors (SEM) were calculated for all data sets.  Data were 
analyzed with a two-way analysis of variance (ANOVA) method to evaluate the main 
treatment effects, diabetes induction and mPHGPx transgene presence (GraphPad 
Software Inc., La Jolla, CA).  Fisher’s Least Significant Difference (LSD) post hoc tests 
were performed to determine the significant differences among means.  When 
appropriate a Student’s T-test was employed.  *P<0.05 was considered significant. 
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RESULTS 
 
Cardiac Contractile Function 
Cardiac contractile function was significantly altered in the diabetic mice as 
compared to control.  Ejection fraction and fractional shortening were significantly 
decreased in the diabetic heart compared to control.  With overexpression of mPHGPx 
in the diabetic heart, ejection fraction and fractional shortening were restored back to 
control values (Table 6.1, *P<0.05). 
 
Mitochondrial Subpopulation Morphology 
Forward scatter (FSC), a measurement of size, was significantly decreased in 
the diabetic IFM as compared to control and restored back to control values with 
overexpression of mPHGPx (Figures 6.1F, *P<0.05), yet no significant changes were 
observed in SSM (Figures 6.1D).  Mitochondrial internal complexity (SSC) was 
significantly decreased in only the diabetic IFM as compared to control IFM (Figure 
6.1G, *P<0.05) with no significant changes in the SSM (Figure 5.1E).  Though it was not 
statistically significant, there was an increase in complexity with over expression of 
mPHGPx in the diabetic IFM (Figure 6.1G). 
 
Mitochondrial Subpopulation Functional Assessment 
Assessment of state 3 and state 4 respiration with the substrates 
glutamate/malate revealed a significant decrease in state 3 and state 4 respiration in 
diabetic IFM as compared to Control IFM (Figure 6.2B; *P<0.05), with no significant 
changes between control and diabetic SSM (Figure 6.2A).  Further, overexpression of 
mPHGPx in the diabetic heart restored state 3 and state 4 respiration in the IFM with no 
significant effects observed in the SSM (Figure 6.2B).  ETC complexes I, III and IV 
activities were also significantly decreased in diabetic IFM as compared to control IFM 
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(Table 6.2; *P<0.05), with no significant differences between control SSM and diabetic 
SSM (Table 6.2).  Overexpression of mPHGPx in the diabetic heart enhanced ETC 
complex I,III and IV activities specifically in the IFM back to control IFM values (Table 
6.2; *P<0.05). 
 
ATP Synthase Activity 
Alterations to ETC function can contribute to altered oxidative phosphorylation.  
ATP synthase activity was significantly decreased in the diabetic IFM as compared to 
control IFM (Figure 6.3B; *P<0.05), with no significant differences observed between the 
diabetic SSM and control SSM (Figure 6.3A).  Overexpression of mPHGPx enhanced 
ATP synthase activity in the diabetic IFM back to control IFM values (Figure 6.3B, 
*P<0.05), with no significant effects on any of the SSM groups (Figure 6.3A). 
 
Hydrogen Peroxide Production 
Hydrogen peroxide can directly be scavenged by mPHGPx.   Glutamate/malate 
driven hydrogen peroxide production was significantly increased in the diabetic IFM as 
compared to control IFM (Figure 6.4B, *P<0.05), with no significant changes in diabetic 
SSM compared to control IFM (Figure 6.4A).  Overexpression of mPHGPx in the 
diabetic heart attenuated H2O2 production in the IFM (6.4B, *P<0.05), with no significant 
changes in the SSM. 
   
Post-translational modifications 
Table 5.3 represents protein post-translational modifications no longer present in 
the diabetic IFM with overexpression of mPHGPx.  Overexpression of mPHGPx 
decreased PTMs identified on 68 peptide sequences of 44 different proteins in the 
diabetic IFM (Table 6.3).  Post-translational modifications that were attenuated include 
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oxidations, deamidations and acetylations. Interestingly, 5 IMM proteins and 4 matrix 
proteins identified no longer contained oxidative modifications with overexpression of 
mPHGPx in the diabetic IFM.  Of the 5 IMM proteins, 3 of these proteins were ETC 
proteins that play important roles in oxidative phosphorylation. Matrix proteins that were 
no longer oxidized with overexpression of mPHGPx included 2 TCA cycle and 2 FAO 
proteins, also proteins that ultimately contribute to proper ATP production.  Reduction of 
deamidations to proteins was even more prevalent than reduction of oxidations with 
overexpression of mPHGPx.  16 IMM proteins and 21 matrix associated proteins 
identified no longer contained deamidations with overexpression of mPHPGx in the 
diabetic IFM. 
 
Lipid Peroxidation 
Lipid peroxidation by-products 4-HAE and MDA were significantly increased in 
the diabetic IFM as compared to control IFM, (Figure 6.5B, *P<0.05), with no significant 
changes in diabetic SSM compared to control SSM (Figure 6.5A, *P<0.05).  Further, 
MPHGPx overexpression specifically decreased accumulation of lipid peroxidation by-
products in the diabetic IFM back to values similar to that of control IFM (Figure 6.5B, 
*P<0.05), suggesting the ability of mPHGPx to attenuate ROS induced damage to lipids 
within the IFM. 
 
Cardiolipin 
Cardiolipin is a phospholipid within the IMM that plays a critical role in proper 
mitochondrial function.  The most predominant species of cardiolipin (m/z 1448) and 
total cardiolipin content were decreased in the diabetic IFM compared to control IFM 
with no changes between diabetic SSM and control SSM.  The oxidized species of 
Cardiolipin, m/z 1496, was increased in the diabetic IFM as compared to control IFM 
with no differences observed between control and diabetic SSM.  Further, 
overexpression of mPHGPx in the diabetic heart increased the most predominant 
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species of cardiolipin and total cardiolipin content in the IFM with no changes in the 
SSM (Table 6.4).  The oxidized form of cardiolipin was attenuated with overexpression 
of mPHGPx in the diabetic IFM with no effect on the SSM. The overall ratio of non-
oxidized to oxidized was higher with overexpression of mPHPGx in the diabetic IFM 
with no changes in the SSM (Table 6.4).  
 
Inner Mitochondrial Membrane Potential (∆Ψm) 
Inner mitochondrial membrane potential, the ratio of orange to green 
fluorescence, was significantly decreased in the diabetic IFM as compared to control 
IFM (Figure 6.6B, *P<0.05), with no changes in diabetic SSM as compared to control 
SSM (Figure 6.6A). Overexpression of mPHGPx enhanced ∆Ψm in the diabetic IFM 
back to control IFM values (Figure 6.6B, *P<0.05), with no significant differences 
observed in SSM (Figure 6.6A).   
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DISCUSSION 
 
Mitochondrial dysfunction has been suggested to play a critical role in the 
pathogenesis of diabetes mellitus.  Enhanced oxidative stress and oxidative damage 
potentiates this dysfunction.  Mitochondria are particularly susceptible to oxidative 
damage because the IMM is the main site of ROS generation and contains components 
that are highly susceptible to oxidation such as polyunsaturated fatty acids (PUFAS) 
and oxidizable electron carriers (12, 23).  Enhanced mitochondrial ROS generation has 
been suggested to disrupt integral components of the IMM such as ETC complexes 
decreasing overall mitochondrial function (46). Previously, we have published 
suggesting that the IFM have enhanced ROS production and increased oxidative 
damage to proteins and lipids within the IMM which was associated with diminished 
mitochondrial function (7).   One potential target within the IMM with type 1 diabetes 
mellitus is the mitochondrial-specific phospholipid, cardiolipin. Cardiolipin plays an 
essential role of stabilizing protein complexes and translocases within the IMM, 
facilitating proper mitochondrial function (4, 19).  Many proteins and lipids within the 
IMM are targets of elevated ROS production, and their oxidative modification may 
contribute to mitochondrial deficiencies.  One antioxidant enzyme within the 
mitochondria that plays a critical role in attenuating ROS induced damage to the IMM is 
mPHGPx.  MPHGPx specifically associates with the IMM and scavenges phospholipid 
hydroperoxides including cardiolipin hydroperoxide in an attempt to preserve the IMM 
integrity and function (20, 50).  As a result, the current study was designed to test the 
hypothesis that mitochondria-specific overexpression of  PHGPx could attenuate ROS-
induced damage to the mitochondria by preservation of the IMM structure and function 
which in turn, improves cardiac contractile function in the diabetic heart.  In attempts to 
delineate the therapeutic potential of overexpression of mPHGPx, we utilized our 
previously generated transgenic mouse line that overexpresses mPHGPx (8).   
Previously, we have published suggesting that transgenic overexpression of 
mPHGPx preserved overall cardiac contractile function with I/R (8).  MPHGPx 
overexpression also improved mitochondrial function and attenuated oxidative damage 
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suggesting its potential as a therapeutic in alleviating ROS mediated dysfunction.   To 
determine whether overexpression of mPHGPx influences diabetic-associated cardiac 
dysfunction, we examined contractile parameters in the STZ-induced type 1 diabetic 
heart.  Cardiac abnormalities, such as decreased ejection fraction and fractional 
shortening, are often present in STZ-induced type 1 diabetic heart.  Cardiac dysfunction 
in the diabetic heart can be attributed to mitochondrial dysfunction through altered 
calcium dynamics (31), enhanced oxidative stress (46) and defects in oxidative 
phosphorylation (13).  In the present study, the decreased ejection fraction and 
fractional shortening observed in the diabetic heart was reversed with overexpression of 
mPHGPx (Table 6.1).  Though the direct link is not entirely clear, it is plausible that 
improved mitochondrial function through attenuation of ROS-induced damage may 
contribute to enhanced ATP production and improved calcium regulation by the 
mitochondria.  To better understand the contribution of mPHGPx to enhanced 
contractile function in the diabetic heart, we then examined the impact of mPHPGx on 
morphological, functional and biochemical characteristics of the subpopulations of 
mitochondria in the diabetic heart with overexpression of mPHGPx.   
Mitochondrial morphological manifestations have been observed in the diabetic 
state (7, 22). Consistent with our previous findings (7), the diabetic IFM were smaller 
and less complex with no changes in the SSM (Figure 6.1F and 6.G).  Overexpression 
of mPHGPx restored mitochondrial size and internal complexity in the diabetic IFM.  It is 
possible that because mPHGPx can directly interact with phospholipids within the IMM, 
that preservation of these phospholipids may contribute to maintenance of mitochondrial 
morphology.  Due to the role played by mPHGPx in scavenging phospholipid 
hydroperoxides and preserving IMM integrity, we explored whether mPHGPx 
overexpression would be protective to ETC complexes.  ETC complexes are 
surrounded by phospholipids in the IMM that contribute to their stability, integrity, and 
function.  Many of these phospholipids are more easily prone to oxidation which in turn 
can damage the ETC (32).  The diabetic IFM had decreased overall state 3 and state 4 
respiration (Figure 6.2B) as well as diminished ETC activity at complexes I,III and IV.  
These results are in agreement with our previous study indicating diminished ETC 
function specific to the IFM.  Overexpression of mPHGPx improved mitochondrial 
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function through enhanced overall state 3/state 4 respiration and increased ETC 
activities in the diabetic IFM (Figure 6.2B).  Alterations in mitochondrial ETC function 
may result in the inability of the mitochondria to adequately provide ATP.  Therefore, we 
examined ATP synthase activity in the diabetic heart.   Overall, there was a significant 
decrease in ATP synthase activity in the diabetic IFM (Figure 6.3B) which was reversed 
with overexpression of mPHGPx.  These data suggest that mPHGPx provides 
protection to the mitochondria by improving ETC function and subsequent ATP 
synthesis.  It is plausible that mPHGPx can attenuate ROS-induced damage to the IMM 
thus preserving IMM constituents, such as oxidative phosporylation machinery, allowing 
for proper mitochondrial function.  
The IMM is the main site of ROS formation therefore making the mitochondrion 
more susceptible to ROS-induced damage (9, 40).  Previously, we have observed 
enhanced superoxide production with glutamate and malate as substrates in the 
diabetic IFM (7).  Superoxide is dismutated into hydrogen peroxide which can react 
readily with iron producing the highly reactive hydroxyl radical.   MPHGPx has the ability 
to directly scavenge mitochondrial hydrogen peroxide thus presumably decreasing 
hydroxyl radical formation.  In the present study, enhanced hydrogen peroxide formation 
was found in the diabetic IFM (Figure 6.4B) which corresponds to our previous findings 
suggesting enhanced ROS specifically in the diabetic IFM (7).  Interestingly, excess 
hydrogen peroxide formation was attenuated in the diabetic heart with overexpression 
of mPHGPx (Figure 6.4B).  Unlike other antioxidants, mPHGPx is a unique enzyme that 
it is associated with subcellular membranes and has been suggested to be the primary 
enzymatic defense against oxidation of phospholipids in biomembranes (50).  Because 
reactive products derived from the oxidation of lipids promote deleterious effects on 
membrane constituents, we examined MDA and 4-HAE content in isolated mitochondria 
in the diabetic heart.  Similar to our previous findings, MDA and 4-HAE were increased 
in the diabetic IFM (Figure 6.5B) with no changes in the SSM (Figure 6.5A).  This effect 
was attenuated with overexpression of mPHGPx in the diabetic IFM, as compared to 
controls (Figure 6.5B), suggesting the ability of mPHPGx to directly reduce oxidative 
damage to lipids within the diabetic IFM.   
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One phospholipid predominantly within the IMM that is absolutely essential for 
proper mitochondrial function through a variety of mechanisms is cardiolipin.  Cardiolipin 
in necessary for the formation of contact sites between inner and outer membranes, 
stabilization of respiratory chain complexes and is involved in mitochondrial apoptotic 
signaling (19, 53). Cardiolipin modulation has been observed in a number of pathologies 
including ischemia/reperfusion, aging and diabetes mellitus (4, 15, 35-38).  In the 
present study, multiple cardiolipin species were examined and were changing in the 
diabetic heart (Table 6.4).  In agreement with our previous study (7), the most 
predominant species of cardiolipin (T18:2) at a m/z of 1448 was decreased in the 
diabetic IFM with no changes in the SSM (Table 6.4).  Overexpression of mPHGPx in 
the diabetic heart increased T18:2 cardiolipin specifically in the IFM beyond control 
values suggesting the ability of mPHPGx to preserve cardiolipin.  This notion has been 
previously suggested (28) due to the ability of PHGPx to directly interact with biological 
membranes.  Further, cardiolipin depletion has been suggested to decrease membrane 
potential disrupting the mitochondrial proton gradient and the ability to generate ATP.  
Analysis of membrane potential in the present study revealed decreases in delta psi in 
the diabetic IFM (Figure 6.6B) which was reversed with overexpression of mPHGPx 
(Figure 6.6B).  The abundance of unsaturated double bonds within cardiolipin’s 
structure makes it more susceptible oxidative modification. Oxidative damage to 
cardiolipin would be detrimental and impact the biochemical function of the IMM such as 
altered membrane fluidity, ion permeability, surface charge, passive electric properties, 
membranous enzyme activity and could even initiate apoptosis (34).  Interestingly, the 
oxidized form of cardiolipin, present at a m/z ratio of 1496, was increased in the diabetic 
IFM (Table 6.4).  Overexpression of mPHGPx decreased the content of oxidized 
cardiolipin which inturn, increased the ratio of non-oxidized to oxidized cardiolipin in the 
diabetic IFM.  These data suggest that mPHGPx is capable of sustaining cardiolipin 
content and attenuated oxidative damage to cardiolipin in the diabetic IFM.  Because 
cardiolipin is necessary for IMM function and integrity, preservation of cardiolipin may 
be a potential mechanism in which mPHGPx provides protection in the diabetic heart.   
An oxidative environment can often lead to enhanced post-translational 
modification (PTM) to proteins including oxidations and deamidations (5).  Though the 
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contribution of deamidation and oxidation to protein dysfunction is somewhat unclear, 
these PTMs may alter protein structure/function making the protein more susceptible for 
degradation by the proteasome system (21, 42).  In the present study, overexpression 
of mPHGPx decreased PTMs identified on 68 peptide sequences of 44 different 
proteins in the diabetic IFM (Table 6.3). Interestingly, majority of the proteins that no 
longer contained oxidative modifications with overexpression of mPHGPx were IMM 
proteins.  Of the 5 IMM proteins, 3 of these proteins were ETC proteins that play 
important roles in oxidative phosphorylation. Oxidative conditions have also been 
considered as a way through which proteins become more susceptible to deamidation.  
Though the underlying mechanism is not clear, the evidence suggests that oxidative 
conditions may induce an increased flexibility of the polypeptide backbone or a transient 
unfolding of the proteins, allowing for deamidation to occur (5).  Moreover, UV 
irradiation, which causes increased ROS formation, leads to an increased protein 
deamdation in cultured cells (5). In the present study, reduction of deamidations to 
proteins was even more prevalent than reduction of oxidations with overexpression of 
mPHGPx (Table 6.3).  16 IMM proteins and 21 matrix associated proteins identified no 
longer contained deamidations with overexpession of mPHPGx in the diabetic IFM.  
Many of these proteins are also involved in oxidative phosphorylation.  Attenuation of 
PTMs of IMM proteins with overexpression of mPHGPx in the diabetic heart may 
contribute to improved functionality of proteins critical for proper oxidative 
phosphorylation and adequate ATP production. 
In conclusion, we report for the first time, that mitochondria-specific transgenic 
overexpression of PHGPx in a mouse model provides cardioprotection through 
enhanced contractile function in the type 1 diabetic heart.  Further, cardioprotection is 
associated with enhanced IMM function and preservation of a key IMM constituent, 
cardiolipin.  These findings provide further rationale for the use of mPHGPx as a 
potential mitochondrially-targeted therapeutic that is capable of providing protection in 
the diabetic heart. 
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Figure 6.1. Mitochondrial size (FSC) and internal complexity (SSC). 
Determination of relative size and internal complexity of mitochondrial 
subpopulations was performed using flow cytometric analyses.  
Mitochondrial subpopulations from control, diabetic, mPHGPx and 
mPHGPx diabetic hearts were stained with mitotracker deep Red 633 and 
gated based on incorporation of the dye.  Analysis of FSC and SSC were 
calculated per 20,000 gated events for samples.  Representative dot plots 
of FSC vs. Mitotracker (A), FSC vs. SSC for SSM (B) and IFM (C).  FSC 
values for SSM (D) and IFM (F) and SSC values for SSM (E) and IFM (G) 
are expressed as arbitrary units (AU) ± SEM; N=5 for each group. *P<0.05 
for diabetic vs. all groups. 
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Figure 6.2 
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Figure 6.2. Mitochondrial respiration.  State 3 (black bars) and state 4 
(white bars) respiration rates with glutamate/malate as substrates in SSM 
(A) and IFM (B) from hearts of control, diabetic, mPHGPx and mPHGPx 
diabetic animals.  State 3 and state 4 respiration rates were determined in 
the presence of the substrates glutamate/malate and state 3 respiration 
examined upon addition of ADP. Values are expressed as 
nanomoles/oxygen/min/mg of protein ± SEM; N=5 for each group. *P<0.05 
for diabetic vs. all groups. 
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Figure 6.3 
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Figure 6.3. ATP synthase activity.  ATP synthase activity was assessed 
in SSM (A) and IFM (B) from hearts of control, mPHGPx, diabetic and 
mPHGPx diabetic animals using an assay coupled with pyruvate kinase 
which converts ADP to ATP and produces pyruvate from 
phosphoenolpyruvate. Final values are expressed as 
nanomoles/NADH/min/mg of protein ± SEM; N=4 for each group. *P<0.05 
for diabetic vs. all groups. 
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Figure 6.4 
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Figure 6.4. Hydrogen peroxide production. H2O2 production in SSM (A) 
and IFM (B) was determined using the oxidation of the fluorogenic indicator 
amplex red in the presence of horseradish peroxidase.  H2O2 production 
was initiated in mitochondria using glutamate/malate as substrates.   
Standard curves were obtained by adding known amounts of H2O2 to the 
assay medium in the presence of the substrates amplex red and 
horseradish peroxidase.  Final values were calculated as pmol/mg of 
protein.  Values are expressed as protein ± SEM; N=6 for each group. 
*P<0.05 for diabetic vs. all groups. 
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Figure 6.5 
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Figure 6.5. Lipid peroxidation by-products.  Oxidative damage to lipids 
was assessed in mitochondrial subpopulations from control, mPHGPx, 
diabetic, mPHGPx diabetic hearts by measuring lipid peroxidation by-
products malondialdehyde (MDA) and 4-hydroxyalkenals (4-HAE) using a 
colorimetric assay and compared against a standard curve of known 4-HAE 
and MDA concentrations.  Data are expressed as µmol of MDA + 4-HAE 
per mg of mitochondrial protein.  Values for lipid peroxidation are 
expressed as mean ± SEM; N=6 for each group.   *P<0.05 for diabetic vs. 
all groups. 
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Figure 6.6 
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Figure 6.6. Flow cytometric analysis of membrane potential (∆Ψm).  
Membrane potential (∆Ψm) was assessed by staining mitochondrial 
subpopulations with JC-1 dye and assessing the shift from green to orange 
fluorescence with flow cytometry.  ∆Ψm was calculated based on 
orange/green fluorescence ratios in control, mPHGPx, diabetic, mPHGPx 
diabetic SSM (A) and IFM (B).  Orange/green fluorescence values are 
expressed as arbitrary units (AU) ± SEM; N=6 for each group. *P<0.05 for 
diabetic vs. all groups. 
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Table 6.1 
 
 
 
 
 
 
 
 
 
 
 
 
Contractile Parameter Control Diabetic MPHGPx MPHGPx Diabetic 
Ejection Fraction (%) 89±1.0 68±3.9* 83±3.3 84±.75 
Fractional Shortening (%) 54±1.5 33±2.8* 46±3.2 47±.88 
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Table 6.1. Cardiac contractile function. Cardiac functional 
measurements were assessed using echocardiography and are expressed 
as ejection fraction (%) and fractional shortening (%).  Values are 
expressed as means ± SEM; N = 5 for each group. *P<0.05 for diabetic vs. 
all groups. 
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Table 6.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample Complex I Complex III Complex IV 
SSM Control 66±5 335±51 1215±39 
SSM MPHGPx 58±7 351±48 1053±129 
SSM Diabetic 68±6 302±29 1126±94 
SSM  MPHGPx Diabetic 56±5 290±28 1158±55 
IFM Control 90±7 392±29 2179±264 
IFM MPHGPx 96±16 434±59 2560±334 
IFM Diabetic 70±12 301±22 1386±45 
IFM MPHGPx Diabetic 102±10* 496±30* 1937±283* 
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Table 6.2. Electron transport chain activity.  ETC function was examined 
in mitochondrial subpopulations from control, mPHGPx, diabetic, mPHGPx 
diabetic hearts.  ETC complex I, III, and IV activities were assessed 
spectrophotometrically by measuring the oxidation of NADH (complex I), 
reduction of cytochrome c (complex III) and oxidation of cytochrome c 
(complex IV).  Enzymatic activities are expressed as activity/min/mg of 
protein ± SEM; N=6 for each group. *P<0.05 for diabetic vs. all groups. 
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Protein Peptide sequence Modification 
Outer Mitochondrial Membrane    
Voltage-dependent anion-selective 
channel protein 2 VNNSSLIGVGYTQTLRPGVK Deamidated(N)@3 
Voltage-dependent anion-selective 
channel protein 2 LTFDTTFSPNTGK Deamidated(N)@10 
Mitochondrial fission 1 protein MEAVLNELVSVEDLK Protein Terminal Acetyl@N-term 
Inner Mitochondrial Membrane   
ATP synthase subunit alpha ELLGRVVDALGNAIDGK Oxidation(R)@5; Deamidated(N)@12 
ATP synthase, H+ transporting,F1 
complex, alpha subunit VVDALGNAIDGKGPVGSK 
Deamidated(N)@7; 
Oxidation(P)@14 
ATP synthase subunit beta IMDPNIVGNEHYDVAR Deamidated(N)@9 
ATP synthase subunit alpha VVDALGNAIDGK Deamidated(N)@7 
ATP synthase subunit gamma QMKNEVAALTAAGK Gln->pyro-Glu@N-term; Deamidated(N)@4 
Cytochrome b-c1 complex subunit 2 RGNNTTSLLSQSVAK Deamidated(N)@3 
Cytochrome b-c1 complex subunit 1 TATFAQALQSVPETQVSILDNGLR Deamidated(N)@21 
Cytochrome b-c1 complex subunit 1 
EMQENDASMQNVVFDYLHA
TAFQGTPLAQAVEGPSENV
R 
Deamidated(Q)@29 
Cytochrome b-c1 complex subunit 
Rieske MLSVAAR 
Protein Terminal Acetyl@N-
term 
Cytochrome c1, heme protein ALAEEVEVQDGPNDDGEMFMRPGK Deamidated(N)@13 
Cytochrome c oxidase subunit 5A AWELRKGMNTLVGYDLVPEPK 
Dioxidation(M)@8; 
Deamidated(N)@9 
Cytochrome c oxidase subunit 5A LNDFASAVR Deamidated(N)@2; Dehydrated(D)@3 
Cytochrome c oxidase subunit 5A RLNDFASAVR Deamidated(N)@3 
Cytochrome c oxidase subunit 5A YEDSNNLGTSHLLR Deamidated(N)@6 
Cytochrome c oxidase subunit 6A2 GDHGGAGANTWR Deamidated(N)@9 
NADH-ubiquinone oxidoreductase 75 
kDa subunit GWNILTNSEK Deamidated(N)@3 
NADH-ubiquinone oxidoreductase 75 
kDa subunit SATYVNTEGR Deamidated(N)@6 
Table 6.3 
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NADH-ubiquinone oxidoreductase 75 
kDa subunit LTEPMVRNEK Deamidated(N)@8 
NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 7 NWASGQDLQAK Deamidated(N)@1 
NADH dehydrogenase [ubiquinone] 
flavoprotein 2 QNGWLPISAMNK Deamidated(N)@2 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 2 IDEVEEMLTNNR Deamidated(N)@10 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 2 
LYTEGYQVPPGATYTAIEAP
K Deamidated(Q)@7 
NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 9, FIHVSHLNASMK Deamidated(N)@8 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 4 PKPKSKSYGANFSWNKR Deamidated(N)@15 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 4 NGWSYDVEEK Deamidated(N)@1 
Carnitine O-palmitoyltransferase 2 LEDTMKRYLSAQKPLLNDSQFR Oxidation(M)@5 
Creatine kinase S-type, mitochondrial ENLRLQKRGTGGVDTAAVADVYDISNIDR 
Deamidated(R)@8; 
Oxidation(D)@14 
Chaperone activity of bc1 complex-like AAMLGDAIMVAK Protein Terminal Acetyl@N-term 
Matrix-Associated Proteins   
Aconitase Hydratase KGEKNTIVTSYNR Deamidated(N)@5 
Aconitase Hydratase LEAPDADELPR Deamidated(N)@1 
Aconitase Hydratase LNRPLTLSEK Deamidated(N)@1 
2-oxoglutarate dehydrogenase E1 
component HHVLHDQNVDKR Deamidated(N)@8 
2-oxoglutarate dehydrogenase E1 
component NGHNEMDEPMFTQPLMYK 
Deamidated(N)@4; 
Deamidated(Q)@13 
2-oxoglutarate dehydrogenase E1 
component 
SWDIFFRNTNAGAPPGTAYQ
SPLSLSR 
Trioxidation(W)@2; 
Deamidated(N)@8 
2-oxoglutarate dehydrogenase E1 
component VIPENGPAAQDPHK Deamidated(N)@5 
2-oxoglutarate dehydrogenase E1 
component VIPENGPAAQDPHKVK Deamidated(N)@5 
2-oxoglutarate dehydrogenase E1 
component NMEEEVAITR Deamidated(N)@1 
Malate dehydrogenase TEVVKAKAGAGSATLSMAYAGAR Dioxidation(K)@5 
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Malate dehydrogenase NLGIGK Deamidated(N)@1 
60 kDa heat shock protein DKYKNIGAKLVQDVANNTNEEAGDGTTTATVLAR 
Didehydroretinylidene(K)@9; 
Deamidated(N)@19 
60 kDa heat shock protein TNEEAGDGTTTATVLAR Deamidated(N)@2 
Trifunctional enzyme subunit alpha INSPNSKVNTLNK Deamidated(N)@5 
Trifunctional enzyme subunit alpha MGLVDQLVEPLGPGIKSPEER Deamidated(Q)@6 
Trifunctional enzyme subunit alpha GQQQVFKGLNDKVK Deamidated(Q)@4 
78 kDa glucose-regulated protein LGGKLSSEDKETMEK Acetyl@N-term 
78 kDa glucose-regulated protein NQLTSNPENTVFDAK Deamidated(N)@1 
Acetyl-CoA acetyltransferase KMNISRQEQDTYALSSYTR Deamidated(Q)@7 
Acetyl-CoA acetyltransferase AGIPKEEVKEVYMGNVIQGGEGQAPTR Deamidated(N)@15 
Electron transfer 
flavoprotein subunit 
beta 
VKPDKSGVVTDGVKHSMNP
F Deamidated(N)@18 
Very long-chain specific acyl-CoA 
dehydrogenase EATQAVLDKPETLSSDASTR Deamidated(Q)@4 
Very long-chain specific acyl-CoA 
dehydrogenase LCDSWCIEAATR 
Carbamidomethyl(C)@2; 
Oxidation(W)@5; 
Carbamidomethyl(C)@6 
Long-chain specific acyl-CoA 
dehydrogenase KFFQEEVIPHHTEWEK Deamidated(Q)@4 
Long-chain specific acyl-CoA 
dehydrogenase 
FIPQMTAGKCIGAIAMTEPGA
GSDLQGVR 
Oxidation(P)@3; 
Deamidated(Q)@4; 
Dioxidation(M)@5; 
Carbamidomethyl(C)@10 
Medium-chain specific acyl-CoA 
dehydrogenase MWITNGGK Deamidated(N)@5 
Grp75 QAVTNPNNTFYATKR Deamidated(N)@8 
3-ketoacyl-CoA thiolase DGTVTAGNASGVSDGAGAVIIASEDAVKK Deamidated(N)@8 
Enoyl-CoA hydratase GKNSSVGLIQLNRPK Deamidated(N)@3 
Electron transfer flavoprotein subunit 
alpha 
GQLRRAASLLRFQSTLVIAE
HANDSLAPITLNTITAAR Deamidated(N)@23 
3,2-trans-enoyl-CoA isomerase EADIQNFTSFISK Deamidated(N)@6 
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Methylmalonate-semialdehyde 
dehydrogenase [acylating] 
IVNDNPYGNGTAIFTTNGATA
R 
Deamidated(N)@9; 
Deamidated(N)@17 
Peroxiredoxin-5 FSMVIDNGIVK Dethiomethyl(M)@3; Deamidated(N)@7 
Fatty acid-binding protein, heart ADAFVGTWK Protein Terminal Acetyl@N-term 
Coiled-coil-helix-coiled-coil-helix 
domain-containing protein 3 RVTFEADENENITVVK Deamidated(N)@9 
Delta-1-pyrroline-5-carboxylate 
dehydrogenase VANEPILAFSQGSPER Deamidated(N)@3 
28S ribosomal protein S22 LMTQAQLEEATR Deamidated(Q)@4 
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Table 6.3. Post-translational modifications. Multidimensional protein 
identification technology (MudPIT) was used to identify post-translational 
modifications of proteins in IFM control, diabetic and mPHGPx diabetic 
hearts.  Peptides presented represent peptides that contain PTMs in the 
diabetic IFM but are non-existent with overexpression of mPHGPx in the 
diabetic heart. 
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Table 6.4 
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Table 6.4. Cardiolipin content.  Multiple cardiolipin species were 
assessed in mitochondrial subpopulations from control, mPHGPx, diabetic, 
mPHGPx diabetic hearts.  The most predominant cardiolipin species is 
represented at an analyte mass range of 1448, while the oxidized 
cardiolipin species is at an analyte mass range of 1496.  Samples 
represented were a pooled n=5 for each group. 
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GENERAL DISCUSSION 
 
The overall objective of this dissertation was to determine the influence of spatial 
location on mitochondrial dysfunction in the diabetic heart.  We further wanted to gain 
insight into whether a mitochondrially-targeted antioxidant, mPHGPx, could provide 
protection in the diabetic heart.  Our long term goal was to mechanistically determine 
how mitochondrial dysfunction is associated with the pathogenesis of diabetes mellitus 
and to examine whether specifically targeted therapeutics are protective.  The Central 
Hypothesis of this dissertation was that the IFM would be more susceptible to diabetes-
associated dysfunction and ultimately contribute to overall mitochondrial and contractile 
dysfunction present with both type 1 and type 2 diabetes mellitus. Further, we 
hypothesized that overexpression of a mitochondrial specific antioxidant capable of 
preserving the IMM may serve as a therapeutic. Our rationale for the proposed research 
was to elucidate differential mechanisms and key components of mitochondrial 
dysfunction with diabetes mellitus that ultimately will aid in developing more spatially 
targeted therapeutics.   
Mitochondrial dysfunction has been suggested to play a major role in the 
pathogenesis of type 1 and type 2 DM [1-4].  However, this dysfunction is complicated 
by the fact that two distinct subpopulations of mitochondria exist in the heart.  Several 
authors have  observed and suggested that these two spatially-distinct subpopulations 
respond differently with various physiological and pathological stimuli including aging, 
I/R, exercise, caloric restriction, high fat feeding and heart failure [2, 3, 5-13].  King et al. 
[11] first reported significantly diminished state 3 and state 4 respiration in both SSM 
and IFM from STZ-induced rat heart which is somewhat in contrast to our initial study 
(Chapter 2), suggesting the IFM had greater respiratory dysfunction than the SSM.  
Differences between the two studies may be due to differences in the animal model 
used, rat vs. mouse, and substrates used for respiration measurements.  Further, in our 
analyses, we examined a multitude of biochemical characteristics that were not present 
in the King et al. [11] study such as ROS generation, oxidative damage, morphology 
and cardiolipin content.  To date, no other examination of mitochondrial subpopulations 
has been made in either a type 1 or type 2 diabetic model.  One of the most intriguing 
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aspects of this dissertation was the fact that mitochondria located in different areas of 
the cell were impacted differentially with type 1 and type 2 DM.   Chapters 2 and 3 were 
focused on examining mitochondrial subpopulation specific dysfunction in STZ-induced 
type 1 diabetic mice. We hypothesized that there would be an increase in oxidative 
stress and damage resulting in diminished mitochondrial membrane integrity, 
accompanied by overall mitochondrial dysfunction in both diabetic mitochondrial 
subpopulations.  More specifically, we believed that IFM would be more susceptible with 
STZ-induced DM primarily due to their higher respiratory rates and subsequent 
oxidative environment. Due to the IFM’s primary role in ATP production for contractile 
function, we believed IFM would contribute to diabetic cardiomyopathy-associated 
dysfunction to a greater extent than the SSM.  In agreement with our hypothesis, 
mitochondrial dysfunction was greatest in the IFM from the type 1 diabetic heart.  We 
observed this through decreases in mitochondrial size and internal complexity (Chapter 
2) and diminished overall ETC function.  We also observed an increase in ROS 
generation and enhanced oxidative damage to proteins and lipids within the IFM.  
Cardiolipin, a phospholipid within the IMM essential for proper mitochondrial function, 
was also decreased in abundance specifically in the IFM.  It is important to note that 
there were some differences observed in the SSM, however, changes were much 
greater in the IFM. Taken together, our results suggested that with type 1 DM, both 
subpopulations seemed to be dysfunctional with the effect being greatest in the IFM.  
Because the IFM population provides ATP for contractile processes [14], the 
compromise in ETC function and enhanced oxidative stress may be particularly 
detrimental to cardiac contractile function, contributing to the contractile deficits 
associated with diabetic cardiomyopathy.  Our initial findings in the type 1 diabetic 
model were complicated by the fact that we saw the opposite phenomenon with type 2 
DM (Chapter 4), in that the SSM were more dysfunctional.  In contrast to our findings in 
the type 1 diabetic heart, the SSM had decreases in size/complexity, decreased overall 
respiratory capacity and enhanced oxidative damage to lipids and proteins with no 
changes in the IFM.  Reasons for the mitochondrial subpopulation specific differences 
between type 1 and type 2 DM are not clearly understood.  These findings are probably 
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due to differences in the phenotypes elicited by the two conditions, resulting from the 
unique pathological etiologies specific for each model.  
Though both type 1 and type 2 DM manifest through decreased cardiac glucose 
utilization and a switch to excessive FA utilization, key differences exist between type 1 
and type 2 diabetic phenotypes.  In regards to cardiac contractile function, both diastolic 
and systolic dysfunction are observed in STZ-induced type 1 diabetic animals between 
4-6 weeks post hyperglycemia onset [4, 15, 16].  It is believed this is mainly due to 
prolonged hypoinsulinemia and chronic hyperglycemia.  On the other hand, with various 
models of type 2 DM, there are conflicting reports, with some studies documenting both 
impaired systolic and diastolic function, whereas other studies argue against a change 
in systolic function [17, 18]. It is possible with Type 2 diabetic models, this discrepancy 
could be due to the severity or duration of hyperinsulinemia, and transient 
hyperglycemia.   
It is important to point out that in multiple models of both type 1 DM [3, 19, 20] 
and type 2 DM [1] increased ROS formation appears to be an underlying contributor to 
mitochondrial dysfunction.  However, the mechanism in which enhanced oxidative 
stress manifests may be different between type 1 and type 2 DM.  Altered substrate 
utilization (mainly increased FAO) and enhanced oxidative stress precedes onset of 
hyperglycemia in the db/db mouse model [1, 21].  It is suggested that pooling of neutral 
fatty acids within the mitochondria contribute to enhanced ROS formation [22].  On the 
other hand, hyperglycemia is present and believed to contribute to enhanced ROS 
production in the STZ mouse model. Persistently high levels of glucose in the STZ 
model can enhance ROS formation which inturn, increases polyol pathway flux, 
advanced-glycation end product formation, protein kinase C and hexosamine pathway 
flux, all of which contribute to cardiac dysfunction [23].  Further, in the db/db model of 
type 2 DM, lipid profiles are much more dramatically increased than in the STZ-induced 
type 1 diabetic mice.  Db/db mice have higher circulating fatty acids (Chapter 4) and 
triglycerides than the STZ mice.  Nielson et al. observed lipid accumulation specifically 
surrounding the SSM in type 2 diabetic skeletal muscle suggesting that the SSM may 
be subject to a more enhanced lipid environment in the type 2 diabetic state based upon 
its proximity [24].   Higher free fatty acids and lipid deposition associated with the 
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subsarcolemmal region during type 2 DM may put the SSM at greater risk due to their 
location at the cell periphery as compared to IFM [25].  It is plausible that an increased 
lipid environment in and surrounding the SSM may enhance the oxidative environment 
within the SSM contributing to their dysfunction.  Such a phenomenon would manifest 
during type 2 DM to a greater extent with an enhanced lipid environment as compared 
to type 1 DM.  Further, it is important to point out that diminished function in either 
subpopulation may have a negative impact on cardiac contraction regardless of 
subpopulation.  Though it has been speculated that each subpopulation provides ATP 
for specific cellular functions, inability to provide ATP for any of these functions may 
translate into contractile abnormalities.   
Proteomic analyses (Chapter 3, Chapter 4) were then utilized to gain further 
insight into other potential contributors to the differences observed between the two 
subpopulations of mitochondria with DM.   Proteomic analyses have played an integral 
role in furthering our understanding of mitochondrial dysfunction in the diabetic heart.  
Several proteomic studies, in a variety of diabetic models, have been employed to 
assess proteomic changes associated with the diabetic heart [26-31].  However, we are 
the first to examine subpopulation-specific proteomic differences in type 1 diabetic and 
type 2 diabetic models. 
 In the initial proteomic analyses of the mitochondrial subpopulations from the 
type 1 diabetic hearts, we utilized both 2D-DIGE and iTRAQ approaches. Utilizing 
iTRAQ and 2D-DIGE methodologies allowed a number of advantages over the use of a 
single proteomic methodology including the ability to confirm experimental results and 
accuracy by essentially comparing results from each method.  By using MudPIT 
analysis combined with iTRAQ labeling, the limitations associated with 2D-DIGE, such 
as solubility and separation, were bypassed.  Further, the iTRAQ approach enabled 
comparison of total protein levels, which can be more difficult using 2D-DIGE 
separation, where PTMs such as phosphorylation can alter pIs and hence gel migration 
[28].   Utilizing 2D-DIGE allowed us to examine proteins that may be in less abundance 
and as a result, less likely to show up with iTRAQ analyses.  Because each method has 
its own unique set of advantages, the combined use of both techniques enhanced our 
level of confidence in the reported findings.  In later studies, iTRAQ was used in 
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assessing mitochondrial subpopulations from the type 2 diabetic hearts mainly due to 
lack of 2D-DIGE resources.  Nevertheless, results from both studies were very 
interesting. The majority of proteins identified as changing with both 2D-DIGE and 
iTRAQ approaches in the type 1 diabetic IFM were FAO and ETC proteins.   In total, we 
identified 9 ETC proteins from iTRAQ analyses and 16 ETC proteins from 2D-DIGE 
analyses as being decreased in the diabetic IFM.  Jullig et al. reported decreases in 
ETC constituents that are involved in oxidative phosphorylation in total mitochondria 
[28], which is somewhat different from our findings examining mitochondrial 
subpopulations, emphasizing the importance of taking into account subcellular location 
when examining mitochondria.  Further, translocases located within the IMM that are 
essential for energy production through synthesis (mitochondrial phosphate carrier) and 
transport of ATP (ANT1) were also significantly decreased only in the diabetic IFM. Our 
proteomic data were consistent with previous reports of decreased respiratory capacity 
in the type 1 diabetic heart as well as functional data indicating down-regulation of ETC 
activities, specifically in the IFM [3, 11, 29].  Down-regulation of multiple components of 
the oxidative phosphorylation machinery and FAO proteins suggests that mitochondria 
in the type 1 diabetic heart, specifically IFM, may be less efficient in producing ATP 
required for contraction and calcium homeostasis.  In the type 2 hearts, we see a similar 
phenomenon but in the SSM. Using the iTRAQ™ approach, ETC complex proteins 
were primarily decreased in db/db SSM, while ETC and TCA cycle proteins were 
increased in the IFM.  The results indicated that protein loss in the SSM may be 
contributing to the decrease in oxidative capacity observed in the SSM.  Further, the 
majority of the proteins lost in the db/db SSM reside in the IMM, including ETC proteins, 
which may have contributed to the decrease in oxidative capacity observed in the SSM.  
Taken together, these results suggest that the formation and/or organization of ETC 
constituents contribute to the respiratory dysfunction observed in both IFM (type 1 DM) 
and SSM (type 2 DM).  In the type 2 diabetic hearts, we further observed an increase in 
FAO proteins in both SSM and IFM of db/db hearts (Chapter 4), which is probably due, 
in part, to the enhanced lipid environment present with type 2 DM [32].  However, 
though the effect occurred in both subpopulations, the result was more pronounced in 
the SSM, which saw a greater number of FAO proteins increased in abundance, 
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suggesting a more enhanced fatty acid environment presented to this subpopulation. As 
stated earlier, due to the fact that the SSM are located at the periphery of the cell, they 
may be impacted to a greater extent by an enhanced lipid environment, as compared to 
IFM, which reside in the interior of the cell.    However, it is important to point out that 
though we observed upregulation of FAO proteins in the SSM, the ability to utilize fatty 
acid substrates (palmitoylcarnitine) was diminished in the SSM suggesting that the 
mitochondrial dysfunction displayed by db/db SSM may be due to limitations to the ETC 
as opposed to FAO.  In the type 1 diabetic IFM, FAO proteins were decreased 
suggesting another potential difference between the two etiologies.  In general, a 
majority of proteins were decreased in abundance in the IFM from the type 1 diabetic 
heart.  This suggests that proteomic dysregulation with type 1 and type 2 DM may be 
through very different mechanisms.  However, of interest is the fact the Grp75, a key 
contributor of nuclear-encoded protein import, was decreased in both the type 1 diabetic 
IFM and the type 2 diabetic SSM suggesting a mechanism of proteomic alterations with 
both pathologies.  This finding is intriguing and warrants further investigation. 
Potential mechanisms of proteomic dysregulation may include alterations in gene 
expression, enhanced PTMs, or upregulation of regulators such as miRNAs [33, 34].  
With both type 1 and type 2 DM,  PTMs identified included oxidations, deamidations, 
deacetylations and methylations, with oxidations and deamidations being the most 
prevalent.  Interestingly, the diabetic IFM displayed the greatest number of oxidatively-
modified proteins in the type 1 diabetic hearts while the SSM contained the most 
oxidations in the type 2 diabetic hearts.  However, the type 1 diabetic IFM had a greater 
number of oxidations identified than the type 2 diabetic SSM.  This suggests that the 
IFM may have a more enhanced oxidative environment in the type 1 diabetic heart than 
the SSM in the type 2 diabetic heart.  Another PTM that is associated with oxidative 
stress that was prevalent in both the type 1 diabetic IFM and type 2 diabetic SSM was 
deamidation.  It has been suggested that deamidation of asparaginyl and glutaminyl 
residues within proteins causes structural and biological alterations to peptide and 
protein structure [35].  Though the contribution of deamidation and oxidation to protein 
dysfunction is somewhat unclear, these PTMs may alter protein structure/function 
making the protein more susceptible for degradation by the proteasome system [35, 36].   
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It is plausible that these modifications may have contributed to altered functionality and 
subsequent proteasomal degradation, all of which may have contributed to the 
morphological and oxidative phosphorylation deficiencies present in both the type 1 and 
type 2 diabetic hearts.  
Of greatest interest from both proteomic analyses (protein abundance and PTMs) 
is the observation that proteins of the IMM, an important locus containing the ETC, ATP 
synthesis machinery, and protein trafficking constituents, were specifically impacted in 
the SSM as a result of type 2 DM and in the IFM as a result of type 1 DM.  Interestingly,  
only 21% of total mitochondrial proteins are located within the IMM, while 69% are 
located in the matrix as shown below [37] 
 
 
 
 
 
However, in our proteomic analysis of mitochondrial protein abundance, we 
observed that approximately 50% of proteins changing in both the type 1 diabetic IFM 
(Figure 7.2A) and type 2 diabetic SSM (Figure 7.2B) were IMM proteins, with only 
approximately 45% of matrix proteins being affected.   
 
 
 
4%
21%
69%
6%
OMM
IMM
MATRIX
IMS
Figure 7.1. The percentage of proteins abundant in each mitochondrial 
subcompartment including OMM (4%), IMS (6%), MATRIX (69%) and IMM 
(21%).
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This emphasizes that fact the IMM is specifically being affected in both type 1 
and type 2 DM regardless of the fact the less proteins reside in the IMM as compared to 
the matrix.  
Further, functional aspects of the IMM, such as ∆Ψm, respiration, ETC activities, 
and ATP synthesis were concomitantly diminished in the IFM with type 1 DM and in the 
SSM with type 2 DM strengthening the argument that the IMM is at risk in the diabetic 
heart.  Taken together, the combination of findings provided by our studies offer 
evidence that not all cardiac mitochondria are impacted equally by diabetic insult (either 
type 1 or type 2), but rather mitochondrial dysfunction is specific to a particular 
subcellular locale.  Our analyses of mitochondrial subpopulation proteomic 
OMM
2.77%
IMM
51.39%
MATRIX
45.83%
Type 1 Diabetic IFM
A
OMM
5%
IMM
50%
MATRIX
45%
Type 2 Diabetic 
SSM
B
Figure 7.2 The percentage of proteins changing in the type 1 diabetic 
IFM (A) and the type 2 diabetic SSM (B) analyses. 
327 
 
compositional changes resulting from type 1 and type 2 diabetic insult reveals 
submitochondrial loci at risk, and identifies specific proteomic targets that may be of 
interest for therapeutic and diagnostic interventions. 
 
Because our initial findings indicated that the IMM seems to be at risk with both 
type 1 and type 2 DM associated dysfunction, we then explored whether overexpression 
of a key mitochondrially-targeted antioxidant enzyme, mPHGPx, could provide 
protection in the type 1 diabetic heart.  MPHGPx is unique in that it is the only 
antioxidant enzyme capable of reducing peroxidized acyl groups in phospholipids, fatty 
acid hydroperoxides and cholesterol peroxides in mitochondrial membranes [38].  Since 
mPHGPx is a lipophilic enzyme, it can interact directly with lipid hydroperoxides within 
the IMM, and it has been suggested to be the primary antioxidant defense against 
biomembrane oxidation within the mitochondrion [39].   Our data suggests that there is 
an enhanced oxidative environment within the mitochondria that is associated with 
increased oxidative damage to proteins and lipids within the type 1 diabetic heart.  The 
data further suggests that the IMM and its protein constituents, including ETC proteins 
and cardiolipin, seem to be particularly at risk.  Cardiolipin is a diphosphatidylglycerol 
enriched in the inner membrane, containing oxidatively-sensitive acyl groups that may 
act as selective targets for ROS [40].  Cardiolipin plays an essential role of stabilizing 
protein complexes and translocases within the IMM, facilitating proper mitochondrial 
function.  Han et al. demonstrated dramatic loss of abundant cardiolipin molecular 
species in STZ-treated hearts at the very earliest stages of DM accompanied by a 
profound remodeling of the remaining CL molecular species [41]. Remodeling of 
cardiolipin can certainly have a positive or negative impact on function and the 
susceptibility of being oxidatively modified.  Future experiments examining remodeling 
of cardiolipin species at earlier time points may provide insight into cardiolipin 
aberrations in the type 1 diabetic heart.    
Damage to these proteins and lipids within the IMM contributes to mitochondrial 
dysfunction by limiting sufficient production of ATP.  As a result, we wanted to examine 
whether mitochondria-specific overexpression of PHGPx could attenuate ROS-induced 
damage to the mitochondria by preservation of the IMM structure and function which 
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inturn, improves cardiac contractile function in the diabetic heart.  We hypothesized that 
overexpression of mPHGPx will decrease oxidative stress and damage with type 1 DM.  
More specifically, overall mitochondrial structure and function will be protected through 
preservation of the phospholipid bi-layer including cardiolipin a phospholipid critical to 
membrane integrity and the stabilization of the ETC.  Our findings were in agreement 
with our hypothesis that overexpression of mPHGPx would preserve overall cardiac and 
mitochondrial function in the type 1 diabetic heart (Chapter 6).  Specifically, cardiac 
contractile function, mitochondrial morphology and mitochondrial respiratory capacity 
were all preserved in the IFM with overexpression of mPHGPx in the diabetic heart.  
Further, overexpression of mPHGPx in the diabetic heart also increased the most 
predominant species of cardiolipin specifically in the IFM suggesting the ability of 
mPHPGx to preserve cardiolipin content.  Interestingly, the oxidized form of cardiolipin 
was increased in the diabetic IFM.  Overexpression of mPHGPx decreased the content 
of oxidized cardiolipin which inturn, increased the ratio of non-oxidized to oxidized 
cardiolipin in the diabetic IFM.  Oxidative damage to cardiolipin would be detrimental 
and alter IMM dynamics such as membrane fluidity, ion permeability, surface charge, 
membrane enzyme activity and could even initiate apoptosis [42].  Because cardiolipin 
is necessary for IMM function and integrity, preservation of cardiolipin may be a 
potential mechanism in which mPHGPx provides protection in the diabetic heart.  
Taken together, these data suggest that mPHGPx provides protection in the type 
1 diabetic heart via preserved mitochondrial dynamics.  Figure 7.3 represents the 
proposed mechanism in which we believe overexpression of mPHGPx preserves  
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mitochondrial function, which inturn, translates into adequate energy production and 
improved contractility in the diabetic heart.  Overexpression of mPHGPx is capable of 
inhibiting ROS induced damage to key protein and lipid constituents within the IMM.  
Further, we believe that preservation of the phospholipid bi-layer, including cardiolipin, 
stabilizes the ETC proteins, retains adequate ATP production and prevents 
mitochondrial dysfunction with type 1 DM.  
In terms of clinical application, MPHGPx mimetics may offer therapeutic 
advantages over other mitochondrial targeted antioxidants.  Several small-scale clinical 
trials have suggested the efficacy of the natural antioxidants α-tocopherol (vitamin E), 
ascorbate (vitamin C), Coenzyme Q, and α-lipoic acid [43, 44] with various degenerative 
diseases.  However, the uptake and distribution to tissues of hydrophobic natural 
antioxidants is often poor [45]. Development of artificial antioxidants, such as mimetics 
of MnSOD or mPHGPx, would be more potent than natural antioxidants and also have 
improved bioavailability and stability [46].  An advantage of using mPHGPx over 
          Figure 7.3. MPHGPx Mechanism of Protection 
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MnSOD is the fact that mPHGPx can directly interact with the main source of ROS 
generation, the IMM, and prevent accumulation of very reactive lipid hydroperoxides.   
In conclusion, our data suggests that subcellular location must be taken into 
account when examining mitochondrial dysfunction in the diabetic heart.  In particular, 
mitochondria located between the myofibrils are more dysfunctional in a type 1 diabetic 
setting, while those mitochondria located at the cell periphery have greater dysfunction 
in a type 2 diabetic setting.  Further, our data suggests that the IMM is particularly at 
risk with DM induced dysfunction and overexpression of a mitochondrially-targeted 
antioxidant enzyme capable of preserving the IMM provides cardioprotection.  Thus, 
development of antioxidants targeted not only to subcellular but also suborganelle 
locations may provide protection in the diabetic heart. 
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